WO1999019304A2 - Alpha-alkylthio substituted pyrimidine ethers and thioethers as viral reverse transcriptase inhibitors - Google Patents

Alpha-alkylthio substituted pyrimidine ethers and thioethers as viral reverse transcriptase inhibitors Download PDF

Info

Publication number
WO1999019304A2
WO1999019304A2 PCT/US1998/018507 US9818507W WO9919304A2 WO 1999019304 A2 WO1999019304 A2 WO 1999019304A2 US 9818507 W US9818507 W US 9818507W WO 9919304 A2 WO9919304 A2 WO 9919304A2
Authority
WO
WIPO (PCT)
Prior art keywords
dihydro
pyridinyl
pyrimidine
amino
methylthio
Prior art date
Application number
PCT/US1998/018507
Other languages
French (fr)
Other versions
WO1999019304A9 (en
WO1999019304A3 (en
Inventor
Joel Morris
Donn G. Wishka
Wade J. Adams
Janice M. Friis
Original Assignee
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company filed Critical Pharmacia & Upjohn Company
Priority to JP2000515877A priority Critical patent/JP2002526378A/en
Priority to EP98966441A priority patent/EP1034167A1/en
Priority to AU23050/99A priority patent/AU750917B2/en
Priority to US09/157,975 priority patent/US6124306A/en
Priority to NZ503586A priority patent/NZ503586A/en
Priority to CA002301800A priority patent/CA2301800A1/en
Priority to KR1020007003158A priority patent/KR20010024271A/en
Publication of WO1999019304A2 publication Critical patent/WO1999019304A2/en
Publication of WO1999019304A9 publication Critical patent/WO1999019304A9/en
Publication of WO1999019304A3 publication Critical patent/WO1999019304A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Definitions

  • the 6-thioalkyl pyrimidine-2-thioalkyl and alkylether derivatives of Formula I are useful in the treatment of individuals who are HIV positive, whether or not they show AIDS symptoms at the present time.
  • the 6-thioalkyl pyrimidine-thioalkyl and alkylether derivatives of Formula I are useful in the preparation of the pyrimidine-thioalkyl and alkylether derivatives of Formula I.
  • R j to R 4 independently of one another, represent hydrogen, lower alkyl, halogen, amino or hydroxy groups
  • R 5 represents a free electron pair or a lower alkyl group
  • m has the value 0 or 1
  • the pyrimidine-thioalkyl group being bonded in the 2-, 3- or 4-position of the pyridine ring, and to therapeutically compatible acid addition salts thereof.
  • the compounds allegedly exhibit surprisingly improved bronchosecretolytic and myucolytic activity as well as having been found to show antiphlogistic activity.
  • J. Med Chem. 1987, 30, 547-551 describes various 2-[(pyridinylmethyl)thio]- pyrimidine derivatives and the influence thereof on bronchosecretolytic properties in the phenol red screening model of the mouse in comparison to the known drug ambroxol.
  • EP 477 778 (Derwent 92-106190/14) describes various benzene, pyridine and pyrimidine derivatives as ACAT enzyme inhibitors, for treating arteriosclerosis, and cerebrovascular disease.
  • J. Org. Chem, 1954, 19, 1793-1801 describes pyrimidine derivatives, including 2-benzylmercapto-4-amino-6-pyrimidinol, 2-benzylmercapto-4-amino-6- chloropyrimidine, 2-benzylmercapto-4-amino-6-diethylaminopyrimidine as well as analogs of 6-dimethylaminopurine.
  • British Patent 744,867 (CA 51:2063i) describes various 2-R'-S-6-RR'N- substituted 4-aminopyrimidines.
  • HIV-1 human immunodeficiency virus type I
  • AZT zidovudine
  • U.S. Patent 4,724,232 claims a method of treating humans having acquired immunodeficiency syndrome utilizing 3'-azido-3'-deoxy-thymidine (azidothymidine, AZT).
  • J. Med. Chem. 1977, 20, 88-92 describes 2-alkoxy and 2-alkylthio-4-amino pyrimidines, including 2-[(phenylmethyl)thio]4-pyrimidinamine, 2-[[(4- chlorophenyl)methyl]thio]-4-pyrimidinamine, 2-[(3-pyridinylmethyl)thio]4- pyrimidinamine, and 2-(phenylmethoxy)-4-pyrimidinamine, and their activity as inhibitors of deoxycytidine kinase. Collect. Czech. Chem. Comrn. 1975, 40, 1078-1088 (CA 83:114326e) describes 5-(3-iodopropargyloxy)pyrimidines as effective fungistatics.
  • J. Med. Chem. 1991, 34, 315-319 describes derivatives of thiouracil which have dihydroxyboryl group at the C-5 position. These compounds are useful for B neutron-capture therapy of malignant melanoma.
  • WO 96/35678 discloses various alpha- substiuted pyrimidine-2-thioalkyl and alkylether compounds of Formula A
  • R 4 is selected from the group consisting of -H, -OH, halo or -NR 15 R 16 where R 15 is -H and R 16 is -H, C 1 -C 6 alkyl, -NH 2 or R 15 and R 16 taken together with the -N form 1-pyrrolidino, 4-morpholino or 1-piperidino;
  • R 5 is selected from the group consisting of -H, -C 2 H 4 OH, -C 2 H 4 -0-TBDMS, halo, -C 3 -C 6 cycloalkyl, C- ⁇ -C alkoxy, -CH 2 CH 2 C1 or C j _-C alkyl, with the proviso that R 5 is not isobutyl; or R 4 and R 5 are taken together to form a five or six-membered saturated or unsaturated ring which together with the pyrimidine ring form the group consisting of 7H-pyrrolo[2,3-d] pyrimidine, 5,6-dihydro-7H-pyrrolo[2,3-d]pyrimidine, furo[2,3- d]pyrimidine, 5,6-dihydro-furo[2,3-d]pyrimidine, thieno[2,3-d]pyrimidine, 5,6-dihydro- thieno[2,3-d] pyrimidine,
  • R is selected from the group consisting of -G ⁇ CH, -CO 2 R 53 , -CONR 54 R 55 ,
  • R ⁇ , R ⁇ , R 2 , R23, R2 , and R25 are the same or different and are selected from -H, C j -C alkyl, C j -Cg alkenyl, C j -Cg alkoxy, C j -Cg alkylthio, -C 3 -C 8 cycloalkyl, -CF 3 , -N0 2 , -halo, -OH, -CN, phenyl, phenylthio, -styryl, -C0 2 (R 31 ),-CON(R 31 ) (R 32 ), -CO(R 31 ), -(CH 2 ) n -N(R 31 )(R3 2 ), -C(OH)(R 31 )(R 33 ), - (CH 2 ) n N(R 31 )(CO(R 33 )), (CH 2 ) n N(R 31 )(CO(R 33 )), (CH
  • n is 0-3 and R ⁇ , R 32 , and R j r ⁇ are the same or different and are selected from
  • R j is selected from the group consisting of -H, C ⁇ -Cg alkyl, -C 3 -C 6 cycloalkyl, -CN, -C(O)NH 2 , -C(O)N(C 1 -C 6 alkyl)(C 1 -C 6 alkyl), -C0 2 H, -C0 2 (C r C 6 alkyl), -CH 2 OH, -CH 2 NH 2 or -CF 3 ;
  • R 13 is selected from the group consisting of -H, C j -Cg alkyl or -CF 3 ;
  • Y is selected from -S-, -S(O)-, -S(0) 2 , or -0-;
  • R 4 is selected from the group consisting of -H, -OH, halo or -NR j gR j where R 15 is -H and R 16 is -H, C j -Cg alkyl, -NH 2 or R 15 and R 16 taken together with the -N form 1-pyrrolidino, 4-morpholino or 1-piperidino;
  • R 5 is selected from the group consisting of -H, -C 2 H 4 OH, -C 2 H 4 -0-TBDMS, halo, -C -Cg cycloalkyl, C j -C alkoxy,
  • R g is not isobutyl; or R 4 and Rg are taken together to form a five or six-membered saturated or unsaturated ring which together with the pyrimidine ring form the group consisting of 7H-pyrrolo[2,3-d]pyrimidine, 5,6-dihydro-7H-pyrrolo[2,3-d] pyrimidine, furo[2,3- dlpyrimidine, 5,6-dihydro-furo[2,3-d] pyrimidine, thieno[2,3-d]pyrimidine, 5,6-dihydro- thieno[2,3-d] pyrimidine, lH-pyrazolo[3,4-d]pyrimidine, lH-purine, pyrimido[4,5- dlpyrimidine, pteridine, pyridol2,3-d]pyrimidine, or quinazoline
  • An embodiment of the present invention are compounds of Formula I where
  • R 12 and R 1 are not both -H.
  • An embodiment of the present invention are 6-thioalkyl pyrimidine-thioalkyl and alklyether anti-AIDS compounds of Formula I where
  • R 4 is selected from the group consisting of -H or -NR 15 R 16 where R 15 is -H and R 16 is -H, C j -Cg alkyl, -NH 2 or R- ⁇ g and R ⁇ g taken together with the -N form 1-pyrrolidino, 4-morpholino or 1-piperidino; and R 6 is -S-C j .g alkyl (preferably -S-CH 3 ).
  • the compounds of Formula I can be prepared in accordance with the procedures disclosed in WO 96/35678 as well as US Patent Application Serial No. 08/436,708; filed 8 May 1995, both of which are incorporated herein by reference.
  • An embodiment of the present invention are compounds of Formula I where Y is -0-.
  • a preferred embodiment of the present invention are compounds of Formula I where s is 0 and Y is selected from the group consisting of -S-, -S(O)- or -S(0) 2 ; more preferably Y is -S-.
  • a preferred embodiment of the present invention are compounds of Formula I where s is 0 and Y is selected from the group consisting of -S-, -S(O)- or -S(0) 2 (more preferably Y is -S-); and with the proviso that R 12 and R 13 are not both -H.
  • R 4 is preferably -NH 2 - m is preferably 0.
  • Rg is preferably -S-CH 3 .
  • R 4j and R 42 are preferably -H.
  • R j2 s preferably -CH 3 .
  • R j3 is preferably -H.
  • R is preferably selected from
  • R j members include: phenyl optionally substituted with one, 2 or 3 C j -C 4 alkyl, C ⁇ -Cg alkoxy, halo, C j - C 3 alkylthio, trifluoromethyl, C 2 -Cg dialkylamino, or nitro; 2- or 3-pyridinyl optionally substituted with C- j -Cg alkyl, C j -C alkenyl, C j -C alkoxy, C j -C alkylthio, -C 3 -Cg cycloalkyl, -CF 3 , -N0 2 , -halo, -OH, -CN, phenyl, phenylthio, -styryl, -C0 2 (R 31 ), -CON(R 31 )(R 32 ), -CO(R 31 ), -(CH 2 ) n -N(R 31 )(R 32 ),
  • AIDS compounds of Formula I include compounds where Y is S, and m is 0.
  • Additional preferred thioalkyl substituted pyrimidine-2-thioalkyl and alkylether anti-AIDS compounds of Formula I include compounds where Y is S, m is 0, R 12 is CH 3 and R 13 is -H.
  • Additional preferred thio-substituted pyrimidine-2-thioalkyl and alkylether anti-AIDS compounds of Formula I include compounds where Y is S, m is 0, R 12 is CH 3 , R 13 is -H, R 4 is NH 2 , R 5 is -H and Rg is -S-CH 3 .
  • More preferred thioalkyl substituted pyrimidine-2-thioalkyl and alkylether anti-AIDS compounds of Formula I include compounds where Y is S, m is 0, s is 0, R 12 is CH 3 , R 13 is -H, R 4 is NH, Rg is -H, Rg is -S-CH 3 , and R j is selected from the group consisting of
  • Most preferred thioalkyl substituted pyrimidine-2-thioalkyl and alkylether compounds of Formula I include compounds where Y is S, m is 0, s is 0, R j is CH 3 , R 1 is -H, R 4 is NH 2 , Rg is -H, Rg is -S-CH 3 , and R j is selected from the group consisting of 3-isoquinolinyl, 1-isoquinolinyl, 2-quinolinyl, 3-quinolinyl, 3- w ⁇ yy/ IKMM PCT/US98/18507
  • the 6-thioalkyl pyrimidine-2-thioalkyl compounds of Formula I are generally and most often prepared by contacting a 6-chloro pyrimidine-2-thioalkyl compound of Formula I with an appropriate alkyl thiolate, e.g. sodium thiomethoxide, sodium thioethoxide, etc. (Chart A)
  • the 6-thioalkyl pyrimidine 2-thioalkyl compounds of Formula I are prepared by contacting a 6-thioalkyl-2-thiopyrimidine with an appropriate alkylating agent, e.g. mesylate or halide.
  • an appropriate alkylating agent e.g. mesylate or halide.
  • the corresponding 6-thioalkyl-2- thiopyrimidine is prepared by, for example, by reacting 4-amino-6-chloro-2-(4- methoxybenzyDthiopyrimidine with an appropriate alkyl thiolate followed by deprotection with an appropriate reagent such as methane sulfonic acid.
  • the appropriate chiral alcohol IV can be prepared from the appropriate ketone V using a chiral reducing agent, such as (+) or (-)-diisopinocampheylchloroborane or other chiral reducing agents known in the art.
  • a chiral reducing agent such as (+) or (-)-diisopinocampheylchloroborane or other chiral reducing agents known in the art.
  • the appropriate chiral alcohol IV is also obtained from the resolution of the racemic alcohol VII via the enzymatic hydrolysis of the appropriate racemic acetate VI with the appropriate enzyme, such as PS-30 amano lipase or L1754 Type VII from candidae cylindracea or other enzymes known in the art.
  • the appropriate chiral alcohol IV is also obtained from the resolution of the racemic alcohol VII via the enzymatic esterification (such as acetylation or butyration) of the racemic alcohol VII (to give chiral VIII) using the appropriate enzyme, such as porcine pancreatic lipase type II, or other enzymes known in the art.
  • the 6-thioalkyl substituted pyrimidine-2-thioalkyl and alkylether compounds of Formula I include the compounds of EXAMPLES 1-304.
  • the pyrimidine-thioalkyl and alkylether compounds of Formula I form acid addition salts; such as mesylate, hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, acetate, propionate, lactate, maleate, malate, succinate, tartrate, and the like.
  • Some of the variable substituents are acids and as such form base addition salts when reacted with bases of sufficient strength.
  • the pharmaceutically acceptable salts include both inorganic and organic bases.
  • the preferred pharmaceutically acceptable salts include salts of the following bases, for example, hydroxide, ammonia, tromethamine (THAM), 2-amino-2-(hydroxymethyl)-l,3-propanediol.
  • Suitable cations include, for example, sodium, potassium, calcium and magnesium.
  • the pyrimidine-thioalkyl and alkylether anti-AIDS compounds of Formula I are useful as inhibitors of viral reverse transcriptase, an enzyme necessary for human immunodeficiency virus replication and therefore would be useful in the treatment of such diseases as AIDS.
  • human retrovirus indicates human immunodeficiency virus type I, or strains thereof apparent to one skilled in the art, which belong to the same viral families and which create similar physiological effects in humans as various human retroviruses.
  • Patients to be treated would include those individuals (1) infected with one or more than one strain of a human retrovirus as determined by the presence of either measurable viral antibody or antigen in the serum and (2) having either a symptomatic AIDS defining infection such as (a) disseminated histoplasmosis, (b) isopsoriasis, (c) bronchial and pulmonary candidiasis including pneumocystic pneumonia (d) non-Hodgkin's lymphoma or (e) Kaposi's sarcoma and being less than sixty years old; or having an absolute CD4 lymphocyte count of less than 200/mm in the peripheral blood.
  • a symptomatic AIDS defining infection such as (a) disseminated histoplasmosis, (b) isopsoriasis, (c) bronchial and pulmonary candidiasis including pneumocystic pneumonia (d) non-Hodgkin's lymphoma or (e) Kaposi's sarcoma
  • the compounds of Formula I can be given orally. Suitable dosage forms include tablets, capsules, suspensions, solutions and elixirs. An effective amount is from about 0.1 to about 500 mg/kg/day. A typical unit dose for a 70 kg human would be from about 10 mg to about 2000 mg, preferably about 100 mg to about 1000 mg taken one to six times per day.
  • the exact dosage and frequency of administration depends on the particular compound of Formula I used, the particular condition being treated, the severity of the condition being treated, the age, weight, general physical condition of the particular patient, other medication the individual may be taking as is well known to those skilled in the art and can be more accurately determined by measuring the blood level or concentration of the compounds of Formula I in the patient's blood and/or the patient's response to the particular condition being treated.
  • ARC AIDS-related complex
  • AIDS patients would typically be treated with higher oral doses (about 1 to about 500 mg/kg/day).
  • the pyrimidine-thioalkyl and alkylether anti-AIDS compounds of Formula I of this invention can be used in conjunction with (or sequentially with) other antiviral agents such as AZT, ddl, ddC, 3TC, d4T, with non-nucleoside anti-AIDS agents such as those disclosed in Serial No. 08/400,095 Case 4788.1 CP, filed March 7, 1995, International Publication No. WO91/09849, published July 11, 1991, and International Publication No. WO93/01181, published January 21, 1993, and with protease inhibitors.
  • other antiviral agents such as AZT, ddl, ddC, 3TC, d4T
  • non-nucleoside anti-AIDS agents such as those disclosed in Serial No. 08/400,095 Case 4788.1 CP, filed March 7, 1995, International Publication No. WO91/09849, published July 11, 1991, and International Publication No. WO93/01181, published January 21, 1993
  • the utility of the pyrimidine-thioalkyl and alkylether anti-AIDS compounds of Formula I of this invention can be determined by their ability to inhibit viral reverse transcriptase, an enzyme essential for human immunodeficiency virus replication.
  • This enzyme has characteristics which differentiate it from other known cellular polymerases and it is a unique enzyme which is not found in uninfected cells.
  • Viral reverse transcriptase (Wild Type) is found in extracts from bacterial clones prepared according to the procedure described in AIDS Virus Reverse Transcriptase defined by high level expression in Escherichia coli, EMBO J. 6:3133- 3137 (1987).
  • P236L viral reverse transcriptase is obtained by PNAS 90: 4713-4717 (1993). Inhibition of this enzyme is determined in a cell free assay which measures the level of radioactive precursors incorporated into DNA.
  • R j and R j would represent monovalent variable substituents if attached to the formula CH 3 -CH 2 -C(R j )(R)H.
  • variable substituents contained in parentheses are bonded to the atom immediately to the left of the variable substituent enclosed in parenthesis.
  • each of the consecutive variable substituents is bonded to the immediately preceding atom to the left which is not enclosed in parentheses.
  • both R- and R: are bonded to the preceding carbon atom.
  • Chemical formulas or portions thereof drawn in a linear fashion represent atoms in a linear chain.
  • the symbol "-" in general represents a bond between two atoms in the chain.
  • CH 3 -0-CH 2 -CH(R j )-CH 3 represents a 2-substituted-l- methoxypropane compound.
  • Chemical formulas of cyclic (ring) compounds or molecular fragments can be represented in a linear fashion.
  • the cyclic molecular fragment, 4- (ethyl)- 1-piperazinyl can be represented by -N -(CH 2 ) 2 -N(C 2 H 5 )-CH 2 -C H 2 .
  • a rigid cyclic (ring) structure for any compounds herein defines an orientation with respect to the plane of the ring for substituents attached to each carbon atom of the rigid cyclic compound.
  • the two substituents may be in either an axial or equatorial position relative to the ring and may change between axial/equatorial.
  • the position of the two substituents relative to the ring and each other remains fixed. While either substituent at times may lie in the plane of the ring (equatorial) rather than above or below the plane (axial), one substituent is always above the other.
  • a substituent (X which is "below” another substituent (X 2 ) will be identified as being in the alpha ( ⁇ ) configuration and is identified by a broken, dashed or dotted line attachment to the carbon atom, i.e., by the symbol "- - -” or "!.
  • the corresponding substituent attached “above” (X 2 ) the other (X j ) is identified as being in the beta ( ⁇ ) configuration and is indicated by an unbroken line attachment to the carbon atom.
  • the valences may be taken together or separately or both in the definition of the variable.
  • R is defined to consist of two monovalent variable substituents
  • the convention used to define the bivalent variable is of the form " ⁇ -R j . ⁇ -R j . ⁇ " or some variant thereof. In such a case both ⁇ - j .
  • the two monovalent variable substituents are ⁇ -Rg.- ⁇ -Rg ⁇ , .... ⁇ -R 6 . 9 : ⁇ -R 6 . 10 , etc, giving -C( ⁇ -Rg_ 1 )( ⁇ -R 6 _ 2 )-, .... -C( ⁇ -R 6 . 9 ) ( ⁇ -R 6 . 10 )-, etc.
  • a bivalent variable may be defined as two separate monovalent variable substituents, two separate monovalent variable substituents may be defined to be taken together to form a bivalent variable.
  • R j and R may be defined to be taken together to form (1) a second bond between C j and C 2 or (2) a bivalent group such as oxa (-0-) and the formula thereby describes an epoxide.
  • R j and R j are taken together to form a more complex entity, such as the group -X-Y-, then the orientation of the entity is such that C j in the above formula is bonded to X and C 2 is bonded to Y.
  • the carbon atom content of variable substituents is indicated in one of two ways.
  • the first method uses a prefix to the entire name of the variable such as "C- C 4 ", where both "1" and "4" are integers representing the minimum and maximum number of carbon atoms in the variable.
  • the prefix is separated from the variable by a space.
  • C j -C, ⁇ alkyl represents alkyl of 1 through 4 carbon atoms, (including isomeric forms thereof unless an express indication to the contrary is given).
  • the prefix indicates the entire carbon atom content of the variable being defined.
  • C 2 -C 4 alkoxycarbonyl describes a group CH 3 -(CH 2 ) n -0-C0- where n is zero, one or two.
  • the carbon atom content of only each portion of the definition is indicated separately by enclosing the "C j -C-" designation in parentheses and placing it immediately (no intervening space) before the portion of the definition being defined.
  • this optional convention (C 1 -C 3 )alkoxycarbonyl has the same meaning as C 2 -C 4 alkoxycarbonyl because the "C j -Cg" refers only to the carbon atom content of the alkoxy group.
  • C 2 -Cg alkoxyalkyl and (C 1 -C 3 )alkoxy(C 1 -C 3 )alkyl define alkoxyalkyl groups containing from 2 to 6 carbon atoms
  • the two definitions differ since the former definition allows either the alkoxy or alkyl portion alone to contain 4 or 5 carbon atoms while the latter definition limits either of these groups to 3 carbon atoms.
  • Chromatography refers to medium pressure chromatography on silica gel.
  • THF refers to tetrahydrofuran.
  • TBDMS refers to tert-butyldimethylsilyl.
  • Saline refers to an aqueous saturated sodium chloride solution.
  • NMR nuclear (proton) magnetic resonance spectroscopy, chemical shifts are reported in ppm ( ⁇ ) downfield from tetramethylsilane.
  • IR refers to infrared spectroscopy.
  • - ⁇ refers to phenyl (CgHg).
  • MS refers to mass spectrometry expressed as m/e or mass/charge unit.
  • [M + H] + refers to the positive ion of a parent plus a hydrogen atom.
  • El refers to electron impact.
  • CI refers to chemical ionization.
  • FAB refers to fast atom bombardment.
  • Ether refers to diethyl ether.
  • Halo refers to a halogen atom (-C1, -Br, -F or -I).
  • Pharmaceutically acceptable refers to those properties and/or substances which are acceptable to the patient from a pharmacological/toxicological point of view and to the manufacturing pharmaceutical chemist from a physical/chemical point of view regarding composition, formulation, stability, patient acceptance and bioavailability.
  • Pyridinyl refers to the pyridyl radical as defined by IUPAC nomenclature.
  • 2-pyridyl pyridine ring substituted in the 2-position.
  • the ratios of solvents used are volume/volume (v/v).
  • HIV refers to HTV-1 (wild type and/or drug resistant mutants thereof e.g. M41L, K65N, K67L, K70R, L74V, V75T, A98G, L100I, K103E, K103N, K103Q, V106A, V108I, E138K, V179D, V179E, Y181C, Y188H, Y188L, G190A, T2.15Y, T215F, K219Q, K219E, P236L and K238T).
  • Treatment refers to inhibition of the HIV virus and will differ depending on the infected individual.
  • the pyrimidine-thioalkyl derivatives of Formula I will delay, or prevent, the onset of symptoms.
  • the pyrimidine-thioalkyl derivatives of Formula I will delay, or prevent, the onset of "full blown AIDS”.
  • the pyrimidine-thioalkyl and alkylether derivatives of Formula I will extend survival time of these individuals.
  • Pyrimidine-thioalkyl and alkylether compounds of Formula I include alpha- substituted pyrimidine-thioalkyl and alkylether compounds.
  • All references to "pyrimidine-thioalkyl and alkylether compounds" and “pyrimidine-thioalkyl and alkylether anti-AIDS compounds” include "alpha-substituted pyrimidine-thioalkyl and alkylether compounds” and "alpha-substituted pyrimidine-thioalkyl and alkylether anti-AIDS compounds” unless specifically indicated otherwise.
  • ExVCpd #6 4-amino-2-(3-trifluoromethylphenylmethylthio)-6- methylthiopyrimidine
  • ExVCpd #7 4-amino-2-(3-methoxyphenylmethylthio)-6-methylthiopyrimidine
  • ExVCpd #11 4-amino-2-(3-bromophenylmethylthio)-6-methylthiopyrimidine
  • Ex-./Cpd #12 4-amino-2-(3-iodophenylmethylthio)-6-methylthiopyrimidine
  • ExVCpd #13 4-amino-2-(3-nitrophenylmethylthio)-6-methylthiopyrimidine
  • ExVCpd #29 4-amino-2-(2-quinolinylmethylthio)-6-methylthiopyrimidine
  • ExVCpd #30 4-amino-2-(6-chloro-5-piperonylmethylthio)-6-methylthiopyrimidine
  • ExVCpd #35 4-amino-6-methylthio-2-(3-bromophenylmethylsulfinyl)-pyrimidine
  • ExVCpd #36 4-amino-6-methylthio2-(2-naphthylmethylsulfinyl)-pyrimidine
  • ExVCpd #37 4-amino-6-methylthio-2-( 3-bromophenylmethylsulfonyl)-pyrimidine
  • ExVCpd #38 4-amino-5-bromo-6-methylthio-2-(2-naphthylmethylthio)-pyrimidine
  • ExVCpd #88 4-hydrazino-6-methylthio-2-(benzylthio)-pyrimidine
  • ExVCpd #89 4-amino-5-methoxy-6-methylthio-2-(2-naphthylmethylthio)- pyrimidine
  • ExVCpd #101 4-amino-6-methylthio-2-(cyclohex-l-enylmethylthio)-pyrimidine
  • ExVCpd #102 4-amino-6-methylthio-2-(Z-styrylthio)-pyrimidine
  • ExVCpd #103 4-amino-6-methylthio-2-(l-naphthylmethyloxy)-pyrimidine
  • ExVCpd #105 4-amino-6-methylthio-2-(2-naphthylmethyloxy)-pyri ⁇ nidine
  • ExVCpd #107 4-amino-6-methylthio-2-(3-bromophenylmethyloxy)-pyrimidine
  • ExVCpd #108 4-amino-6-methylthio-2-(3-hydroxyphenylmethylthio)-pyrimidine
  • ExVCpd #109 4-amino-6-methylthio-2-(3-isopropoxyphenylmethylthio)-pyrimidine
  • ExVCpd #110 4-amino-6-methylthio-2-thio-pyrimidine
  • ExVCpd #111 4-amino-6-methylthio-2-t2-(4-chloro)-pyridylmethylthio]-pyrimidine
  • Ex./Cpd #112 4-amino-6-methylthio-2-[2-(6-chloro)pyridylmethylthio]-pyrimidine
  • ExVCpd #113 4-amino-6-methylthio-2-[2-(6-methyl)pyridylmethylthiol-pyrimidine
  • ExVCpd #114 4-amino-6-methylthio-2-[2-(4-methyl)pyridylmethylthio]-pyrimidine
  • Ex./Cpd #115 4-amino-6-methylthio-2-[2-(4-ethoxy)pyridylmethylthio]-pyrimidine
  • ExVCpd #116 4-amino-6-methylthio-2-[2-(4-thiophenyl)pyridylmethylthio]-pyrimi- dine
  • ExVCpd #117 4-amino-6-methylthio-2-[2-(3-methyl)pyridylmethylthio]-pyrimidine
  • ExVCpd #118 4-amino-6-methylthiol-2-[2-(5-methyl)pyridylmethylthiol-pyrimidine
  • ExVCpd #120 4-amino-6-methylthio-2-[2-(4-methoxy-6-methyl)-pyridylmethylthio] -pyrimidine
  • ExVCpd #121 4-amino-6-methylthio-2- [2-(4,6-dimethyl)pyridylmethylthio] -pyrimidine
  • ExVCpd #122 4-amino-6-methylthio-2- [2-(4-ethyl)pyridylmethylthio] -pyrimidine
  • ExVCpd #123 4-amino-6-methylthio-2- [2-(4-methoxy )pyridylmethylthio] -pyrimidine
  • ExVCpd #124 4-amino-6-methylthio-2-[2-(4-(2-methylpropyl))pyridylmethylthio]- pyrimidine
  • ExVCpd #125 4-amino-6-methylthio-2-[2-(6-chloro-4-methyl)pyridylmethylthio]- pyrimidine
  • ExVCpd #127 4-amino-6-methylthio-2- [2-(4,6-dimethyl)pyrimidinylmethylthio] - pyrimidine
  • ExVCpd #128 4-amino-6-methylthio-2- [2-(4-cyano)pyridylmethylthiol -pyrimidine
  • ExVCpd #130 4-amino-6-methylthio-2-[4-(6-methyl)pyrimidinylmethylthio]- P3rrimidine
  • ExVCpd #131 4-amino-6-methylthio-2-[2-(4-propyl)pyridylmethylthio]-pyrimidine
  • ExVCpd #132 4-amino-6-methylthio-2-(2-(4-isopropyl)pyridylmethylthio]-pyrimi- dine
  • ExVCpd #133 4-amino-6-methylthio-2-[2-(5-phenyl)pyridylmethylthiol-pyrimidine
  • ExVCpd #134 4-amino-6-methylthio-2- [2-(4-ethyl)pyridylmethylthio] -pyrimidine
  • ExVCpd #135 4-amino-6-methylthio-2- [2-(4-( ⁇ -hydroxy, ⁇ -methyl)ethyl)pyridyl- methylthio] -pyrimidine
  • ExVCpd # 138 4-amino-6-methylthio-2-[2-(4-cyclopentyl)pyridylmethylthio]-pyrimi- dine
  • ExVCpd #140 4-amino-6-methylthio-2- [2-(4,5-dimethyl)pyridylmethylthio] -pyrimi- dine
  • ExVCpd #142 4-amino-6-methylthio-2-[4-(2,6-dimethyl)pyrimidinylmethylthio]- pyrimidine
  • ExVCpd #143 4-amino-6-methylthio-2-[2-(4-pyrrolidino)pyridylmethylthio]-pyrimi- dine
  • ExVCpd #144 4-Amino-6-methylthio-2-[(5-chlorothiophen-2-ylmethyl)thio] pyrimidine
  • ExVCpd #145 4-amino-6-methylthio-2-[2-(4-(2-butyl))pyridylmethylthio]-pyrimidine
  • ExVCpd #146 4-amino-6-methylthio-2- [2-(4-dimethylamino)pyridylmethylthio] - pyrimidine
  • ExVCpd #147 2-[2-(4-amino-6-methylthio)pyrimidinylthiomethyl]-pyridine-l-oxide
  • ExVCpd #148 4-Amino-6-methylthio-2- [(furan-3-ylmethyl)thio] pyrimidine
  • ExVCpd #149 4-amino-6-methylthio-5-fiuoro-2-[2-(4-chloro)pyridylmethylthio] pyrimidine
  • ExVCpd #151 4-amino-6-methylthio-2-[2-(4-(3-pentyl))pyridylmethylthio]- pyrimidine
  • ExVCpd #152 4-amino-6-methylthio-2- [2-(4-acetyl)pyridylmethylthio] -pyrimidine
  • ExVCpd #153 4-Amino-6-methylthio-2-[(benzofuran-2-ylmethyl)thio]pyrimidine
  • ExVCpd #154 4-amino-6-methylthio-2-[2-(6-dimethylamino4-methyl)pyridylmethyl- thio] -pyrimidine
  • ExVCpd #155 4-amino-6-methylthio-2- [( lH-inden-3-ylmethyl)thio] pyrimidine
  • ExVCpd #156 4-amino-6-methylthio-2 [2-(4-carbomethoxy)pyridylmethylthio] - pyrimidine
  • ExVCpd #157 4-Amino-6-methylthio-2-[((S)-(-)perillyl)thio]pyrimidine
  • ExVCpd #158 4-Amino-6-methylthio-2-[(benzothiophen-2-ylmethyl)thio]pyrimidine
  • ExVCpd #159 4-Amino-6-methylthio-2-[(2H-l-benzopyran-3-ylmethyl)thio] pyrimidine
  • ExVCpd #163 4-amino-6-methylthio-2-[2-(4-carboxamido)-pyridylmethylthio]- pyrimidine
  • ExVCpd #165 4-amino-5-bromo-6-methylthio-2- [2-(4-methyl)pyridyl ⁇ iethylthio] - pyrimidine
  • ExVCpd #166 4-amino-5-bromo-6-methylthio-2-[2-(4-isopropyl)-pyridylmethylthioJ- pyrimidine
  • ExVCpd #167 4-amino-6-methylthio-2-(2,6-dichlorophenyl)methylthio-pyrimidine
  • ExVCpd #168 4-Amino-6-methylthio-2-[(2,3-dihydrobenzofuran-5-ylmethyl)thio] pyrimidine
  • ExVCpd #167 4-amino-6-methylthio-2-( 2 ,6-dichlorophenyl)methylthio-pyrimidine
  • Ex./Cpd #168 4-Amino-6 ⁇ methylthio-2-[(2,3-dihydrobenzofuran-5-ylmethyl)thio] pyrimidine
  • ExVCpd #169 4-Amino-6-methylthio-2-[(5-phenylisoxazol-3-ylmethyl)thio]- pyrimidine
  • ExVCpd #170 4-Amino-6-methylthio-2-[(2,3-dihydrobenzofuran-2-ylmethyl)thio] pyrimidine
  • ExVCpd #171 4-Amino-6-methylthio-2-[[(3,4-dihydro-l-na
  • ExVCpd #177 4-Amino-6-methylthio-2- [(3-methylpyrazin-2-ylmethyl)thio] pyrimidine
  • ExVCpd #178 4-Amino-6-methylthio-2-[(quinolin-6-ylmethyl)thio] pyrimidine
  • ExVCpd #179 4-Amino-6-methylthio-2-[(quinoxalin-2-ylmethyl)thio] pyrimidine
  • ExVCpd # 180 4-Amino-6-methylthio-2-[(quinolin-8-ylmethyl)thio] pyrimidine
  • ExVCpd #181 4-Amino-6-methylthio-2-[(quinolin-4- ylmethyDthio] pyrimidine
  • ExVCpd #182 4-Amino-6-methylthio-2-[(isoquinolin-3-ylmethyl)thio]pyrimidine
  • ExVCpd #183 4-Amino-6-methylthio-2-[(quinolin-5-
  • ExVCpd #189 4-amino-6-methylthio-2 [2-(4-cyclohexyl)pyridylmethylthio] pyrimidine
  • ExVCpd #191 4-chloro-5-fluoro-6-methylthio-2- [2-(4-chloro)pyridyl- methylthio] pyrimidine
  • ExVCpd #192 4-amino-5-fluoro-6-methylthio-2-[2-(4-chloro)pyridyl- methylthio] pyrimidine
  • ExVCpd #193 (2£)-4-[(4-Amino-6-methylthio-2-pyrimidinyl)thio]-2-butenoic acid methyl ester
  • ExVCpd #194 (£)-N V-Diethyl-4-[(4-amino-6-methylthio-2-pyrimidinyl)thio]-2- butenamide
  • Ex./Cpd #195 (£)-4-methyl-l-[4-[(4-amino-6-methylthio-2-pyrimidinyl)thio]-l-oxo-2- butenyl] piperazine
  • ExVCpd #196 (£)-N-ethyl-4-[(4-amino-6-methylthio-2-pyrimidinyl)thio]-2- butenamide
  • ExVCpd #197 (E)-l-[4-[(4-amino-6-methylthio-2-pyrimidinyl)thio]-l-oxo-2- buteny
  • ExVCpd #210 4-Amino-6-methylthio-2-(l-(4-(l,l-dimethyl)ethyl-2- pyridyl )ethyl )thio-pyrimidine
  • ExVCpd #213 4-Amino-6-methylthio-2-(l-(2-(4-methyl)pyridyl)-l-methylethyl)thio- pyridine
  • ExVCpd #215 4-Amino-6-methylthio-2-(l-(4-methyl-2-pyridyl)ethyl)thio- pyrimidine hydrochloride
  • ExVCpd #216 4-Amino-6-methylthio-2-(l-(4-ethyl-2-pyridyl)ethyl)thio-pyrimidine
  • ExVCpd #217 4-Amino-6-methylthio-2-(l-(4-methyl-2-pyridyl)-l-cyanomethyl)thio- pyrimidine
  • ExVCpd #218 4-Amino-6-methylthio-2-(l-(4-methyl-2-pyridyl)propyl)thio- pyrimidine
  • ExVCpd #220 4-Amino-6-methylthio-2-(l-(4-methyl-2-pyridyl)-l-carbomethoxy- methyDthio-pyrimidine
  • ExVCpd #221 4-Amino-6-methylthio-2-(l-(4-(l-methylethenyl)-2-pyridyl)ethyl)thio- pyrimidine
  • ExVCpd #223 4-Amino-6-methylthio-2-(l-(4-(l-methylethyl)-2-pyridyl)ethyl)thio- pyrimidine
  • ExVCpd #224 4-Amino-6-methylthio-2-(l-(4-methyl-2-pyridyl)pentyl)thio- pyrimidine
  • ExVCpd #225 4-Amino-5-bromo-6-methylthio-2-(l-(4-methylethyl)-2- pyridyl)ethyl)thio-pyrimidine
  • ExVCpd #226 4-Amino-6-methylthio-2-(l-(4-methyl-2-pyridyl)-l-cyclopropyl- methyDthio-pyrimidine mesylate
  • ExVCpd #227 4-Amino-6-methylthio-2-(l-(4-(4-morpholinyl)methyl-2- pyridyDethyDthio-pyrimidine
  • ExVCpd #228 4-Amino-6-methylthio-2-(l-(4-dimethylaminomethyl-2- pyridyl)ethyl)thio-pyrimidine
  • ExVCpd #229 4-Amino-6-methylthio-2-(l-(2-naphthalenyl)ethyl)thio-pyrimidine
  • ExVCpd #230 4-Amino-6-methylthio-2-(l-(3-isoquinolyl)ethyl)thio-pyrimidine
  • ExVCpd #231 4-Amino-5-bromo-6-methylthio-2-(l-(3-isoquinolyl)ethyl)thio- pjrrimidine
  • ExVCpd #232 4-Amino-6-methylthio-2-( l-( l-isoquinolyl)ethyl)thio-pyrimidine
  • ExVCpd #233 4-Amino-6-methylthio-2-(l-(3-(5,6,7,8-tetrahydro- isoquinolyl ) )ethyl)thio-pyrimidine
  • ExVCpd #235 4-Amino-6-methylthio-2-(
  • ExVCpd #237 4-Amino-6-methylthio-2-(l-(7-chlorofuro[2,3-c]pyridine-5- yl)ethyl)thio-pyrimidine
  • ExVCpd #238 4-Amino-6-methylthio-2-(l-(furo[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine
  • Ex./Cpd #240 4-Amino-6-methylthio-2-(l-(7-chloro-2-methylfuro[2,3-c]pyridine-5- yl)ethyl)thio-pyrimidine
  • ExVCpd #242 4-Amino-6-methylthio-2-(l-(2-methylfurot2,3-c]pyridine-5- yl)ethyl)thio-pyrimidine
  • ExVCpd #244 4-Amino-6-methylthio-2-( l-(6-chloro-5-methoxy-4-viny
  • ExVCpd #245 4-Amino-6-methylthio-2-(l-(4-ethyl-5-methoxy-2-pyridyl)ethyl)thio- pyrimidine
  • Ex./Cpd #246 4-Amino-6-methylthio-2-(l-(3-methylfuro[2,3-c]pyridine-5- yl)ethyl)thio-pyrimidine
  • ExVCpd #247 4-Amino-6-methylthio-2-(l-(2,3-dihydrofuro[2,3-c]pyridine-5- yl)ethyl)thio-pyrimidine
  • ExVCpd #248 4-Amino-6-methylthio-2-(l-(3,3-dimethyl-2,3-dihydrofuro[2,3- c]pyridine-5-yl)ethyl)thio-pyrimidine
  • Ex./Cpd #249 4-Amino-6-methylthio-2-(l-(3
  • ExVCpd #250 4-Amino-6-methylthio-2-(l-(7-chloro-3,3-dimethyl-2,3- dihydrofuro[2,3-c]pyridine-5-yl)ethyl)thio-pyrimidine
  • ExVCpd #251 4-Amino-6-methylthio-2-(l-(7-chloro-3-ethylfuro-[2,3-c]pyridine-5- yl)ethyl)thio-pyrimidine
  • ExVCpd #252 4-Amino-6-methylthio-2-(l-(3-(l-methylethyl)furo[2,3-c]-pyridin-5- yl)ethyl)thio-pyrimidine
  • ExVCpd #253 4-amino-6-methylthio-2-(l-(4-cylcopentyl)-2-pyridyl)- ethyDthio-pyrimidine
  • ExVCpd #255 4-a
  • ExVCpd #256 4-amino-6-methylthio-2-( l-(4-( l-methylpropyl)-2-pyridyl)- ethyl )thio-pyrimidine
  • Ex./Cpd #257 4-amino-6-methylthio-2-(l-(4-cylcohexyl)-2-pyridyl)- ethyl )thio-pyrimidine
  • ExVCpd #258 4-amino-6-methylthio-2-(l-(4-(l-pyrryl))-2-pyridyl)- ethyDthio-pyrimidine
  • ExVCpd #259 4-amino-6-methylthio-2-( l-(4-dimethylamino)-2-pyridyl)- ethyDthio-pyrimidine
  • ExVCpd #260 4-amino-6-methylthio-2-( l-(5-( l-methylethyl)-3-pyridyl)- ethyDthio-pyrimidine
  • ExVCpd #261 4-amino-6-methylthio-2-(l-(4-(l-ethylpropyl)-2-pyridyl)- ethyDthio-pyrimidine
  • ExVCpd #262 4-amino-6-methylthio-2-( l-(4-methyl-6-( l-pyrryl))-2-pyridyl)- ethyDthio-pyrimidine
  • ExVCpd #263 4-amino-6-methylthio-2-(l-(4-(2-propyloxy))-2
  • ExVCpd #282 4-amino-6-methylthio-2-(l-(3-chloro-[2,3-c]pyridine-5- yl)ethyl)thio-pyrimidine
  • ExVCpd #283 4-Amino-6-methylthio-2-(l-(3,7-dichlorofuro[2,3-c]pyridine-5- yl)ethyl)thio-pyrimidine
  • Ex./Cpd #284 4-Amino-6-methylthio-2-(l-(3-bromofuro[2,3-c]pyridine-5- yl)ethyl)thio-pyrimidine
  • ExVCpd #285 4-Amino-6-methylthio-2-( l-(3-bromo-7-chlorofuro [2,3-c] pyridine-5- yl)ethyl)thio-pyrimidine
  • ExVCpd #286 4-Amino-6-methylthio-2-(l-(7-ch
  • ExVCpd #289 (R)-(+)-4-Amino-6-methylthio-2-(l-(3-methylfuro[2,3-c]pyridine-5- yl)ethyl)thio-pyrimidine
  • ExVCpd #290 (S)-(-)-4-Amino-6-methylthio-2-(l-(3-methylfurot2,3-c]pyridine-5- yl)ethyl)thio-pyrimidine, mp 80-82°C
  • ExVCpd #291 R-(+)-4-Amino-6-methylthio-2-(l-(4-ethyl-2-pyridyl)ethyl)thio- pyrimidine
  • ExVCpd #292 (-)-4-Amino-6-methylthio-2-( l-(4-ethyl-2-pyridyl)ethyl)thio-
  • ExVCpd #294 4-Amino-6-methylthio-2-(l-(3-trifluoromethyl)-furo[2,3-c]pyridin-5- yl )ethylthio )-pyrimidine
  • ExVCpd #301 S)-(-)-4-Amino-6-methylthio-2-(l-(furo[2,3-c]pyridin-5-yl)ethylthio)- pyrimidine mesylate salt

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The subject invention relates to pyrimidine-thioalkyl and alkylether compounds of Formula (I) and pyrimidine-thiolkyl and alkylethers of Formula (I), where R4 is selected from the group consisting of -H or -NR15R16 where R15 is -H and R16 is -H, C1-C6 alkyl, -NH2 or R15 and R16 taken together with the -N form 1-pyrrolidino, 1-morpholino or 1-piperidino; and R6 is -S-C1-6 alkyl (preferably -SCH3). The compounds of Formula (I) are useful in the treatment of individuals who are HIV positive.

Description

THIOALKYL ALPHA SUBSTITUTED PYRIMIDINE COMPOUNDS BACKGROUND OF THE INVENTION 1. Field of Invention The 6-thioalkyl pyrimidine-2-thioalkyl and alkylether derivatives of Formula I are useful in the treatment of individuals who are HIV positive, whether or not they show AIDS symptoms at the present time. The 6-thioalkyl pyrimidine-thioalkyl and alkylether derivatives of Formula I are useful in the preparation of the pyrimidine-thioalkyl and alkylether derivatives of Formula I.
2. Description of the Related Art U.S. Patent 5,025,016 (and EP 124 630) pyrimidine-thioalkyl pyridine derivatives corresponding to the general formula
Figure imgf000003_0001
in which Rj to R4, independently of one another, represent hydrogen, lower alkyl, halogen, amino or hydroxy groups, R5 represents a free electron pair or a lower alkyl group, a halogen atom, m has the value 0 or 1, the pyrimidine-thioalkyl group being bonded in the 2-, 3- or 4-position of the pyridine ring, and to therapeutically compatible acid addition salts thereof. The compounds allegedly exhibit surprisingly improved bronchosecretolytic and myucolytic activity as well as having been found to show antiphlogistic activity. J. Med Chem. 1987, 30, 547-551 describes various 2-[(pyridinylmethyl)thio]- pyrimidine derivatives and the influence thereof on bronchosecretolytic properties in the phenol red screening model of the mouse in comparison to the known drug ambroxol.
EP 477 778 (Derwent 92-106190/14) describes various benzene, pyridine and pyrimidine derivatives as ACAT enzyme inhibitors, for treating arteriosclerosis, and cerebrovascular disease.
J. Org. Chem, 1954, 19, 1793-1801 describes pyrimidine derivatives, including 2-benzylmercapto-4-amino-6-pyrimidinol, 2-benzylmercapto-4-amino-6- chloropyrimidine, 2-benzylmercapto-4-amino-6-diethylaminopyrimidine as well as analogs of 6-dimethylaminopurine. British Patent 744,867 (CA 51:2063i) describes various 2-R'-S-6-RR'N- substituted 4-aminopyrimidines.
An estimated one to one and one-half million people in the United States are infected with a human retrovirus, the human immunodeficiency virus type I (HIV-1) which is the etiological agent of acquired immunodeficiency syndrome, AIDS, see Science, 661-662 (1986). Of those infected, an estimated two hundred and fifty thousand people will develop AIDS in the next five years, see Science, 1352-1357 (1985). On March 20, 1987, the FDA approved the use of the compound, AZT (zidovudine), to treat AIDS patients with a recent initial episode of pneumocystis carinii pneumonia, AIDS patients with conditions other than pneumocystis carinii pneumonia or patients infected with the virus with an absolute CD4 lymphocyte count of less than 200/mm in the peripheral blood. AZT is a known inhibitor of viral reverse transcriptase, an enzyme necessary for human immunodeficiency virus replication. U.S. Patent 4,724,232 claims a method of treating humans having acquired immunodeficiency syndrome utilizing 3'-azido-3'-deoxy-thymidine (azidothymidine, AZT).
It is known in the art that certain antibiotics and polyanionic dyes inhibit retrovirus reverse transcriptase. Many publications have reported the ability of various sulfated compounds to inhibit virus replication, including HIV.
Nature 343, 470 (1990) and Science 250, 1411 (1990) disclose potent benzodiazepin type reverse transcriptase inhibitors. The compounds of the present invention are not benzodiazepin type compounds. J. Org. Chem. 1962, 27, 181-185 describes various 2-benzylthio pyrimidine derivatives, including 4-chloro-5-methyl-2-[(phenylmethyl)thio]-pyrimidine, 4-chloro- 5-methyl-2- [ [(2,4-dichloro-phenyl)methyl]thio]-pyrimidine, 4-chloro-5-methyl-2- [ [(2- chloro-phenyl)methyl]thio]-pyrimidine, and 4-chloro-5-methyl-2-[[(4-chloro- phenyl)methyl]thio] -pyrimidine and their activity as antitumor compounds in screens against SA-180, CA 755, and L-1210 tumor systems.
J. Med. Chem. 1977, 20, 88-92 describes 2-alkoxy and 2-alkylthio-4-amino pyrimidines, including 2-[(phenylmethyl)thio]4-pyrimidinamine, 2-[[(4- chlorophenyl)methyl]thio]-4-pyrimidinamine, 2-[(3-pyridinylmethyl)thio]4- pyrimidinamine, and 2-(phenylmethoxy)-4-pyrimidinamine, and their activity as inhibitors of deoxycytidine kinase. Collect. Czech. Chem. Comrn. 1975, 40, 1078-1088 (CA 83:114326e) describes 5-(3-iodopropargyloxy)pyrimidines as effective fungistatics.
Synthesis 1981, 397-400 describes peroxypyrimidines
J. Org. Chem. 1961, 26, 1884 describes the synthesis of aziridinyl pyrimidines as analogs of methioprim.
J. Med. Chem. 1991, 34, 315-319 describes derivatives of thiouracil which have dihydroxyboryl group at the C-5 position. These compounds are useful for B neutron-capture therapy of malignant melanoma.
WO 96/35678 (published 14 November 1996) discloses various alpha- substiuted pyrimidine-2-thioalkyl and alkylether compounds of Formula A
Figure imgf000005_0001
wherein
R4 is selected from the group consisting of -H, -OH, halo or -NR15R16 where R15 is -H and R16 is -H, C1-C6 alkyl, -NH2 or R15 and R16 taken together with the -N form 1-pyrrolidino, 4-morpholino or 1-piperidino;
R5 is selected from the group consisting of -H, -C2H4OH, -C2H4-0-TBDMS, halo, -C3-C6 cycloalkyl, C-^-C alkoxy, -CH2CH2C1 or Cj_-C alkyl, with the proviso that R5 is not isobutyl; or R4 and R5 are taken together to form a five or six-membered saturated or unsaturated ring which together with the pyrimidine ring form the group consisting of 7H-pyrrolo[2,3-d] pyrimidine, 5,6-dihydro-7H-pyrrolo[2,3-d]pyrimidine, furo[2,3- d]pyrimidine, 5,6-dihydro-furo[2,3-d]pyrimidine, thieno[2,3-d]pyrimidine, 5,6-dihydro- thieno[2,3-d] pyrimidine, lH-pyrazolo[3,4-d]pyrimidine, lH-purine, pyrimido[4,5- d.pyrimidine, pteridine, pyrido[2,3-d]pyrimidine, or quinazoline, where the unsaturated ring may be optionally substituted with 1, 2 or 3, Cj-Cg alkyl, Cj-Cg alkoxy, -OH, -CH2OH, or -(CH2)n-N(R31)(R32), -C3-C8 cycloalkyl, -CF3, -halo, -C02{R31), -CON(R31)(R32), -CO(R31), -(CH2)nN(R31)(CO(R33)), -(CH^WR^) (SO2(R33)), and the saturated ring may be optionally substituted with 1, 2 or 3, -CrC6 alkyl, -C1-C6 alkoxy, -OH, -CH2OH, or -(CH2)n-N(R31)(R32) or one oxo (=0); and Rg is selected from the group consisting of -H, -OH, halo (preferably -CD, -CN, -CF3, -C02(R61), -C(0)R61 or -C(0)N(R61)(R62) where R61 and R62 are the same or different and are selected from -H,
CrC6 alkyl, phenyl optionally substituted with 1, 2, or 3 -halo, C-^-Cg alkyl, Cj-C alkoxy, -CF3, -OH, -CN, or where Rgl and Rg2 taken together with the attached nitrogen to form a ring selected from -pyrrolidinyl, -piperidinyl, -4-morpholinyl, -4-thiomorpholinyl, -4-piperazinyl, or -4-(C1-Cg alkyDpiperazinyl; with the overall proviso that R4 and Rg are not both -H; and with the further proviso that and R12 and R13 are not both -H except when Rg is selected from -CN, -CF3, -C02(R61), -C(0)R61 or -C(0)N(R61)(R62), or Rχ is selected from -C02R53 or -C(O)N(R54)(R55);
SUMMARY OF INVENTION Disclosed are 6-thioalkyl pyrimidine-2-thioalkyl and alkylether compounds of Formula I
Figure imgf000006_0001
and therapeutically/pharmaceutically compatible acid addition salts thereof. The compounds corresponding to Formula I may exist in various tautomeric formulas, and are included within the scope of Formula I.
DETAILED DESCRIPTION OF THE INVENTION Disclosed are 6-thioalkyl pyrimidine-2-thioalkyl and alkylether compounds of Formula I
Figure imgf000007_0001
where m is 0 or 1;
R is selected from the group consisting of -G≡CH, -CO2R53, -CONR54R55,
Figure imgf000007_0002
where s is 0 or 1 (preferably 0) and R^, R^, R 2, R23, R2 , and R25 are the same or different and are selected from -H, Cj-C alkyl, Cj-Cg alkenyl, Cj-Cg alkoxy, Cj-Cg alkylthio, -C3-C8 cycloalkyl, -CF3, -N02, -halo, -OH, -CN, phenyl, phenylthio, -styryl, -C02(R31),-CON(R31) (R32), -CO(R31), -(CH2)n-N(R31)(R32), -C(OH)(R31)(R33), - (CH2)nN(R31)(CO(R33)), (CH2)nN(R31)(S02 (R33)), or where R20 and R21, or R21 and R22, or R 2 and R^ are taken together to form a five or six-membered saturated or unsaturated ring containing 0 or 1 oxygen, nitrogen or sulfur, where the unsaturated ring may be optionally substituted with 1, 2 or 3, C^-Cg alkyl, Cj-C alkoxy, -OH, -CH2OH, -(CH2)n-N(R31)(R32), -C3-C8 cycloalkyl, -CF3, -halo, CO2(R31), -CON(R31)(R32), -CO(R31), -(CH2)nN(R31)(CO(R33)), -(CH2)nN(R31)(S02(R33)), -CN, -CH2CF3 or -CH(CF3)2, or phenyl, and the saturated ring may be optionally substituted with 1, 2 or 3, -Cj-Cg alkyl, -C C6 alkoxy, -OH, -CH2OH or -(CH2)n-N(R31)(R32) or one oxo (=0);
where n is 0-3 and R^, R32, and Rjrø are the same or different and are selected from
-H.
CrC6 alkyl, phenyl optionally substituted with 1, 2, or 3 -halo, C^C alkyl,
CrC6 alkoxy, -CF3, -OH or -CN, or where R j and R32 taken together with the attached nitrogen to form a ring selected from -pyrrolidinyl, -piperidinyl, -4-morpholinyl, -4-thiomorpholinyl, -4- piperazinyl, -4-(l-C^-Cgalkyl)piperazinyl, or a member selected from the group consisting of: 1-cyclohexenyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-imidazolyl, 4-imidazolyl, 2-benzothiazolyl, 2-benzoxazolyl, 2-benzimidazolyl, 2-oxazolyl, 4-oxazolyl, 2-thiazolyl, 3-isoxazolyl, 5-isoxazolyl, 5-methyl-3-isoxazolyl, 5- phenyl-3-isoxazolyl, 4-thiazolyl, 3-methyl-2-pyrazinyl, 5-methyl-2-pyrazinyl, 6- methyl-2-pyrazinyl, 5-chloro-2-thienyl, 3-furyl, benzofuran-2-yl, benzothien-2- yl, 2flr-l-benzopyran-3-yl, 2,3-dihydrobenzopyran-5-yl, l-methylimidazol-2-yl, quinoxalin-2-yl, piperon-5-yl, 4,7-dichlorobenzoxazol-2-yl, 4,6-dimethyl- pyrimidin-2-yl, 4-methylpyrimidin-2-yl, 2,4-dimethylpyrimidin-6-yl, 2- methylpyrimidin-4-yl, 4-methylpyrimidin-6-yl, 6-chloropiperon-5-yl, 5- chloroimidazo[l,2-a]pyridin-2-yl, l-H-inden-3-yl, l-H-2-methyl-inden-2-yl, 3,4- dihydronaphth-1-yl, S-4-isopropenylcyclohexen-l-yl or 4-dihydronaphth-2-yl; where Rg3 is selected from the group consisting of -H, Cj-Cgβlkyl, C3- Cgcycloalkyl, phenyl (optionally substituted with 1, 2, or 3 -halo, Cj-Cg alkyl, Cj-Cg alkoxy, -CF3, -OH, -CN), or a five or six-membered unsaturated ring containing 0 or 1 oxygen, nitrogen or sulfur, where the unsaturated ring may be optionally substituted with -H, C^-Cg alkyl, CrC6 alkoxy, -OH, -CH2OH, or -(CH2)n-N(R31)(R32); where Rg and Rgg being the same or different are selected from -H, ^-Cg lkyl* allyl, or phenyl (optionally substituted with 1, 2, or 3
-halo, Cj-Cg alkyl, Cj-Cg alkoxy or -CF3), or taken together with the attached nitrogen to form a ring selected from -pyrrolidinyl, -piperidinyl, -4-morpholinyl, -4-thiomorpholinyl, -4-piperazinyl, ^-(l-Cj-CgalkyDpiperazinyl; R41 and R42, being the same or different, are selected from the group consisting of -H and Cj-C4 alkyl;
Rj is selected from the group consisting of -H, C^-Cg alkyl, -C3-C6 cycloalkyl, -CN, -C(O)NH2, -C(O)N(C1-C6alkyl)(C1-C6alkyl), -C02H, -C02(CrC6alkyl), -CH2OH, -CH2NH2 or -CF3; R13 is selected from the group consisting of -H, Cj-Cg alkyl or -CF3;
Y is selected from -S-, -S(O)-, -S(0)2, or -0-; R4 is selected from the group consisting of -H, -OH, halo or -NRjgRj where R15 is -H and R16 is -H, Cj-Cg alkyl, -NH2 or R15 and R16 taken together with the -N form 1-pyrrolidino, 4-morpholino or 1-piperidino;
R5 is selected from the group consisting of -H, -C2H4OH, -C2H4-0-TBDMS, halo, -C -Cg cycloalkyl, Cj-C alkoxy,
-CH2CH2C1 or C1-C4 alkyl, with the proviso that Rg is not isobutyl; or R4 and Rg are taken together to form a five or six-membered saturated or unsaturated ring which together with the pyrimidine ring form the group consisting of 7H-pyrrolo[2,3-d]pyrimidine, 5,6-dihydro-7H-pyrrolo[2,3-d] pyrimidine, furo[2,3- dlpyrimidine, 5,6-dihydro-furo[2,3-d] pyrimidine, thieno[2,3-d]pyrimidine, 5,6-dihydro- thieno[2,3-d] pyrimidine, lH-pyrazolo[3,4-d]pyrimidine, lH-purine, pyrimido[4,5- dlpyrimidine, pteridine, pyridol2,3-d]pyrimidine, or quinazoline, where the unsaturated ring may be optionally substituted with 1, 2 or 3, C-^-Cg alkyl, Cj-Cg alkoxy, -OH, -CH2OH, or -(CH2)n-N(R31)(R32), -C3-C8 cycloalkyl, -CF3, -halo, - C02(R31), -CON(R31)(R32), -CO(R31), -(CH2)nN(R31)(CO(R33)), -(CH^N R^)
(S02(R33)), and the saturated ring may be optionally substituted with 1, 2 or 3, -Cj- C6 alkyl, -CrCg alkoxy, -OH, -CH2OH, or -(CH2)n-N(R31)(R32) or one oxo (=0); and R6 is -S-C^g alkyl (preferably -S-CH3); pharmaceutically acceptable salts, hydrates, N-oxides and solvates thereof. An embodiment of the present invention are compounds of Formula I where
R12 and R1 are not both -H.
An embodiment of the present invention are 6-thioalkyl pyrimidine-thioalkyl and alklyether anti-AIDS compounds of Formula I where
R4 is selected from the group consisting of -H or -NR15R16 where R15 is -H and R16 is -H, Cj-Cg alkyl, -NH2 or R-^g and R^g taken together with the -N form 1-pyrrolidino, 4-morpholino or 1-piperidino; and R6 is -S-Cj.g alkyl (preferably -S-CH3).
The compounds of Formula I can be prepared in accordance with the procedures disclosed in WO 96/35678 as well as US Patent Application Serial No. 08/436,708; filed 8 May 1995, both of which are incorporated herein by reference. An embodiment of the present invention are compounds of Formula I where Y is -0-.
A preferred embodiment of the present invention are compounds of Formula I where s is 0 and Y is selected from the group consisting of -S-, -S(O)- or -S(0)2; more preferably Y is -S-.
A preferred embodiment of the present invention are compounds of Formula I where s is 0 and Y is selected from the group consisting of -S-, -S(O)- or -S(0)2 (more preferably Y is -S-); and with the proviso that R12 and R13 are not both -H.
R4 is preferably -NH2- m is preferably 0.
Rg is preferably -S-CH3.
R4j and R42 are preferably -H.
Rj2 s preferably -CH3.
Rj3 is preferably -H.
R is preferably selected from
Figure imgf000010_0001
more preferably a member selected from the group consisting of: 3-isoquinolinyl, 1-isoquinolinyl, 2-quinolinyl, 3-quinølinyl, 3-(5,6,7,8-tetrahydro)- isoquinolinyl, l-(5,6,7,8-tetrahydro)-isoquinolinyl, 2-(5,6,7,8-tetrahydro)-quinolinyl, 3- (5,6,7,8-tetrahydro)-quinolinyl, 3-(5,6-dihydro)-2H-2-pyrindinyl, l-(5,6-dihydro)-2H-2- pyrindinyl, 2-(5,6-dihydro)-lH-l-pyrindinyl, 3-(5,6-dihydro)-lH-l-pyrindinyl, 5- furo[2,3-c]pyridinyl, 6-furo[3,2-c]pyridinyl, 4-furo[3,2-c]pyridinyl, 7-furo[2,3- cjpyridinyl, 6-furo[2,3-b]pyridinyl, 5-furo[3,2-b]pyridinyl, 5-(2,3-dihydro)-furo[2,3- c]pyridinyl, 6-(2,3-dihydro)-furo[3,2-c]pyridinyl, 4-(2,3-dihydro)-furo[3,2-c]pyridinyl, 7-
(2,3-dihydro)-furo[2,3-c]pyridinyl, 6-(2,3-dihydro)-furo[2,3-b]pyridinyl, 5-(2,3-dihydro)- furo[3,2-b]pyridinyl, 6-(l,3-dihydro)-furo[3,4-c]pyridinyl) 4-(l,3-dihydro)-furo[3,4- cjpyridinyl, 2-(5,7-dihydro)-furo[3,4-b)pyridinyl, 6-(3,4-dihydro)-2H-pyrano[2,3- c]pyridinyl, 6-(3,4-dihydro)-lH-pjrτanol3,4-c]pyridinyl, 7-(3,4-dihydro)-lH-pyrano[4,3- clpyridinyl, 7-(3,4-dihydro)-2H-pyrano[3,2-clpyridinyl, 5-(3,4-dihydro)-2H-pyrano[3,2- cjpyridinyl, 5-(3,4-dihydro)-lH-pyrano[4,3-c]pyridinyl, 8-(3,4-dihydro)-lH-pyrano[3,4- clpyridinyl, 8-(3,4-dihydro)-2H-pyrano[2,3-clpyridinyl, 7-(3,4-dihydro)-2H-pyrano[2,3- blpyridinyl, 2-(5,6-dihydro)-lH-pyrano[3,4-b]pyridinyl, 2-(5,6-dihydro)-2H-pyrano[4,3- bjpyridinyl, 6-(3,4-dihydro)-2H-pyrano[3,2-b]pyridinyl, 5-lH-pyrrolo[2,3-c]pyridinyl, 6-lH-pyrrolo[3,2-c]pyridinyl, 4-lH-pyrrolo[3,2-c]pyridinyl, 7-lH-pyrrolo[2,3- cjpyridinyl, 6-lH-pyrrolo[2,3-blpyridinyl, 5-lH-pyrrolo[3,2-b]pyridinyl, 5-(2,3- dihydro)-lH-pyrrolo[2,3-c]pyridinyl, 6-(2,3-dihydro)-lH-pyrrolo[3,2-c]pyridinyl, 4-(2,3- dihydro)-lH-pyrrolo[3,2-c]pyridinyl, 7-(2,3-dihydro)-lH-pyrrolo[2,3-c]pyτidinyl, 6-(2,3- dihydro)-lH-pyrrolo[2,3-b]pyridinyl, 5-(2,3-dihydro)-lH-pyrrolo[3,2-b]pyridinyl, 6- (l,3-dihydro)-lH-pyrrolo[3,4-c]pyridinyl, 4-(l,3-dihydro)-lH-pyrrolo[3,4-c]pyridinyl, 2- (5,7-dihydro)-lH-pyrrolo[3,4-b]pyridinyl, 6-1,7-naphthyridinyl, 6-2,7-naphthyridinyl, 7-2,6-naphthyridinyl, 7-1,6-naphthyridinyl, 5-1,6-naphthyridinyl, 5-2,6- naphthyridinyl, 8-2,7-naphthyridinyl, 8-1,7-naphthyridinyl, 7-1,8-naphthyridinyl, 2- 1,7-naphthyridinyl, 2-1,6-naphthyridinyl, 6-1,5-naphthyridinyl, 6-(l,2,3,4- tetrahydro)-l,7-naphthyridinyl, 6-(l,2,3,4-tetrahydro)-2,7-naphthyridinyl, 7-( 1,2,3,4- tetrahydro)-2,6-naphthyridinyl, 7-(l,2,3,4-tetrahydro)-l,6-naphthyridinyl, 5-(l,2,3,4- tetrahydro)-l,6-naphthyridinyl, 5-(l,2,3,4-tetrahydro)-2,6-naphthyridinyl, 8-(l,2,3,4- tetrahydro)-2,7-naphthyridinyl, 8-(l,2,3,4-tetrahydro)-l,7-naphthyridinyl, 7-(l,2,3,4- tetrahydro)-l,8-naphthyridinyl, 2-(5,6,7,8-tetrahydro)-l,7-naphthyridinyl, 2-(5,6,7,8- tetrahydro)-l,6-naphthyridinyl, 6-( l,2,3,4-tetrahydro)-l,5-naphthyridinyl, 1-naphthyl, 2-naphthyl, 5-(l,2,3,4-tetrahydro)-naphthyl, 6-(l,2,3,4-tetrahydro)-naphthyl, 4-(2,3- dihydro)-lH-indenyl, 5-(2,3-dihydro)-lH-indenyl, 5-benzofuranyl, 4-benzofuranyl, 6- benzofuranyl, 7-benzofuranyl, 5-(2,3-dihydro)-benzofuranyl, 4-(2,3-dihydro)- benzofuranyl, 6-(2,3-dihydro)-benzofuranyl, 7-(2,3-dihydro)-benzofuranyl, 4-(l,3- dihydro)-isobenzofuran, 5-(l,3-dihydro)-isobenzofuran, 4-lH-indolyl, 5-lH-indolyl, 6- lH-indolyl, 7-lH-indolyl, 4-(2,3-dihydro)-lH-indolyl, 5-(2,3-dihydro)-lH-indolyl, 6- (2,3-dihydro)-lH-indolyl, 7-(2,3-dihydro)-lH-indolyl, 4-(l,3-dihydro)-lH-isoindolyl, 5- (l,3-dihydro)-lH-isoindolyl, 5-(3,4-dihydro)-lH-2-benzopyranyl, 6-(3,4-dihydro)-lH-2- benzopyranyl, 7-(3,4-dihydro)-lH-2-benzopyranyl, 8-(3,4-dihydro)- lH-2-benzopyranyl, 5-(3,4-dihydro)-2H-l-benzopyranyl, 6-(3,4-dihydro)-2H-l- benzopyranyl, 7-(3,4-dihydro)-2H-l-benzopyranyl, 8-(3,4-dihydro)-2H-l-benzopyranyl, 5-(l,2,3,4-tetrahydro)-isoquinolinyl, 6-(l,2,3,4-tetrahydro)-isoquinolinyl, 7-(l,2,3,4- tetrahydro)-isoquinolinyl, 8-(l,2,3,4-tetrahydro)-isoquinolinyl, 5-(l,2,3,4-tetrahydro)- quinolinyl, 6-(l,2,3,4-tetrahydro)-quinolinyl, 7-(l,2,3,4-tetrahydro)-quinolinyl, 8- (l,2,3,4-tetrahydro)-quinolinyl, 5-thieno[2,3-c]pyridinyl, 6-thieno[3,2-c]pyridinyl, 4- thieno[3,2-c]pyridinyl, 7-thieno[2,3-c]pyridinyl, 6-thieno[2,3-b]pyridinyl, 5-thieno[3,2- bjpyridinyl, 5-(2,3-dihydro)-thieno[2,3-c]pyridinyl, 6-(2,3-dihydro)-thieno[3,2- c]pyridinyl> 4-(2,3-dihydro)-thieno[3,2-c]pyridinyl, 7-(2,3-dihydro)-thieno[2,3- clpyridinyl, 6-(2,3-dihydro)-thieno[2,3-b]pyridinyl, 5-(2,3-dihydro)-thieno(3,2- blpyridinyl, 6-(l,3-dihydro)-thieno[3,4-c]pyridinyl, 4-(l,3-dihydro)-thieno[3,4- clpyridinyl, 2-(5,7-dihydro)-thieno[3,4-b]pyridinyl, 6-(3,4-dihydro)-2H-thiopyrano[2,3- clpyridinyl, 6-(3,4-dihydro)-lH-thiopyrano[3,4-c]pyridinyl, 7-(3,4-dihydro)-lH- thiopyrano[4,3-c]pyridinyl, 7-(3,4-dihydro)-2H-thiopyrano[3,2-c]pyridinyl, 5-(3,4- dihydro)-2H-thiopyrano[3,2-c]pyridinyl, 5-(3,4-dihydro)-lH-thiopyrano[4,3-c]pyridinyl, 8-(3,4-dihydro)-lH-thiopyrano[3,4-c]pyridinyl, 8-(3,4-dihydro)-2H-thiopyrano[2,3- yridinyl, 7-(3,4-dihydro)-2H-thiopyrano[2,3-b]pyridinyl, 2-(5,6-dihydro)-lH- thiopyrano[3,4-b]pyridinyl, 2-(5,6-dihydro)-2H-thiopyrano[4,3-b]pyridinyl, 6-(3,4- dihydro)-2H-thiopyranot3,2-b]pyridinyl, 5-benzo[b)thiophenyl, 4-benzo[b]thiophenyl, 6-benzo[b]thiophenyl, 7-benzo[b]thiophenyl, 5-(2,3-dihydro)-benzo[b]thiophenyl, 4- (2,3-dihydro)-benzo[b]thiophenyl, 6-(2,3-dihydro)-benzo[b]thiophenyl, 7-(2,3-dihydro)- benzo[b]thiophenyl, 4-(l,3-dihydro)-benzo[c]thiophenyl, 5-(l,3-dihydro)- benzo[c]thiophenyl, 5-(3,4-dihydro)-lH-2-benzothiopyranyl, 6-(3,4-dihydro)-lH-2- benzothiopyranyl, 7-(3,4-dihydro)-lH-2-benzothiopyranyl, 8-(3,4-dihydro)-lH-2- benzothiopyranyl, 5-(3,4-dihydro)-2H-l-benzothiopyranyl, 6-(3,4-dihydro)-2H-l- benzothiopyranyl, 7-(3,4-dihydro)-2H-l-benzothiopyranyl, or 8-(3,4-dihydro)-2H-l- benzothiopyranyl; wherein such member is optionally substituted as described above; most preferably a member selected from the group consisting of: 3-isoquinolinyl, 1-isoquinolinyl, 2-quinolinyl, 3-quinolinyl, 3-(5,6,7,8-tetrahydro)τ isoquinolinyl, l-(5,6,7,8-tetrahydro)-isoquinolinyl, 2-(5,6,7,8-tetrahydro)-quinolinyl, 3- (5,6,7,8-tetrahydro)-quinolinyl, 3-(5,6-dihydro)-2H-2-pyrindinyl, l-(5,6-dihydro)-2H-2- pyrindinyl, 2-(5,6-dihydro)-lH-l-pyrindinyl, 3-(5,6-dihydro)-lH-l-pyrindinyl, 5- furo[2,3-c]pyridinyl, 6-furo[3,2-c]pyridinyl, 4-furo[3,2-c]pyridinyl, 7-furo[2,3- c]pyridinyl, 6-furo[2,3-b]pyridinyl, 5-furo[3,2-b]pyridinyl, 5-(2,3-dihydro)-furo[2,3- clpyridinyl, 6-(2,3-dihydro)-furo[3,2-c]pyridinyl, 4-(2,3-dihydro)-furo[3,2-c]pyridinyl, 7-(2,3-dihydro)-furo[2,3-c]pyridinyl, 6-(2,3-dihydro)-furo[2,3-b]pyridinyl, 5-(2,3- dihydro)-furo[3,2-b]pyridinyl, 6-(l,3-dihydro)-furo[3,4-c]pyridinyl, 4-(l,3-dihydro)- furo[3,4-c]pyridinyl, 2-(5,7-dihydro)-furo[3,4-b]pyridinyl, 6-(3,4-dihydro)-2H- pyrano[2,3-c]pyridinyl, 6-(3,4-dihydro)-lH-pyrano[3,4-c]pyridinyl, 7-(3,4-dihydro)-lH- pyrano[4,3-c]pyridinyl, 7-(3,4-dihydro)-2H-pyrano[3,2-c]pyridinyl, 5-(3,4-dihydro)-2H- pyrano[3,2-c]pyridinyl, 5-(3,4-dihydro)-lH-pyrano[4,3-c]pyridinyl, 8-(3,4-dihydro)-lH- pyrano[3,4-c]pyridinyl, 8-(3,4-dihydro)-2H-pyrano[2,3-c]pyridinyl, 7-(3,4-dihydro)-2H- pyrano[2,3-b]pyridinyl, 2-(5,6-dihydro)-lH-pyrano[3,4-b]pyridinyl, 2-(5,6-dihydro)-2H- pyrano[4,3- b]pyridinyl, or 6-(3,4-dihydro)-2H-pyrano[3,2-b]pyridinyl; wherein such member is optionally substituted as described above. Illustrative Rj members include: phenyl optionally substituted with one, 2 or 3 Cj-C4 alkyl, C^-Cg alkoxy, halo, Cj- C3 alkylthio, trifluoromethyl, C2-Cg dialkylamino, or nitro; 2- or 3-pyridinyl optionally substituted with C-j-Cg alkyl, Cj-C alkenyl, Cj-C alkoxy, Cj-C alkylthio, -C3-Cg cycloalkyl, -CF3, -N02, -halo, -OH, -CN, phenyl, phenylthio, -styryl, -C02(R31), -CON(R31)(R32), -CO(R31), -(CH2)n-N(R31)(R32), -C(OH)(R31)(R33), -(CH2)nN(R31)(CO(R33)), -(CH2)nN(R31)(S02(R33)); naphthyl optionally substituted with one or 2 Cj-C4 alkyl, C-^-Cg alkoxy, halo, trifluoromethyl, C2-Cg dialkylamino, Cj-Cg alkylthio or nitro; -C≡CH; as well as 3-isoquinolinyl, 1-isoquinolinyl, 2- quinolinyl, 3-quinolinyl, 3-(5,6,7,8-tetrahydro)-isoquinolinyl, l-(5,6,7,8-tetrahydro)- isoquinolinyl, 2-(5,6,7,8-tetrahydro)-quinolinyl, 3-(5,6,7,8-tetrahydro)-quinolinyl, 3- (5,6-dihydro)-2H-2-pyrindinyl) l-(5,6-dihydro)-2H-2-pyrindinyl, 2-(5,6-dihydro)-lH-l- pyrindinyl, 3-(5,6-dihydro)-lH-l-pyrindinyl, 5-furo[2,3-c]pyridinyl, 6-furo[3,2- clpyridinyl, 4-furo[3,2-c]pyridinyl, 7-furo[2,3-c]pyridinyl, 6-furo[2,3-b]pyridinyl, 5- furo[3,2-b]pyridinyl, 5-(2,3-dihydro)-furo[2,3-c]pyridinyl, 6-(2,3-dihydro)-furo[3,2- c]pyridinyl, 4-(2,3-dihydro)-furo[3,2-c]pyridinyl, 7-(2,3-dihydro)-furo[2,3-c]pyridinyl, 6-(2,3-dihydro)-furo[2,3-b]pyridinyl, 5-(2,3-dihydro)-furo[3,2-b]pyridinyl, 6-(l,3- dihydro)-furo[3,4-c]pyridinyl, 4-(l,3-dihydro)-furo[3,4-c]pyridinyl, 2-(5,7-dihydro)- furo[3,4-b]pyridinyl, 6-(3,4-dihydro)-2H-pyrano[2,3-c]pyridinyl, 6-(3,4-dihydro)-lH- pyrano [3 ,4-c] pyridinyl, 7-(3 ,4-dihydro)- lH-pyrano [4,3-c] pyridinyl, 7-( 3 ,4-dihydro)-2H- pyrano[3,2-c]pyridinyl, 5-(3,4-dihydro)-2H-pyrano[3,2-c] pyridinyl, 5-(3,4-dihydro)-lH- pyrano[4,3-c]pyridinyl, 8-(3,4-dihydro)-lH-pyrano[3,4-c]pyridinyl, 8-(3,4-dihydro)-2H- pyrano[2,3-c] pyridinyl, 7-(3,4-dihydro)-2H-pyrano[2,3-b] pyridinyl, 2-(5,6-dihydro)-lH- pyrano[3,4-b]pyridinyl, 2-(5,6-dihydro)-2H-pyrano[4,3-b]pyridinyl, 6-(3,4-dihydro)-2H- pyrano[3,2-b]pyridinyl, 5-lH-pyrrolo[2,3-Cjlpyridinyl, 6-lH-pyrrolo[3,2-c]pyridinyl. 4- lH-pyrrolo[3,2-c]pyridinyl, 7-lH-pyrrolo[2,3-c]pyridinyl, 6-lH-pyrrolo[2,3-b]pyridinyl, 5-lH-pyrrolo[3,2-b]pyridinyl, 5-(2,3-dihydro)-lH-pyrrolo[2,3-c]pyridinyl, 6-(2,3- dihydro)-lH-pyrrolo[3,2-c]pyridinyl, 4-(2,3-dihydro)-lH-pyrrolo[3,2-c]pyridinyl, 7-(2,3- dihydro)-lH-pyrrolo [2,3-c] pyridinyl, 6-(2,3-dihydro)-lH-pyrrolo [2,3-b] pyridinyl, 5-(2,3- dihydro)-lH-pyrrolo[3,2-b]pyridinyl, 6-(l,3-dihydro)-lH-pyrrolo[3,4-c]pyridinyl, 4-(l,3- dihydro)- lH-pyrrolo [3,4-c] pyridinyl, 2-(5, 7-dihydro)-lH-pyrrolo [3 ,4-b] pyridinyl, 6-1,7- naphthyridinyl, 6-2,7-naphthyridinyl, 7-2,6-naphthyridinyl, 7-1,6-naphthyridinyl, 5- 1,6-naphthyridinyl, 5-2,6-naphthyridinyl, 8-2,7-naphthyridinyl, 8-1,7-naphthyridinyl, 7-1,8-naphthyridinyl, 2-1,7-naphthyridinyl, 2-1,6-naphthyridinyl, 6-1,5- naphthyridinyl, 6-(l,2,3,4-tetrahydro)-l,7-naphthyridinyl, 6-(l,2,3,4-tetrahydro)-2,7- naphthyridinyl, 7-(l,2,3,4-tetrahydro)-2,6-naphthyridinyl, 7-(l,2,3,4-tetrahydro)-l,6- naphthyridinyl, 5-(l,2,3,4-tetrahydro)-1.6-naphthyridinyl, 5-(l,2,3,4-tetrahydro)-2,6- naphthyridinyl, 8-(l,2,3,4-tetrahydro)-2,7-naphthyridinyl, 8-(l,2,3,4-tetrahydro)-l,7- naphthyridinyl, 7-(l,2,3,4-tetrahydro)-l,8-naphthyridinyl, 2-(5,6,7,8-tetrahydro)-l,7- naphthyridinyl, 2-(5,6,7,8-tetrahydro)-l,6-naphthyridinyl, 6-(l,2,3,4-tetrahydro)-l,5- naphthyridinyl, 1-naphthyl, 2-naphthyl, 5-(l,2,3,4-tetrahydro)-naphthyl, 6-(l,2,3,4- tetrahydro)-naphthyl, 4-(2,3-dihydro)-lH-indenyl, 5-(2,3-dihydro)-lH-indenyl, 5- benzofuranyl, 4-benzofuranyl, 6-benzofuranyl, 7-benzofuranyl, 5-(2,3-dihydro)- benzofuranyl, 4-(2,3-dihydro)-benzofuranyl, 6-(2,3-dihydro)-benzofuranyl, 7-(2,3- dihydro)-benzofuranyl, 4-( l,3-dihydro)-isobenzofuran, 5-( l,3-dihydro)-isobenzofuran, 4-lH-indolyl, 5-lH-indolyl, 6-lH-indolyl, 7-lH-indolyl, 4-(2,3-dihydro)-lH-indolyl, 5- (2,3-dihydro)-lH-indolyl, 6-(2,3-dihydro)-lH-indolyl, 7-(2,3-dihydro)-lH-indolyl, 4- (l,3-dihydro)-lH-isoindolyl, 5-(l,3-dihydro)-lH-isoindolyl, 5-(3,4-dihydro)-lH-2- benzopyranyl, 6-(3,4-dihydro)-lH-2-benzopyranyl, 7-(3,4-dihydro)-lH-2-benzopyranyl, 8-(3,4-dihydro)-lH-2-benzopyranyl, 5-(3,4-dihydro)-2H-l-benzopyranyl, 6-(3,4- dihydro)-2H-l-benzopyranyl, 7-(3,4-dihydro)-2H-l-benzopyranyl, 8-(3,4-dihydro)-2H- 1-benzopyranyl, 5-(l,2,3,4-tetrahydro)-isoquinolinyl, 6-(l,2,3,4-tetrahydro)- isoquinolinyl, 7-(l,2,3,4-tetrahydro)-isoquinolinyl, 8-(l,2,3,4-tetrahydro)-isoquinolinyl, 5-(l,2,3,4-tetrahydro)-quinolinyl, 6-(l,2,3,4-tetrahydro)-quinolinyl, 7-( 1,2,3,4- tetrahydro)-quinolinyl, 8-(l,2,3,4-tetrahydro)-quinolinyl, 5-thieno[2,3-c]pyridinyl, 6- thieno[3,2-c]pyridinyl, 4-thieno[3,2-c]pyridinyl, 7-thieno[2,3-c] pyridinyl, 6-thieno[2,3- blpyridinyl, 5-thieno [3, 2-b] pyridinyl, 5-(2,3-dihydro)-thieno[2,3-c]pyridinyl, 6-(2,3- dihydro)-thieno[3,2-c]pyridinyl, 4-(2,3-dihydro)-thieno[3,2-c]pyridinyl, 7-(2,3-dihydro)- thieno[2,3-c]pyridinyl, 6-(2,3-dihydro)-thieno[2,3-b]pyridinyl, 5-(2,3-dihydro)- thieno[3,2-b]pyridinyl, 6-(l,3-dihydro)-thieno[3,4-c]pyridinyl, 4-(l,3-dihydro)- thieno[3,4-c]pyridinyl, 2-(5,7-dihydro)-thieno[3,4-b]pyridinyl, 6-(3,4-dihydro)-2H- thiopyrano[2,3-c]pyridinyl, 6-(3,4-dihydro)-lH-thiopjrrano[3,4-c]pyridinyl, 7-(3,4- dihydro)-lH-thiopyrano[4,3-c]pyridinyl, 7-(3,4-dihydro)-2H-thiopyrano[3,2-c]pyridinyl, 5-(3,4-dihydro)-2H-thiopyranot3,2-c]pyridinyl, 5-(3,4-dihydro)-lH-thiopyrano[4,3- clpyridinyl, 8-(3,4-dihydro)-lH-thiopyrano[3,4-c]pyridinyl, 8-(3,4-dihydro)-2H- thiopyrano[2,3-c]pyridinyl, 7-(3,4-dihydro)-2H-thiopyrano[2,3-b]pyridinyl, 2-(5,6- dihydro)-lH-thiopyrano[3,4-b]pyridinyl, 2-(5,6-dihydro)-2H-thiopyrano[4,3- bjpyridinyl, 6-(3,4-dihydro)-2H-thiopyrano[3,2-b]pyridinyl, 5-benzo[b]thiophenyl, 4- benzo[b]thiophenyl, 6-benzo[b]thiophenyl, 7-benzo[b]thiophenyl, 5-(2,3-dihydro)- benzo[b]thiophenyl, 4-(2,3-dihydro)-benzo[b]thiophenyl, 6-(2,3-dihydro)- benzo[b]thiophenyl, 7-(2,3-dihydro)-benzo[b]thiophenyl, 4-(l,3-dihydro)- benzo[c]thiophenyl, 5-(l,3-dihydro)-benzo[c]thiophenyl, 5-(3,4-dihydro)-lH-2- benzothiopyranyl, 6-(3,4-dihydro)-lH-2-benzothiopyranyl, 7-(3,4-dihydro)-lH-2- benzothiopyranyl, 8-(3,4-dihydro)-lH-2-benzothiopyranyl, 5-(3,4-dihydro)-2H-l- benzothiopyranyl, 6-(3,4-dihydro)-2H-l-benzothiopyranyl, 7-(3,4-dihydro)-2H-l- benzothiopyranyl, 8-(3,4-dihydro)-2H-l-benzothiopyranyl; or a member selected from the group consisting of: 4-quinolinyl, 5-quinolinyl, 6-quinolinyl, 7-quinolinyl, 8-quinolinyl, 1-cyclohexenyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-imidazolyl, 4-imidazolyl, 2-benzothiazolyl, 2-benzoxazolyl, 2- benzimidazolyl, 2-oxazolyl, 4-oxazolyl, 2-thiazolyl, 3-isoxazolyl, 5-isoxazolyl, 5- methyl-3-isoxazolyl, 5-phenyl-3-isoxazolyl, 4-thiazolyl, 3-methyl-2-pyrazinyl, 5- methyl-2-pyrazinyl, 6-methyl-2-pyrazinyl, 5-chloro-2-thienyl, 3-furyl, benzofuran-2-yl, benzothien-2-yl, 2H-l-benzopyran-3-yl, 2,3-dihydrobenzopyran-5-yl, 2,3- dihydrobenzofuran-2-yl, l-methylimidazol-2-yl, quinoxalin-2-yl, isoquinolin-3-yl, piperon-5-yl, 4,7-dichlorobenzoxazol-2-yl, 4,6-dimethylpyrimidin-2-yl, 4- methylpyrimidin-2-yl, 2,4-dimethylpyrimidin-6-yl, 2-methylpyrimidin-4-yl, 4- methylpyrimidin-6-yl, 6-chloropiperon-5-yl, 5-chloroimidazo[l,2-a]pyridin-2-yl, 1-H- inden-3-yl, l-H-2-methyl-inden-2-yl, 3,4-dihydronaphth-l-yl, S-4-isopropenyl- cylcohexen-1-yl and 4-dihydronaphth-2-yl. Preferred thioalkyl-substituted pyrimidine-2-thioalkyl and alkylether anti-
AIDS compounds of Formula I include compounds where Y is S, and m is 0. Additional preferred thioalkyl substituted pyrimidine-2-thioalkyl and alkylether anti-AIDS compounds of Formula I include compounds where Y is S, m is 0, R12 is CH3 and R13 is -H. Additional preferred thio-substituted pyrimidine-2-thioalkyl and alkylether anti-AIDS compounds of Formula I include compounds where Y is S, m is 0, R12 is CH3, R13 is -H, R4 is NH2, R5 is -H and Rg is -S-CH3.
More preferred thioalkyl substituted pyrimidine-2-thioalkyl and alkylether anti-AIDS compounds of Formula I include compounds where Y is S, m is 0, s is 0, R12 is CH3, R13 is -H, R4 is NH, Rg is -H, Rg is -S-CH3, and Rj is selected from the group consisting of
Figure imgf000015_0001
Most preferred thioalkyl substituted pyrimidine-2-thioalkyl and alkylether compounds of Formula I include compounds where Y is S, m is 0, s is 0, Rj is CH3, R1 is -H, R4 is NH2, Rg is -H, Rg is -S-CH3, and Rj is selected from the group consisting of 3-isoquinolinyl, 1-isoquinolinyl, 2-quinolinyl, 3-quinolinyl, 3- wυ yy/ IKMM PCT/US98/18507
(5,6,7,8-tetrahydro)-isoquinolinyl, l-(5,6,7,8-tetrahydro)-isoquinolinyl, 2-(5,6,7,8- tetrahydro)-quinolinyl, 3-(5,6,7,8-tetrahydro)-quinolinyl, 3-(5,6-dihydro)-2H-2- pyrindinyl, l-(5,6-dihydro)-2H-2-pyrindinyl, 2-(5,6-dihydro)-lH-l-pyrindinyl, 3-(5,6- dihydro)-lH-l-pyrindinyl, 5-furo[2,3-c]pyridinyl, 6-furo[3,2-c]pyridinyl, 4-furo[3,2- clpyridinyl, 7-furo[2,3-clpyridinyl, 6-furo[2,3-b]pyridinyl, 5-furo[3,2-b] pyridinyl, 5- (2,3-dihydro)-furo[2,3-clpyridinyl, 6-(2,3-dihydro)-furo[3,2-clpyridinyl, 4-(2,3-dihydro)- furol3,2-c]pyridinyl, 7-(2,3-dihydro)-furo[2,3-clpyridinyl, 6-(2,3-dihydro)-furo[2,3- blpyridinyl, 5-(2,3-dihydro)-furo[3,2-b]pyridinyl, 6-(l,3-dihydro)-furo[3,4-c]pyridinyl, 4-(l,3-dihydro)-furo[3,4-c]pyridinyl, 2-(5,7-dihydro)-furo[3,4-b]pyridinyl, 6-(3,4- dihydro)-2H-pyranol2,3-clpyridinyl, 6-(3,4-dihydro)-lH-pyrano[3,4-c]pyridinyl, 7-(3,4- dihydro)-lH-pyrano[4,3-clpyridinyl, 7-(3,4-dihydro)-2H-pyrano.3,2-c]pyridinyl, 5-(3,4- dihydro)-2H-pyrano[3,2-c]pyridinyl, 5-(3,4-dihydro)-lH-pyrano[4,3-clpyridinyl, 8-(3,4- dihydro)-lH-pyrano [3, 4-cl pyridinyl, 8-(3,4-dihydro)-2H-pyrano[2,3-c]pyridinyl, 7-(3,4- dihydro)-2H-pyrano[2,3-blpyridinyl, 2-(5,6-dihydro)-lH-pyrano[3,4-blpyridinyl, 2-(5,6- dihydro)-2H-pyrano[4,3-blρyridinyl, 6-(3,4-dihydro)-2H-pyrano[3,2-b]pyridinyl, 5-1H- pyrrolo[2,3-c]pyridinyl, 6-lH-pyrrolo[3,2-c]pyridinyl, 4-lH-pyrrolo[3,2-clpyridinyl, 7- lH-pyrrolo[2,3-c]pyridinyl, 6-lH-pyrrolo[2,3-blpyridinyl, 5-lH-pyrrolo[3,2-blpyridinyl, 5-(2,3-dihydro)-lH-pyrrolol2,3-clpyridinyl, 6-(2,3-dihydro)-lH-pyrrolo[3,2-clpyridinyl, 4-(2,3-dihydro)-lH-pyrrolol3,2-clpyridinyl, 7-(2,3-dihydro)-lH-pyrrolo[2,3-clpyridinyl, 6-(2,3-dihydro)-lH-pyrrolo[2,3-b]pyridinyl, 5-(2,3-dihydro)-lH-pyrrolo[3,2-blρyridinyl, 6-(l,3-dihydro)-lH-pyrrolo[3,4-c]pyridinyl, 4-(l,3-dihydro)-lH-pyrrolo[3,4-c]pyridinyl, 2-(5,7-dihydro)-lH-pyrrolo[3,4-b]pyridinyl, 6-1,7-naphthyridinyl, 6-2,7- naphthyridinyl, 7-2,6-naphthyridinyl, 7-1,6-naphthyridinyl, 5-1,6-naphthyridinyl, 5- 2,6-naphthyridinyl, 8-2,7-naphthyτidinyl, 8-1,7-naphthyridinyl, 7-1,8-naphthjτidinyl, 2-1,7-naphthyridinyl, 2-1,6-naphthyridinyl, 6-1,5-naphthyridinyl, 6-(l,2,3,4- tetrahydro)-l,7-naphthyridinyl, 6-(l,2,3,4-tetrahydro)-2,7-naphthyridinyl, 7-( 1,2,3,4- tetrahydro)-2,6-naphthyridinyl, 7-(l,2,3,4-tetrahydro)-l,6-naphthyridinyl, 5-(l,2,3,4- tetrahydro)-l,6-naphthyridinyl, 5-(l,2,3,4-tetrahydro)-2,6-naphthyridinyl, 8-(l,2,3,4- tetrahydro)-2,7-naphthyridinyl, 8-(l,2,3,4-tetrahydro)-l,7-naphthyridinyl, 7-(l,2,3,4- tetrahydro)-l,8-naphthyridinyl, 2-(5,6,7,8-tetrahydro)-l,7-naphthyridinyl, 2-(5,6,7,8- tetrahydro)-l,6-naphthyridinyl, 6-(l,2,3,4-tetrahydro)-l,5-naphthyridinyl, 1-naphthyl, 2-naphthyl, 5-(l,2>3,4-tetrahydro)-naphthyl, 6-(l,2,3,4-tetrahydro)-naphthyl, 4-(2,3- dihydro)-lH-indenyl, 5-(2,3-dihydro)-lH-indenyl, 5-benzofuranyl, 4-benzofuranyl, 6- benzofuranyl, 7-benzofuranyl, 5-(2,3-dihydro)-benzofuranyl, 4-(2,3-dihydro)- benzofuranyl, 6-(2,3-dihydro)-benzofuranyl, 7-(2,3-dihydro)-benzofuranyl, 4-(l,3- dihydro sobenzofuran, 5-(l,3-dihydro)-isobenzofuran, 4-lH-indolyl, 5-lH-indolyl, 6- lH-indolyl, 7-lH-indolyl, 4-(2,3-dihydro)-lH-indolyl, 5-(2,3-dihydro)-lH-indolyl, 6- (2,3-dihydro)-lH-indolyl, 7-(2,3-dihydro)-lH-indolyl, 4-(l,3-dihydro)-lH-isoindolyl, 5- (l,3-dihydro)-lH-isoindolyl, 5-(3,4-dihydro)-lH-2-benzopyranyl, 6-(3,4-dihydro)-lH-2- benzopyranyl, 7-(3,4-dihydro)-lH-2-benzopyranyl, 8-(3,4-dihydro)-lH-2-benzopyranyl, 5-(3,4-dihydro)-2H-l-benzopyranyl, 6-(3,4-dihydro)-2H-l-benzopyranyl, 7-(3,4- dihydro)-2H-l-benzopyranyl, 8-(3,4-dihydro)-2H-l-benzopyranyl, 5-(l,2,3,4- tetrahydro)-isoquinolinyl, 6-(l,2,3,4-tetrahydro)-isoquinolinyl, 7-( 1,2,3, 4-tetrahydro)- isoquinolinyl, 8-(l,2,3,4-tetrahydro)-isoquinolinyl, 5-(l,2,3,4-tetrahydro)-quinolinyl, 6- (l,2,3,4-tetrahydro)-quinolinyl, 7-(l,2,3,4-tetrahydro)-quinolinyl, 8-(l,2,3,4- tetrahydro)-quinolinyl,5-thieno[2,3-clpyridinyl, 6-thieno[3,2-c]pyridinyl, 4-thieno[3,2- clpyridinyl, 7-thieno[2,3-c]pyridinyl, 6-thieno[2,3-b]pyridinyl, 5-thieno[3,2- blpyridinyl, 5-(2,3-dihydro)-thieno[2,3-c]pyridinyl, 6-(2,3-dihydro)-thieno[3,2- clpyridinyl, 4-(2,3-dihydro)-thieno[3,2-clpyridinyl, 7-(2,3-dihydro)-thieno[2,3- φyridinyl, 6-(2,3-dihydro)-thieno[2,3-blpyridinyl, 5-(2,3-dihydro)-thieno[3,2- blpyridinyl, 6-(l,3-dihydro)-thieno[3,4-c]pyridinyl, 4-(l,3-dihydro)-thieno[3,4- clpyridinyl, 2-(5,7-dihydro)-thieno[3,4-bJpyridinyl, 6-(3,4-dihydro)-2H-thiopyrano[2,3- clpyridinyl, 6-(3,4-dihydro)-lH-thiopyrano[3,4-c]pyridinyl, 7-(3,4-dihydro)-lH- thiopyrano[4,3-c]pyridinyl, 7-(3,4-dihydro)-2H-thiopyrano[3,2-c]pyridinyl, 5-(3,4- dihydro)-2H-thiopyrano[3,2-clpyridinyl, 5-(3,4-dihydro)-lH-thiopyrano[4,3-c]pyridinyl, 8-(3,4-dihydro)-lH-thiopyrano[3,4-c]pyridinyl, 8-(3,4-dihydro)-2H-thiopyrano[2,3- cjpyridinyl, 7-(3,4-dihydro)-2H-thiopyrano[2,3-b]pyridinyl, 2-(5,6-dihydro)-lH- thiopyrano[3,4-b]pyridinyl, 2-(5,6-dihydro)-2H-thiopyrano[4,3-b]pyridinyl, 6-(3,4- dihydro)-2H-thiopyrano[3,2-b]pyridinyl, 5-benzo[b]thiophenyl, 4-benzo[blthiophenyl, 6-benzo[b]thiophenyl, 7-benzo[b]thiophenyl, 5-(2,3-dihydro)-benzo[b]thiophenyl, 4- (2,3-dihydro)-benzo[b]thiophenyl, 6-(2,3-dihydro)-benzo[blthiophenyl, 7-(2,3-dihydro)- benzo[b]thiophenyl, 4-(l,3-dihydro)-benzo[c]thiophenyl, 5-(l,3-dihydro)- benzo[c]thiophenyl, 5-(3,4-dihydro)-lH-2-benzothiopyranyl, 6-(3,4-dihydro)-lH-2- benzothiopyranyl, 7-(3,4-dihydro)-lH-2-benzothiopyranyl, 8-(3,4-dihydro)-lH-2- benzothiopyranyl, 5-(3,4-dihydro)-2H-l-benzothiopyranyl, 6-(3,4-dihydro)-2H- 1- benzothiopyranyl, 7-(3,4-dihydro)-2H-l-benzothiopyranyl, 8-(3,4-dihydro)-2H-l- benzothiopyranyl; most preferably a member selected from the group consisting of: 3-isoquinolinyl, 1-isoquinolinyl, 2-quinolinyl, 3-quinolinyl, 3-(5,6,7,8-tetrahydro)- isoq inolinyl, l-(5,6,7,8-tetrahydro)-isoquinolinyl, 2-(5,6,7,8-tetrahydro)-quinolinyl, 3- (5,6,7,8-tetrahydro)-quinolinyl, 3-(5,6-dihydro)-2H-2-pyrindinyl, l-(5,6-dihydro)-2H-2- pyrindinyl, 2-(5,6-dihydro)-lH-l-pyrindinyl, 3-(5,6-dihydro)-lH-l-pyrindinyl, 5- furo[2,3-c]pyridinyl, 6-furo [3, 2-c] pyridinyl, 4-furo[3,2-clpyridinyl, 7-furo[2,3- clpyridinyl, 6-furo[2,3-b] pyridinyl, 5-furo[3,2-b]pyridinyl, 5-(2,3-dihydro)-furo[2,3- clpyridinyl, 6-(2,3-dihydro)-furo[3,2-c]pyridinyl, 4-(2,3-dihydro)-furo[3,2-c]pyridinyl, 7-(2,3-dihydro)-furo[2,3-clpyridinyl, 6-(2,3-dihydro)-furo[2,3-bl pyridinyl, 5-(2,3- dihydro)-furo[3,2-b]pyridinyl, 6-(l,3-dihydro)-furo[3,4-clpyridinyl, 4-(l,3-dihydro)- furo[3,4-clpyridinyl, 2-(5,7-dihydro)-furo[3,4-b]pyridinyl, 6-(3,4-dihydro)-2H- pyrano[2,3-c]pyridinyl, 6-(3,4-dihydro)-lH-pyrano[3,4-clpyridinyl, 7-(3,4-dihydro)-lH- pyrano[4,3-c]pyridinyl, 7-(3,4-dihydro)-2H-pyrano[3,2-c]pyridinyl, 5-(3,4-dihydro)-2H- pyrano[3,2-c]pyridinyl, 5-(3,4-dihydro)-lH-pyrano[4,3-clpyridinyl, 8-(3,4-dihydro)-lH- pyrano[3,4-c]pyridinyl, 8-(3,4-dihydro)-2H-pyrano[2,3-c]pyridinyl, 7-(3,4-dihydro)-2H- pyrano[2,3-b]pyridinyl, 2-(5,6-dihydro)-lH-pyrano[3,4-b]pyridinyl, 2-(5,6-dihydro)-2H- pyrano[4,3-b]pyridinyl, 6-(3,4-dihydro)-2H-pyrano[3,2-b]pyridinyl.
The 6-thioalkyl pyrimidine-2-thioalkyl compounds of Formula I are generally and most often prepared by contacting a 6-chloro pyrimidine-2-thioalkyl compound of Formula I with an appropriate alkyl thiolate, e.g. sodium thiomethoxide, sodium thioethoxide, etc. (Chart A)
Alternatively, the 6-thioalkyl pyrimidine 2-thioalkyl compounds of Formula I are prepared by contacting a 6-thioalkyl-2-thiopyrimidine with an appropriate alkylating agent, e.g. mesylate or halide. The corresponding 6-thioalkyl-2- thiopyrimidine is prepared by, for example, by reacting 4-amino-6-chloro-2-(4- methoxybenzyDthiopyrimidine with an appropriate alkyl thiolate followed by deprotection with an appropriate reagent such as methane sulfonic acid. (Chart B) When R12 an<^ R13 are different, the compounds of Formula I are drawn as the racemic mixture and include the R and S isomers, which can be resolved from the racemic mixture by HPLC using a chiral column, such as Chiralcel OD-H, eluting with an appropriate solvent mixture, such as isopropanol/hexane. The R and S isomers of Formula I (when R12 and R13 are different) can be prepared from an appropriate chiral halide (or mesylate) II (see Chart B). The appropriate chiral halide (or mesylate) II is prepared from a chiral alcohol IV. The appropriate chiral alcohol IV can be prepared from the appropriate ketone V using a chiral reducing agent, such as (+) or (-)-diisopinocampheylchloroborane or other chiral reducing agents known in the art. The appropriate chiral alcohol IV is also obtained from the resolution of the racemic alcohol VII via the enzymatic hydrolysis of the appropriate racemic acetate VI with the appropriate enzyme, such as PS-30 amano lipase or L1754 Type VII from candidae cylindracea or other enzymes known in the art. The appropriate chiral alcohol IV is also obtained from the resolution of the racemic alcohol VII via the enzymatic esterification (such as acetylation or butyration) of the racemic alcohol VII (to give chiral VIII) using the appropriate enzyme, such as porcine pancreatic lipase type II, or other enzymes known in the art.
The 6-thioalkyl substituted pyrimidine-2-thioalkyl and alkylether compounds of Formula I include the compounds of EXAMPLES 1-304. Preferred are the anti- AIDS compounds of EXAMPLES 230, 231, 233, 234, 237, 238, 239, 240, 241, 242, 243, 246, 247, 248, 249, 250, 251, 252, 256, 269, 270, 271, 272, 273, 277, 194, 199, 203, 207, 282, 283, 284, 285, 286, 287, 289, 290, 297, 1 and preferrably 237, 238, 239, 246, 289, 290, 297, 1 and more preferably 290, 297, 1 and salts thereof (e.g. 302, 306 and 301).
The pyrimidine-thioalkyl and alkylether compounds of Formula I form acid addition salts; such as mesylate, hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, acetate, propionate, lactate, maleate, malate, succinate, tartrate, and the like. Some of the variable substituents are acids and as such form base addition salts when reacted with bases of sufficient strength. The pharmaceutically acceptable salts include both inorganic and organic bases. The preferred pharmaceutically acceptable salts include salts of the following bases, for example, hydroxide, ammonia, tromethamine (THAM), 2-amino-2-(hydroxymethyl)-l,3-propanediol. Suitable cations include, for example, sodium, potassium, calcium and magnesium. The pyrimidine-thioalkyl and alkylether anti-AIDS compounds of Formula I are useful as inhibitors of viral reverse transcriptase, an enzyme necessary for human immunodeficiency virus replication and therefore would be useful in the treatment of such diseases as AIDS.
The term human retrovirus (HRV) indicates human immunodeficiency virus type I, or strains thereof apparent to one skilled in the art, which belong to the same viral families and which create similar physiological effects in humans as various human retroviruses.
Patients to be treated would include those individuals (1) infected with one or more than one strain of a human retrovirus as determined by the presence of either measurable viral antibody or antigen in the serum and (2) having either a symptomatic AIDS defining infection such as (a) disseminated histoplasmosis, (b) isopsoriasis, (c) bronchial and pulmonary candidiasis including pneumocystic pneumonia (d) non-Hodgkin's lymphoma or (e) Kaposi's sarcoma and being less than sixty years old; or having an absolute CD4 lymphocyte count of less than 200/mm in the peripheral blood.
The compounds of Formula I can be given orally. Suitable dosage forms include tablets, capsules, suspensions, solutions and elixirs. An effective amount is from about 0.1 to about 500 mg/kg/day. A typical unit dose for a 70 kg human would be from about 10 mg to about 2000 mg, preferably about 100 mg to about 1000 mg taken one to six times per day. The exact dosage and frequency of administration depends on the particular compound of Formula I used, the particular condition being treated, the severity of the condition being treated, the age, weight, general physical condition of the particular patient, other medication the individual may be taking as is well known to those skilled in the art and can be more accurately determined by measuring the blood level or concentration of the compounds of Formula I in the patient's blood and/or the patient's response to the particular condition being treated.
Patients who are HrV positive but asymptomatic would typically be treated with lower oral doses (about 0.2 to about 100 mg/kg day. ARC (AIDS-related complex) and AIDS patients would typically be treated with higher oral doses (about 1 to about 500 mg/kg/day).
The pyrimidine-thioalkyl and alkylether anti-AIDS compounds of Formula I of this invention can be used in conjunction with (or sequentially with) other antiviral agents such as AZT, ddl, ddC, 3TC, d4T, with non-nucleoside anti-AIDS agents such as those disclosed in Serial No. 08/400,095 Case 4788.1 CP, filed March 7, 1995, International Publication No. WO91/09849, published July 11, 1991, and International Publication No. WO93/01181, published January 21, 1993, and with protease inhibitors.
The utility of the pyrimidine-thioalkyl and alkylether anti-AIDS compounds of Formula I of this invention can be determined by their ability to inhibit viral reverse transcriptase, an enzyme essential for human immunodeficiency virus replication. This enzyme has characteristics which differentiate it from other known cellular polymerases and it is a unique enzyme which is not found in uninfected cells. Viral reverse transcriptase (Wild Type) is found in extracts from bacterial clones prepared according to the procedure described in AIDS Virus Reverse Transcriptase defined by high level expression in Escherichia coli, EMBO J. 6:3133- 3137 (1987). P236L viral reverse transcriptase is obtained by PNAS 90: 4713-4717 (1993). Inhibition of this enzyme is determined in a cell free assay which measures the level of radioactive precursors incorporated into DNA.
Assessment of the antiviral activities of the Compounds 1 and 290 versus the panel of viruses used in these studies was carried out in MT4 cells. Cells were batch infected with the appropriate virus stock at a multiplicity of infection of 0.001- 0.005 TCIDgQ per cell for 2 hours at 37°C. The cells were washed, resuspended in RPMI FBS and plated in 24 well dishes at a final concentration of 1.5 x 10 cells/ml to which were added 2X drug treatments prepared in RPMI/FBS. All treatment concentrations were tested in duplicate. The final DMSO concentration for all treatments or vehicle control cultures was 0.1%. At four days post-infection culture fluid samples were collected for HIV-1 p24 core antigen quantitation to determine antiviral effects. Linear regression analysis was used to calculate the drug concentration necessary to inhibit 90% (inhibitory concentration 90, ICg0) of non- drug treated p24 antigen production.
Figure imgf000021_0001
DEFINITIONS AND CONVENTIONS
The definitions and explanations below are for the terms as used throughout this entire document including both the specification and the claims.
I. CONVENTIONS FOR FORMULAS AND DEFINITIONS OF VARIABLES The chemical formulas representing various compounds or molecular frag- ments in the specification and claims may contain variable substituents in addition to expressly defined structural features. These variable substituents are identified by a letter or a letter followed by a numerical subscript, for example, "Zj" or "Rj" where "i" is an integer. These variable substituents are either monovalent or bivalent, that is, they represent a group attached to the formula by one or two chemical bonds. For example, a group Zj would represent a bivalent variable if attached to the formula CH3-C(=Zj)H. Groups Rj and Rj would represent monovalent variable substituents if attached to the formula CH3-CH2-C(Rj)(R)H. When chemical formulas are drawn in a linear fashion, such as those above, variable substituents contained in parentheses are bonded to the atom immediately to the left of the variable substituent enclosed in parenthesis. When two or more consecutive variable substituents are enclosed in parentheses, each of the consecutive variable substituents is bonded to the immediately preceding atom to the left which is not enclosed in parentheses. Thus, in the formula above, both R- and R: are bonded to the preceding carbon atom.
Chemical formulas or portions thereof drawn in a linear fashion represent atoms in a linear chain. The symbol "-" in general represents a bond between two atoms in the chain. Thus CH3-0-CH2-CH(Rj)-CH3 represents a 2-substituted-l- methoxypropane compound. In a similar fashion, the symbol "=" represents a double bond, e.g., CH2=C(Ri)-0-CH3, and the symbol "= ' represents a triple bond, e.g., HCHC-CH(R-)-CH2-CH3. Carbonyl groups are represented in either one of two ways: -CO- or -C(=0)-, with the former being preferred for simplicity.
Chemical formulas of cyclic (ring) compounds or molecular fragments can be represented in a linear fashion. Thus, the compound 4-chloro-2-methylpyridine can be represented in linear fashion by N*=C(CH3)-CH=CC1-CH=C*H with the convention that the atoms marked with an asterisk (*) are bonded to each other resulting in the formation of a ring. Likewise, the cyclic molecular fragment, 4- (ethyl)- 1-piperazinyl can be represented by -N -(CH2)2-N(C2H5)-CH2-C H2. A rigid cyclic (ring) structure for any compounds herein defines an orientation with respect to the plane of the ring for substituents attached to each carbon atom of the rigid cyclic compound. For saturated compounds which have two substituents attached to a carbon atom which is part of a cyclic system, -C(X1)(X2)- the two substituents may be in either an axial or equatorial position relative to the ring and may change between axial/equatorial. However, the position of the two substituents relative to the ring and each other remains fixed. While either substituent at times may lie in the plane of the ring (equatorial) rather than above or below the plane (axial), one substituent is always above the other. In chemical structural formulas depicting such compounds, a substituent (X which is "below" another substituent (X2) will be identified as being in the alpha (α) configuration and is identified by a broken, dashed or dotted line attachment to the carbon atom, i.e., by the symbol "- - -" or "...". The corresponding substituent attached "above" (X2) the other (Xj) is identified as being in the beta (β) configuration and is indicated by an unbroken line attachment to the carbon atom. When a variable substituent is bivalent, the valences may be taken together or separately or both in the definition of the variable. For example, a variable 1^ attached to a carbon atom as -C(=Ri)- might be bivalent and be defined as oxo or keto (thus forming a carbonyl group (-CO-) or as two separately attached monovalent variable substituents α-Rj.,- and β-Rj.jj. When a bivalent variable, R , is defined to consist of two monovalent variable substituents, the convention used to define the bivalent variable is of the form "α-Rj .^β-Rj.^" or some variant thereof. In such a case both α- j.j and β-Rj.fc are attached to the carbon atom to give -C(α-Rj •)(β-Rj_jς)- . For example, when the bivalent variable Rg, -C(=Rg)- is defined to consist of two monovalent variable substituents, the two monovalent variable substituents are α-Rg.-^β-Rg^, .... α-R6.9:β-R6.10, etc, giving -C(α-Rg_1)(β-R6_2)-, .... -C(α-R6.9) (β-R6. 10)-, etc. Likewise, for the bivalent variable R11( -C(=R11)-, two monovalent variable substituents are α-Rn-ι:β-Rιi-2- F°r a ^ng substituent for which separate α and β orientations do not exist (e.g., due to the presence of a carbon double bond in the ring), and for a substituent bonded to a carbon atom which is not part of a ring the above convention is still used, but the α and β designations are omitted. Just as a bivalent variable may be defined as two separate monovalent variable substituents, two separate monovalent variable substituents may be defined to be taken together to form a bivalent variable. For example, in the formula -C1(Ri)H-C2(R:)H- (Cj and C2 define arbitrarily a first and second carbon atom, respectively) Rj and R may be defined to be taken together to form (1) a second bond between Cj and C2 or (2) a bivalent group such as oxa (-0-) and the formula thereby describes an epoxide. When Rj and Rj are taken together to form a more complex entity, such as the group -X-Y-, then the orientation of the entity is such that Cj in the above formula is bonded to X and C2 is bonded to Y. Thus, by convention the designation "... j and R- are taken together to form -CH2-CH2-0- CO- ..." means a lactone in which the carbonyl is bonded to C2. However, when designated "... R- and Rj are taken together to form -CO-0-CH2-CH2-the convention means a lactone in which the carbonyl is bonded to C^.
The carbon atom content of variable substituents is indicated in one of two ways. The first method uses a prefix to the entire name of the variable such as "C- C4", where both "1" and "4" are integers representing the minimum and maximum number of carbon atoms in the variable. The prefix is separated from the variable by a space. For example, "Cj-C,^ alkyl" represents alkyl of 1 through 4 carbon atoms, (including isomeric forms thereof unless an express indication to the contrary is given). Whenever this single prefix is given, the prefix indicates the entire carbon atom content of the variable being defined. Thus C2-C4 alkoxycarbonyl describes a group CH3-(CH2)n-0-C0- where n is zero, one or two. By the second method the carbon atom content of only each portion of the definition is indicated separately by enclosing the "Cj-C-" designation in parentheses and placing it immediately (no intervening space) before the portion of the definition being defined. By this optional convention (C1-C3)alkoxycarbonyl has the same meaning as C2-C4 alkoxycarbonyl because the "Cj-Cg" refers only to the carbon atom content of the alkoxy group. Similarly while both C2-Cg alkoxyalkyl and (C1-C3)alkoxy(C1-C3)alkyl define alkoxyalkyl groups containing from 2 to 6 carbon atoms, the two definitions differ since the former definition allows either the alkoxy or alkyl portion alone to contain 4 or 5 carbon atoms while the latter definition limits either of these groups to 3 carbon atoms.
When the claims contain a fairly complex (cyclic) substituent, at the end of the phrase naming/designating that particular substituent will be a notation in (parentheses) which will correspond to the same name/designation in one of the CHARTS which will also set forth the chemical structural formula of that particular substituent.
II. DEFINITIONS All temperatures are in degrees Centigrade. TLC refers to thin-layer chromatography.
Chromatography refers to medium pressure chromatography on silica gel. THF refers to tetrahydrofuran.
TBDMS refers to tert-butyldimethylsilyl. Saline refers to an aqueous saturated sodium chloride solution. NMR refers to nuclear (proton) magnetic resonance spectroscopy, chemical shifts are reported in ppm (δ) downfield from tetramethylsilane. IR refers to infrared spectroscopy.
-φ refers to phenyl (CgHg).
MS refers to mass spectrometry expressed as m/e or mass/charge unit. [M + H]+ refers to the positive ion of a parent plus a hydrogen atom. El refers to electron impact. CI refers to chemical ionization. FAB refers to fast atom bombardment. Ether refers to diethyl ether.
Halo refers to a halogen atom (-C1, -Br, -F or -I).
Pharmaceutically acceptable refers to those properties and/or substances which are acceptable to the patient from a pharmacological/toxicological point of view and to the manufacturing pharmaceutical chemist from a physical/chemical point of view regarding composition, formulation, stability, patient acceptance and bioavailability.
Pyridinyl refers to the pyridyl radical as defined by IUPAC nomenclature. For example, 2-pyridyl (pyridine ring substituted in the 2-position).
When solvent pairs are used, the ratios of solvents used are volume/volume (v/v).
HIV refers to HTV-1 (wild type and/or drug resistant mutants thereof e.g. M41L, K65N, K67L, K70R, L74V, V75T, A98G, L100I, K103E, K103N, K103Q, V106A, V108I, E138K, V179D, V179E, Y181C, Y188H, Y188L, G190A, T2.15Y, T215F, K219Q, K219E, P236L and K238T).
Treatment refers to inhibition of the HIV virus and will differ depending on the infected individual. For individuals who are HIV positive (infected) but who are asymptomatic, the pyrimidine-thioalkyl derivatives of Formula I will delay, or prevent, the onset of symptoms. For individuals who are HIV positive, symptomatic and are pre-AIDS or ARC patients, the pyrimidine-thioalkyl derivatives of Formula I will delay, or prevent, the onset of "full blown AIDS". For individuals who have "full blown AIDS", the pyrimidine-thioalkyl and alkylether derivatives of Formula I will extend survival time of these individuals.
Pyrimidine-thioalkyl and alkylether compounds of Formula I include alpha- substituted pyrimidine-thioalkyl and alkylether compounds. All references to "pyrimidine-thioalkyl and alkylether compounds" and "pyrimidine-thioalkyl and alkylether anti-AIDS compounds" include "alpha-substituted pyrimidine-thioalkyl and alkylether compounds" and "alpha-substituted pyrimidine-thioalkyl and alkylether anti-AIDS compounds" unless specifically indicated otherwise.
EXAMPLES Without further elaboration, it is believed that one skilled in the art can, using the preceding description, practice the present invention to its fullest extent. The following detailed examples describe how to prepare the various compounds and/or perform the various processes of the invention and are to be construed as merely illustrative, and not limitations of the preceding disclosure in any way whatsoever. Those skilled in the art will promptly recognize appropriate variations from the procedures both as to reactants and as to reaction conditions and techniques.
Example 1: Preparation of (S)-(-)-4-Amino-2-(l-(furo[2,3c]pyridin-5- yl)ethyl)thio)-6-methylthio-pyrimidine; Compound #1
Figure imgf000025_0001
(S)-(-) -4-Amino-6-chloro-2-( l-(furo[2,3c]pyridin-5-yl)ethyl)thio)-pyrimidine (920 mg, 3.0 mmole) is combined with sodium thiomethoxide (263 mg, 3. 75 mmole) in 5 ml dimethylformamide in a 25 ml one neck round bottom flask under nitrogen. The reaction is warmed to 65 °C for 45 min, cooled, and is diluted with 25 ml ethyl acetate. The organics are washed with 4 x 25 ml of 50% saturated 1:1 sodium chloride/sodium bicarbonate, are dried over anhydrous potassium carbonate, and are concentrated in vacuo to a pale oil. The crude material is chromatographed over 60 g of silica gel (230-400 mesh), eluting with 45% ethyl acetate/hexane while collecting 9 ml fractions. Fractions 51-92 are combined and concentrated to a pale oil which is crystallized from diethyl ether to afford the title compound as a pale yellow solid.
*H NMR (dgDMSO): δ 1.69 (d, J=7 Hz, 3), 2.40 (s, 3), 5.16 (q, J=7, Hz, 1), 5.97 (s, 1), 6.83 (s, 2), 7.00 (m, 1), 7.77 (m, 1), 8.20 (m, 1), 8.87 (s, 1) ppm.
13C NMR (dgDMSO): δ 12.5, 22.5, 45.1, 95.5, 106.8, 114.5, 133.3, 134.8, 150.3, 151.2, 154.9, 162.9, 167.5, 169.3 ppm.
Melting Point: 147-149 °C.
IR (mull): 3427, 3306, 3176, 2375, 2252, 2144, 1996, 1969, 1633, 1556, 1521, 1282, 1270, 1126, 1118 cm _1.
MS (El ) m/z (rel. intensity): 318 (M+, 12), 318 (12), 286 (18), 285 (99), 178 (1 5), 147 (11), 146 (58), 145 (9), 144 (10), 118 (11), 91 (7).
Specific Rotation (25 °C, D) = -269 ° (c 0.98).
UV λ max: 227(49500, 95% ETHANOL).
Following the general procedure of Example 1 and making noncritical changes, but using the appropriate chloro-pyrimidine, the following compounds are prepared
ExVCpd #2 4-amino-2-(benzylthio)-6-methylthiopyrimidine
ExVCpd #3 4-amino-2-( 2-methylphenylmethylthio)-6-methylthiopyrimidine Ex Cpd #4 4-amino-2-(3-methylphenylmethylthio)-6-methylthiopyrimidine
ExVCpd #5 4-amino-2-(4-methylphenylmethylthio)-6-methylthiopyrimidine
ExVCpd #6 4-amino-2-(3-trifluoromethylphenylmethylthio)-6- methylthiopyrimidine ExVCpd #7 4-amino-2-(3-methoxyphenylmethylthio)-6-methylthiopyrimidine
ExVCpd #8 4-amino-2-(4-methoxyphenylmethylthio)-6-methylthiopyrimidine
ExVCpd #9 4-amino-2-( 3-fluorophenylmethylthio)-6-methylthiopyrimidine
ExVCpd #10 4-amino-2-(3-chlorophenylmethylthio)-6-methylthiopyrimidine
ExVCpd #11 4-amino-2-(3-bromophenylmethylthio)-6-methylthiopyrimidine Ex-./Cpd #12 4-amino-2-(3-iodophenylmethylthio)-6-methylthiopyrimidine
ExVCpd #13 4-amino-2-(3-nitrophenylmethylthio)-6-methylthiopyrimidine
ExVCpd #14 4-amino-2-(3-carbomethoxyphenylmethylthio)-6- methylthiopyrimidine
ExVCpd #15 4-amino-2-(4-t-butylphenylmethylthio)-6-methylthiopyrimidine ExVCpd #16 4-amino-2-(3,4-difluorophenylmethylthio)-6-methylthiopyrimidine
ExVCpd #17 4-amino-2-(3,4-dichlorophenylmethylthio)-6-methylthiopyrimidine
ExVCpd #18 4-amino-2-(3,5-dichlorophenylmethylthio)-6-methylthiopyrimidine
ExVCpd #19 4-amino-2-(2,4-dichlorophenylmethylthio)-6-methylthiopyrimidine
ExVCpd #20 4-amino-2-(3,5-dibromophenylmethylthio)-6-methylthiopyrimidine ExVCpd #21 4-amino-5-cyclohexyl-2-(benzylthio)-6-methylthiopyrimidine
ExVCpd #22 4-amino-5-isopropyl-2-(benzylthio)-6-methylthiopyrimidine
ExVCpd #23 4-amino-2-(2-pyridylmethylthio)-6-methylthiopyrimidine
ExVCpd #24 4-amino-2- [2-(3-ethoxy)pyridylmethylthiol -6-methylthiopyrimidine
ExVCpd #25 4-amino-2-(3-pyridylmethylthio)-6-methylthiopyrimidine ExVCpd #26 4-amino-2-(l-naphthylmethylthio)-6-methylthiopyrimidine
ExVCpd #27 4-amino-2-(2-naphthylmethylthio)-6-methylthiopyrimidine
ExVCpd #28 4-amino-2-(6,7-difluoro-2-naphthylmethylthio)-6- methylthiopyrimidine
ExVCpd #29 4-amino-2-(2-quinolinylmethylthio)-6-methylthiopyrimidine ExVCpd #30 4-amino-2-(6-chloro-5-piperonylmethylthio)-6-methylthiopyrimidine
ExVCpd #32 4-amino-2-(E-styrylmethylthio)-6-methylthiopyrimidine
ExVCpd #33 4-amino-2-(propargylthio)-6-methylthiopyrimidine
ExVCpd #34 4-amino-6-methylthio-2-(2,6-difluorophenylmethylthio)-pyrimidine
ExVCpd #35 4-amino-6-methylthio-2-(3-bromophenylmethylsulfinyl)-pyrimidine ExVCpd #36 4-amino-6-methylthio2-(2-naphthylmethylsulfinyl)-pyrimidine
ExVCpd #37 4-amino-6-methylthio-2-( 3-bromophenylmethylsulfonyl)-pyrimidine ExVCpd #38 4-amino-5-bromo-6-methylthio-2-(2-naphthylmethylthio)-pyrimidine
ExVCpd #39 4-amino-5-bromo-6-methylthio-2-(2-pyridylmethylthio)-pyrimidine
ExVCpd #78 4-chloro-6-methylthio-2-(benzylthio)-pyrimidine
ExVCpd #79 4-chloro-6-methylthio-5-methoxy-2-(2-naphthylmethylthio)- pyrimidine
Ex./Cpd #80 4-chloro-5-fluoro-6-methylthio-2-(2-naphthylmethylthio)-pyrimidine
ExVCpd #81 4-chloro-5-methyl-6-methylthio-2-(2-naphthylmethylthio)-pyrimidine
ExVCpd #82 4-chloro-5-fluoro-6-methylthio-2-(2-pyridylmethylthio)-pyrimidine
ExVCpd #83 4-chloro-6-methylthhio-2-(4-methoxyphenylmethylthio)-pyrimidine ExVCpd #84 4-piperido-6-methylthio-2-(benzylthio)-pyrimidine
ExVCpd #85 4-pyrrolidino-6-methylthio-2-(benzylthio)-pyrimidine
ExVCpd #86 4-morpholino-6-methylthio-2-(benzylthio)-pyrimidine
ExVCpd #87 4-propylamino-6-methylthio-2-(benzylthio)-pyrimidine
ExVCpd #88 4-hydrazino-6-methylthio-2-(benzylthio)-pyrimidine ExVCpd #89 4-amino-5-methoxy-6-methylthio-2-(2-naphthylmethylthio)- pyrimidine
ExVCpd #90 4-amino-5-methyl-6-methylthio-2-(2-naphthylmethylthio)-pyrimidine
ExVCpd #91 4-amino-5-fluoro-6-methylthio-2-(2-naphthylmethylthio)-pyrimidine
ExVCpd #92 4-amino-5-fluoro-6-methylthio-2-(2-pyridylmethylthio)-pyrimidine ExVCpd #93 4-amino-6-methylthio-2-(4-methoxyphenylmethylthio)-pyrimidine
ExVCpd #99 4-amino-6-methylthio-2-(2-benzothiazolomethylthio)-pyrimidine
ExVCpd #100 4-amino-6-methylthio-2-[2-(l-phenyl-l-ethanon)thiol-pyrimidine
ExVCpd #101 4-amino-6-methylthio-2-(cyclohex-l-enylmethylthio)-pyrimidine
ExVCpd #102 4-amino-6-methylthio-2-(Z-styrylthio)-pyrimidine ExVCpd #103 4-amino-6-methylthio-2-(l-naphthylmethyloxy)-pyrimidine;
ExVCpd #104 4-amino-6-methylthio-2-(benzyloxy)-pyrimidine
ExVCpd #105 4-amino-6-methylthio-2-(2-naphthylmethyloxy)-pyriιnidine
ExVCpd #106 4-amino-6-methylthio-2-(3-methylphenylmethyloxy)-pyrimidine
ExVCpd #107 4-amino-6-methylthio-2-(3-bromophenylmethyloxy)-pyrimidine ExVCpd #108 4-amino-6-methylthio-2-(3-hydroxyphenylmethylthio)-pyrimidine
ExVCpd #109 4-amino-6-methylthio-2-(3-isopropoxyphenylmethylthio)-pyrimidine
ExVCpd #110 4-amino-6-methylthio-2-thio-pyrimidine
ExVCpd #111 4-amino-6-methylthio-2-t2-(4-chloro)-pyridylmethylthio]-pyrimidine
Ex./Cpd #112 4-amino-6-methylthio-2-[2-(6-chloro)pyridylmethylthio]-pyrimidine ExVCpd #113 4-amino-6-methylthio-2-[2-(6-methyl)pyridylmethylthiol-pyrimidine
ExVCpd #114 4-amino-6-methylthio-2-[2-(4-methyl)pyridylmethylthio]-pyrimidine Ex./Cpd #115 4-amino-6-methylthio-2-[2-(4-ethoxy)pyridylmethylthio]-pyrimidine ExVCpd #116 4-amino-6-methylthio-2-[2-(4-thiophenyl)pyridylmethylthio]-pyrimi- dine
ExVCpd #117 4-amino-6-methylthio-2-[2-(3-methyl)pyridylmethylthio]-pyrimidine ExVCpd #118 4-amino-6-methylthiol-2-[2-(5-methyl)pyridylmethylthiol-pyrimidine
ExVCpd #119 4-amino-6-methylthio-2- [2-(4-bromo)pyridylmethylthio] -pyrimidine
ExVCpd #120 4-amino-6-methylthio-2-[2-(4-methoxy-6-methyl)-pyridylmethylthio] -pyrimidine
ExVCpd #121 4-amino-6-methylthio-2- [2-(4,6-dimethyl)pyridylmethylthio] -pyrimidine
ExVCpd #122 4-amino-6-methylthio-2- [2-(4-ethyl)pyridylmethylthio] -pyrimidine ExVCpd #123 4-amino-6-methylthio-2- [2-(4-methoxy )pyridylmethylthio] -pyrimidine ExVCpd #124 4-amino-6-methylthio-2-[2-(4-(2-methylpropyl))pyridylmethylthio]- pyrimidine ExVCpd #125 4-amino-6-methylthio-2-[2-(6-chloro-4-methyl)pyridylmethylthio]- pyrimidine
ExVCpd #126 4-amino-6-methylthio-2-[2-(4-isopropoxy)pyridylmethylthio]-pyrimi- dine
ExVCpd #127 4-amino-6-methylthio-2- [2-(4,6-dimethyl)pyrimidinylmethylthio] - pyrimidine
ExVCpd #128 4-amino-6-methylthio-2- [2-(4-cyano)pyridylmethylthiol -pyrimidine ExVCpd #130 4-amino-6-methylthio-2-[4-(6-methyl)pyrimidinylmethylthio]- P3rrimidine
ExVCpd #131 4-amino-6-methylthio-2-[2-(4-propyl)pyridylmethylthio]-pyrimidine ExVCpd #132 4-amino-6-methylthio-2-(2-(4-isopropyl)pyridylmethylthio]-pyrimi- dine
ExVCpd #133 4-amino-6-methylthio-2-[2-(5-phenyl)pyridylmethylthiol-pyrimidine ExVCpd #134 4-amino-6-methylthio-2- [2-(4-ethyl)pyridylmethylthio] -pyrimidine ExVCpd #135 4-amino-6-methylthio-2- [2-(4-(α-hydroxy, α-methyl)ethyl)pyridyl- methylthio] -pyrimidine
ExVCpd # 137 4-amino-6-methylthio-2-[2-(4-cyclopropyl)pyridylmethylthio]-pyrimi- dine
ExVCpd # 138 4-amino-6-methylthio-2-[2-(4-cyclopentyl)pyridylmethylthio]-pyrimi- dine ExVCpd #140 4-amino-6-methylthio-2- [2-(4,5-dimethyl)pyridylmethylthio] -pyrimi- dine ExVCpd #142 4-amino-6-methylthio-2-[4-(2,6-dimethyl)pyrimidinylmethylthio]- pyrimidine
ExVCpd #143 4-amino-6-methylthio-2-[2-(4-pyrrolidino)pyridylmethylthio]-pyrimi- dine ExVCpd #144 4-Amino-6-methylthio-2-[(5-chlorothiophen-2-ylmethyl)thio] pyrimidine
ExVCpd #145 4-amino-6-methylthio-2-[2-(4-(2-butyl))pyridylmethylthio]-pyrimidine ExVCpd #146 4-amino-6-methylthio-2- [2-(4-dimethylamino)pyridylmethylthio] - pyrimidine ExVCpd #147 2-[2-(4-amino-6-methylthio)pyrimidinylthiomethyl]-pyridine-l-oxide ExVCpd #148 4-Amino-6-methylthio-2- [(furan-3-ylmethyl)thio] pyrimidine ExVCpd #149 4-amino-6-methylthio-5-fiuoro-2-[2-(4-chloro)pyridylmethylthio] pyrimidine
ExVCpd #151 4-amino-6-methylthio-2-[2-(4-(3-pentyl))pyridylmethylthio]- pyrimidine
ExVCpd #152 4-amino-6-methylthio-2- [2-(4-acetyl)pyridylmethylthio] -pyrimidine ExVCpd #153 4-Amino-6-methylthio-2-[(benzofuran-2-ylmethyl)thio]pyrimidine ExVCpd #154 4-amino-6-methylthio-2-[2-(6-dimethylamino4-methyl)pyridylmethyl- thio] -pyrimidine
ExVCpd #155 4-amino-6-methylthio-2- [( lH-inden-3-ylmethyl)thio] pyrimidine
ExVCpd #156 4-amino-6-methylthio-2 [2-(4-carbomethoxy)pyridylmethylthio] - pyrimidine
ExVCpd #157 4-Amino-6-methylthio-2-[((S)-(-)perillyl)thio]pyrimidine
ExVCpd #158 4-Amino-6-methylthio-2-[(benzothiophen-2-ylmethyl)thio]pyrimidine
ExVCpd #159 4-Amino-6-methylthio-2-[(2H-l-benzopyran-3-ylmethyl)thio] pyrimidine
ExVCpd #163 4-amino-6-methylthio-2-[2-(4-carboxamido)-pyridylmethylthio]- pyrimidine
ExVCpd #164 4-amino-6-methylthio-2- [2-(4-hydroxymethyl)-pyridylmethylthio] - pyrimidine
ExVCpd #165 4-amino-5-bromo-6-methylthio-2- [2-(4-methyl)pyridylπiethylthio] - pyrimidine
ExVCpd #166 4-amino-5-bromo-6-methylthio-2-[2-(4-isopropyl)-pyridylmethylthioJ- pyrimidine
ExVCpd #167 4-amino-6-methylthio-2-(2,6-dichlorophenyl)methylthio-pyrimidine
ExVCpd #168 4-Amino-6-methylthio-2-[(2,3-dihydrobenzofuran-5-ylmethyl)thio] pyrimidine ExVCpd #167 4-amino-6-methylthio-2-( 2 ,6-dichlorophenyl)methylthio-pyrimidine Ex./Cpd #168 4-Amino-6~methylthio-2-[(2,3-dihydrobenzofuran-5-ylmethyl)thio] pyrimidine ExVCpd #169 4-Amino-6-methylthio-2-[(5-phenylisoxazol-3-ylmethyl)thio]- pyrimidine ExVCpd #170 4-Amino-6-methylthio-2-[(2,3-dihydrobenzofuran-2-ylmethyl)thio] pyrimidine ExVCpd #171 4-Amino-6-methylthio-2-[[(3,4-dihydro-l-naphthalen-2-yl)methyl] thio] -pyrimidine
Ex./Cpd# 172 4-Amino-6-methylthio-2-t[(5-chloroimidazo[l,2-a]pyridin-2- yl)methyl] thio] -pyrimidine Ex./Cpd #173 4-Amino-6-methylthio-2-[(6-methylpyrazin-2-ylmethyl) thio] pyrimidine ExVCpd #174 4-Amino-6-methylthio-2-[(5-methylisoxazol-3-ylmethyl)thio] pyrimidine ExVCpd #175 4-Amino-6-methylthio-2-[(5-methylpyrazin-2-ylmethyl)thio] pyrimidine Ex./Cpd #176 4-Amino-6-methylthio-2- [( l-methylimidazol-2-ylmethyl)thio] pyrimidine
ExVCpd #177 4-Amino-6-methylthio-2- [(3-methylpyrazin-2-ylmethyl)thio] pyrimidine ExVCpd #178 4-Amino-6-methylthio-2-[(quinolin-6-ylmethyl)thio] pyrimidine ExVCpd #179 4-Amino-6-methylthio-2-[(quinoxalin-2-ylmethyl)thio] pyrimidine ExVCpd # 180 4-Amino-6-methylthio-2-[(quinolin-8-ylmethyl)thio] pyrimidine ExVCpd #181 4-Amino-6-methylthio-2-[(quinolin-4- ylmethyDthio] pyrimidine ExVCpd #182 4-Amino-6-methylthio-2-[(isoquinolin-3-ylmethyl)thio]pyrimidine ExVCpd #183 4-Amino-6-methylthio-2-[(quinolin-5-ylmethyl)thio]pyrimidine ExVCpd #184 4-Amino-6-methylthio-2-[(quinolin-7-ylmethyl)thio]pyrimidine ExVCpd #186 4-Amino-6-methylthio-2- [(piperon-5-ylmethyl)thio]pyrimidine ExVCpd #187 4-Amino-6-methylthio-2-[[(3,4-dihydro-l-naphthalenyl)methyl]thio] pyrimidine ExVCpd #188 4-amino-6-methylthio-2 [2-(5-carbomethyoxy)pyridylmethylthio] pyrimidine
ExVCpd #189 4-amino-6-methylthio-2 [2-(4-cyclohexyl)pyridylmethylthio] pyrimidine ExVCpd #191 4-chloro-5-fluoro-6-methylthio-2- [2-(4-chloro)pyridyl- methylthio] pyrimidine ExVCpd #192 4-amino-5-fluoro-6-methylthio-2-[2-(4-chloro)pyridyl- methylthio] pyrimidine
ExVCpd #193 (2£)-4-[(4-Amino-6-methylthio-2-pyrimidinyl)thio]-2-butenoic acid methyl ester ExVCpd #194 (£)-N V-Diethyl-4-[(4-amino-6-methylthio-2-pyrimidinyl)thio]-2- butenamide Ex./Cpd #195 (£)-4-methyl-l-[4-[(4-amino-6-methylthio-2-pyrimidinyl)thio]-l-oxo-2- butenyl] piperazine ExVCpd #196 (£)-N-ethyl-4-[(4-amino-6-methylthio-2-pyrimidinyl)thio]-2- butenamide ExVCpd #197 (E)-l-[4-[(4-amino-6-methylthio-2-pyrimidinyl)thio]-l-oxo-2- butenyl]piperidine
ExVCpd #198 CE)-4-[4-[(4-amino-6-methylthio-2-pyrimidinyl)thio]-l-oxo-2- butenyl] morpholine ExVCpd #199 (£)-l-[4-[(4-amino-6-methylthio-2-pyrimidinyl)thio]-l-oxo-2- butenyl] pyrrolidine ExVCpd #200 (JE)-N-methyl-N-phenyl-4-[(4-amino-6-methylthio-2-pyrimidinyl)thio]- 2-butenamide ExVCpd #201 (β)-N-allyl-N-methyl-4-[(4-amino-6-methylthio-2-pyrimidinyl)thio]-2- butenamide ExVCpd #202 (£)-N-N-Dipropyl-4- [(4-amino-6-methylthio-2-pyrimidinyl)thio] -2- butenamide
ExVCpd #203 (E)-N-ethyl-N-methyl-4- [(4-amino-6-methylthio-2-pyrimidinyl)thio] -
2-butenamide ExVCpd #204 (#)-N,N-Dimethyl-4- _(4-amino-6-methylthio-2-pyrimidinyl)thio] -2- butenamide ExVCpd #207 (£)-N-N-Diethyl-4-[(4-amino-6-methylthio-2-pyrimidinyl)thio]-2- pentenamide ExVCpd #208 CE.)-4-[(4-Amino-6-methylthio-2-pyrimidinyl)thio]-3- methyl-2-butenoic acid methyl ester ExVCpd #209 (E)-4- [(4-Amino-6-methylthio-2-pyrimidinyl)thio]-3-methyl-2- pentenoic acid methyl ester
ExVCpd #210 4-Amino-6-methylthio-2-(l-(4-(l,l-dimethyl)ethyl-2- pyridyl )ethyl )thio-pyrimidine
ExVCpd #211 4-Amino-6-methylthio-2-(l-(2-pyridyl)ethyl)thio-pyrimidine
ExVCpd #212 4-Amino-6-methylthio-2-(l-(2-pyridyl)-l-methylethyl)thio-pyrimidine
ExVCpd #213 4-Amino-6-methylthio-2-(l-(2-(4-methyl)pyridyl)-l-methylethyl)thio- pyridine
ExVCpd #214 4-Aamino-6-methylthio-2-(l-(4-cyano-2-pyridyl)ethyl)thio-pyrimidine
ExVCpd #215 4-Amino-6-methylthio-2-(l-(4-methyl-2-pyridyl)ethyl)thio- pyrimidine hydrochloride
ExVCpd #216 4-Amino-6-methylthio-2-(l-(4-ethyl-2-pyridyl)ethyl)thio-pyrimidine
ExVCpd #217 4-Amino-6-methylthio-2-(l-(4-methyl-2-pyridyl)-l-cyanomethyl)thio- pyrimidine
ExVCpd #218 4-Amino-6-methylthio-2-(l-(4-methyl-2-pyridyl)propyl)thio- pyrimidine
ExVCpd #219 4-Amino-6-methylthio-2-(l-(4-acetyl-2-pyridyl)ethyl)thio-pyrimidine
ExVCpd #220 4-Amino-6-methylthio-2-(l-(4-methyl-2-pyridyl)-l-carbomethoxy- methyDthio-pyrimidine
ExVCpd #221 4-Amino-6-methylthio-2-(l-(4-(l-methylethenyl)-2-pyridyl)ethyl)thio- pyrimidine
ExVCpd #223 4-Amino-6-methylthio-2-(l-(4-(l-methylethyl)-2-pyridyl)ethyl)thio- pyrimidine
ExVCpd #224 4-Amino-6-methylthio-2-(l-(4-methyl-2-pyridyl)pentyl)thio- pyrimidine
ExVCpd #225 4-Amino-5-bromo-6-methylthio-2-(l-(4-methylethyl)-2- pyridyl)ethyl)thio-pyrimidine
ExVCpd #226 4-Amino-6-methylthio-2-(l-(4-methyl-2-pyridyl)-l-cyclopropyl- methyDthio-pyrimidine mesylate
ExVCpd #227 4-Amino-6-methylthio-2-(l-(4-(4-morpholinyl)methyl-2- pyridyDethyDthio-pyrimidine
ExVCpd #228 4-Amino-6-methylthio-2-(l-(4-dimethylaminomethyl-2- pyridyl)ethyl)thio-pyrimidine
ExVCpd #229 4-Amino-6-methylthio-2-(l-(2-naphthalenyl)ethyl)thio-pyrimidine ExVCpd #230 4-Amino-6-methylthio-2-(l-(3-isoquinolyl)ethyl)thio-pyrimidine ExVCpd #231 4-Amino-5-bromo-6-methylthio-2-(l-(3-isoquinolyl)ethyl)thio- pjrrimidine ExVCpd #232 4-Amino-6-methylthio-2-( l-( l-isoquinolyl)ethyl)thio-pyrimidine ExVCpd #233 4-Amino-6-methylthio-2-(l-(3-(5,6,7,8-tetrahydro- isoquinolyl ) )ethyl)thio-pyrimidine ExVCpd #235 4-Amino-6-methylthio-2-(l-( l-(5,6,7,8-tetrahydroisoquinolyl))- ethyDthio-pyrimidine ExVCpd #236 4-Amino-5-bromo-6-methylthio-2-(l-(l-(5,6,7,8-tetrahydro- isoquinolyl ))ethyl)thio-pyrimidine
ExVCpd #237 4-Amino-6-methylthio-2-(l-(7-chlorofuro[2,3-c]pyridine-5- yl)ethyl)thio-pyrimidine ExVCpd #238 4-Amino-6-methylthio-2-(l-(furo[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine Ex./Cpd #240 4-Amino-6-methylthio-2-(l-(7-chloro-2-methylfuro[2,3-c]pyridine-5- yl)ethyl)thio-pyrimidine ExVCpd #242 4-Amino-6-methylthio-2-(l-(2-methylfurot2,3-c]pyridine-5- yl)ethyl)thio-pyrimidine ExVCpd #244 4-Amino-6-methylthio-2-( l-(6-chloro-5-methoxy-4-vinyl-2- pyridyl)ethyl)thio-pyrimidine
ExVCpd #245 4-Amino-6-methylthio-2-(l-(4-ethyl-5-methoxy-2-pyridyl)ethyl)thio- pyrimidine Ex./Cpd #246 4-Amino-6-methylthio-2-(l-(3-methylfuro[2,3-c]pyridine-5- yl)ethyl)thio-pyrimidine ExVCpd #247 4-Amino-6-methylthio-2-(l-(2,3-dihydrofuro[2,3-c]pyridine-5- yl)ethyl)thio-pyrimidine ExVCpd #248 4-Amino-6-methylthio-2-(l-(3,3-dimethyl-2,3-dihydrofuro[2,3- c]pyridine-5-yl)ethyl)thio-pyrimidine Ex./Cpd #249 4-Amino-6-methylthio-2-(l-(3-ethylfuro[2,3-c]pyridine-5-yl)ethyl)thio- pyrimidine
ExVCpd #250 4-Amino-6-methylthio-2-(l-(7-chloro-3,3-dimethyl-2,3- dihydrofuro[2,3-c]pyridine-5-yl)ethyl)thio-pyrimidine ExVCpd #251 4-Amino-6-methylthio-2-(l-(7-chloro-3-ethylfuro-[2,3-c]pyridine-5- yl)ethyl)thio-pyrimidine ExVCpd #252 4-Amino-6-methylthio-2-(l-(3-(l-methylethyl)furo[2,3-c]-pyridin-5- yl)ethyl)thio-pyrimidine ExVCpd #253 4-amino-6-methylthio-2-(l-(4-cylcopentyl)-2-pyridyl)- ethyDthio-pyrimidine ExVCpd #255 4-amino-6-methylthio-2-(l-(4-cylcopropyl)-2-pyridyl)- ethyDthio-pyrimidine
ExVCpd #256 4-amino-6-methylthio-2-( l-(4-( l-methylpropyl)-2-pyridyl)- ethyl )thio-pyrimidine Ex./Cpd #257 4-amino-6-methylthio-2-(l-(4-cylcohexyl)-2-pyridyl)- ethyl )thio-pyrimidine ExVCpd #258 4-amino-6-methylthio-2-(l-(4-(l-pyrryl))-2-pyridyl)- ethyDthio-pyrimidine
ExVCpd #259 4-amino-6-methylthio-2-( l-(4-dimethylamino)-2-pyridyl)- ethyDthio-pyrimidine ExVCpd #260 4-amino-6-methylthio-2-( l-(5-( l-methylethyl)-3-pyridyl)- ethyDthio-pyrimidine ExVCpd #261 4-amino-6-methylthio-2-(l-(4-(l-ethylpropyl)-2-pyridyl)- ethyDthio-pyrimidine ExVCpd #262 4-amino-6-methylthio-2-( l-(4-methyl-6-( l-pyrryl))-2-pyridyl)- ethyDthio-pyrimidine ExVCpd #263 4-amino-6-methylthio-2-(l-(4-(2-propyloxy))-2-pyridyD- ethyDthio-pyrimidine
ExVCpd #282 4-amino-6-methylthio-2-(l-(3-chloro-[2,3-c]pyridine-5- yl)ethyl)thio-pyrimidine ExVCpd #283 4-Amino-6-methylthio-2-(l-(3,7-dichlorofuro[2,3-c]pyridine-5- yl)ethyl)thio-pyrimidine Ex./Cpd #284 4-Amino-6-methylthio-2-(l-(3-bromofuro[2,3-c]pyridine-5- yl)ethyl)thio-pyrimidine ExVCpd #285 4-Amino-6-methylthio-2-( l-(3-bromo-7-chlorofuro [2,3-c] pyridine-5- yl)ethyl)thio-pyrimidine ExVCpd #286 4-Amino-6-methylthio-2-(l-(7-chloro-3-methylfuro[2,3-c]pyridine-5- yl)ethyl)thio-pyrimidine
ExVCpd #289 (R)-(+)-4-Amino-6-methylthio-2-(l-(3-methylfuro[2,3-c]pyridine-5- yl)ethyl)thio-pyrimidine ExVCpd #290 (S)-(-)-4-Amino-6-methylthio-2-(l-(3-methylfurot2,3-c]pyridine-5- yl)ethyl)thio-pyrimidine, mp 80-82°C ExVCpd #291 R-(+)-4-Amino-6-methylthio-2-(l-(4-ethyl-2-pyridyl)ethyl)thio- pyrimidine ExVCpd #292 (-)-4-Amino-6-methylthio-2-( l-(4-ethyl-2-pyridyl)ethyl)thio-
P3π^midine ExVCpd #293 4-amino-6-methylthio-2-(l-(7-chloro-3-trifluoromethyl)-furo[2,3- c]pyridin-5-yl)ethylthio)-pyrimidine
ExVCpd #294 4-Amino-6-methylthio-2-(l-(3-trifluoromethyl)-furo[2,3-c]pyridin-5- yl )ethylthio )-pyrimidine ExVCpd #300 (R)-(+)-4-Amino-6-methylthio-2-(l-(furo[2,3-c]pyridin-5-yl)ethylthio)- pyrimidine ExVCpd #301 (S)-(-)-4-Amino-6-methylthio-2-(l-(furo[2,3-c]pyridin-5-yl)ethylthio)- pyrimidine mesylate salt
ExVCpd #302 (S)-(-)-4-Amino-6-methylthio-2-(l-(3-methylfuro[2,3-c]pyridin-5- yl)ethylthio)-pyrimidine, esylate salt ExVCpd #303 4-amino-6-methylthio-2-(((5-benzyloxy-6-chloro)-2-pyridyl)-ethyl)thio- pyrimidine ExVCpd #304 4-amino-6-methylthio-2-(furo[2,3-b]pyridin-5-yl-methylthio)- pyrimidine
Following the above procedures and making non-critical variations, the following compounds are prepared:
4-Amino-6-methylthio-2-(l-(3-trifluoromethylfuro[2)3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-( l-(7-chloro-3-trifluoromethylfuro [2,3-c] pyridin-5- yl)ethyl)thio-pyrimidine,
4-Ax-_ino-6-methylthio-2-(l-(3-fluorofuro[2,3-c]pyridin-5-yDethyDthio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-((2,2,2-trifluoro)ethyDfuro[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-(l-(3-((l-trifluoromethyl-2,2,2-trifluoro)ethyl)furo[2,3- c]pyridin-5-yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-cyanofuro[2,3-c]pyridin-5-yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-carbomethoxyfuro[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-( l-(3-aminocarbinylfuro [2,3-c] pyridin-5-yl)ethyl)thio- pyrimidine, 4-Amino-6-methylthio-2-(l-(3-(N,N-dimethylaminocarbinyl)furo[2,3-c]pyridin-5- yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-(methylsulfonylamino)furo[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-(l-(3-(methylcarboxyamino)furo[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-(l-(3-phenylfuro[2,3-c]pyridin-5-yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-( l-(3-(tert-butyl)furo [2,3-c] pyridin-5-yl)ethyDth.io-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-cyclopropylfuro[2,3-c]pyridin-5-yDethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-fluorothieno[2,3-c]pyridin-5-yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-((2,2,2-trifluoro)ethyl)thieno[2,3-c]pyridin-5- yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-((l-trifluoromethyl-2,2,2-trifluoro)ethyl)thieno[2,3- c]pyridin-5-yl)ethyDthio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-cyanothieno[2,3-c]pyridin-5-yDethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-carbomethoxythieno[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-( l-(3-aminocarbinylthieno [2,3-c] pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-(l-(3-(N,N-dimethylaminocarbinyl)thieno[2,3-c]pyridin-5- yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-(methylsulfonylamino)thieno[2,3-c]pyridin-5- yl)ethyl)thio-pyrimidine, 4-Amino-6-methylthio-2-(l-(3-(methylcarboxyamino)thieno[2,3-c]pyridin-5- yl )ethyl )thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-phenylthieno [2,3-c] pyridin-5-yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-(tert-butyl)thieno[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-(l-(3-cyclopropylthieno[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-( l-(3-fluoro- lH-pyrrolo [2,3-c] pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-(l-(3-((2,2,2-trifluoro)ethyl)-lH-pyrrolo[2,3-c]ρyridin-5- yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-((l-trifluoromethyl-2,2,2-trifluoro)ethyl)-lH-pyrrolo[2,3- c]pyridin-5-yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-cyano-lH-pyrrolo[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-(l-(3-carbomethoxy-lH-pyrrolo[2,3-c]pyridin-5-yl)ethyl)thio- P3τimidine,
4-Amino-6-methylthio-2-(l-(3-aminocarbinyl-lH-pyrrolo[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-(l-(3-(N,N-dimethylaminocarbinyl)-lH-pyrrolo[2,3-c]pyridin- 5-yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-(methylsulfonylamino)-lH-pyrrolo[2,3-c]pyridin-5- yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-(methylcarboxyamino)-lH-pyrrolo[2,3-c]pyridin-5- yl )ethyl )thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-phenyl-lH-pyrrolo [2,3-c] pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-(l-(3-(tert-butyl)-lH-pyrrolo[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-(l-(3-cyclopropyl-lH-pyrrolo[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-( l-(3-fluoro- 1 -methyl- IH-pyrrolo [2 , 3-c] pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-(l-(3-((2,2,2-trifluoro)ethyl)-l-methyl-lH-pyrrolo[2,3- c] pyridin-5-yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-((l-trifluoromethyl-2,2,2-trifluoro)ethyl)-l-methyl-lH- pyrrolo[2,3-c]pyridin-5-yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-cyano-l-methyl-lH-pyrrolo[2,3-c]pyridin-5-yl)ethyl)thio- pjrimidine,
4-Amino-6-methylthio-2-(l-(3-carbomethoxy-l-methyl-lH-pyrrolo[2,3-c]pyridin-5- yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-aminocarbinyl-l-methyl-lH-pyrrolo[2,3-c]pyridin-5- yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-(N,N-dimethylaminocarbinyl)-l-methyl-lH-pyrrolo[2,3- c]pyridin-5-yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-(methylsulfonylamino)-l-methyl-lH-pyrrolo[2,3- c]pyridin-5-yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-( l-(3-(methylcarboxyamino)-l-methyl- IH-pyrrolo [2,3- c]pyridin-5-yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-phenyl-l-methyl-lH-pyrrolo[2,3-c]pyridin-5- yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-(tert-butyl)-l-methyl-lH-pyrrolo[2,3-c]pyridin-5- yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-cyclopropyl-l-methyl-lH-pyrrolo[2,3-c]pyridin-5- yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(7-chlorothieno[2,3-c]pyridin-5-yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(thieno[2,3-c]pyridin-5-yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(7-chloro-2-methylthieno[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-(l-(2-methylthieno[2,3-c]pyridin-5-yl)ethyDthio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-methylthieno[2,3-c]pyridin-5-yl)ethyl)thio-pyrimidine
4-Amino-6-methylthio-2-(l-(2,3-dihydrothieno[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-(l-(3,3-dimethyl-2,3-dihydrothieno[2,3-c]pyridin-5- yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-ethylthieno[2,3-c]pyridin-5-yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(7-chloro-3,3-dimethyl-2,3-dihydrothieno[2,3-c]pyridin-5- yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(7-chloro-3-ethylthieno[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine, 4-Amino-6-methylthio-2-(l-(3-(l-methylethyl)thieno[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-(l-(7-chloro-lH-pyrrolo[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-( l-( IH-pyrrolo [2,3-c] pyridin-5-yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(7-chloro-2-methyl-lH-pyrrolo[2,3-c]pyridin-5- yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(2-methyl-lH-pyrrolo[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-(l-(3-methyl-lH-pyrrolo[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-(l-(2,3-dihydro-lH-pyrrolo[2,3-c]pyridin-5-yDethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-(l-(3,3-dimethyl-2,3-dihydro-lH-pyrrolol2,3-c]pyridin-5- yDethyDthio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-ethyl-lH-pyrrolo[2,3-c]p3rridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-(l-(7-chloro-3,3-dimethyl-2,3-dihydro-lH-pyrrolo[2,3- c]pyridin-5-yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-( l-(7-chloro-3-ethyl-lH-pyrrolo[2,3-c] pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-(l-(3-(l-methylethyl)-lH-pyrrolo[2,3-c]pyridin-5-yl)ethyl)thio- P3rrimidine,
4-Amino-6-methylthio-2-(l-(7-chloro-l-methyl-lH-pyrrolo[2,3-c]pyridin-5- yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(l-methyl-lH-pyrrolo[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4- Amino-6-methylthio-2-( l-(7-chloro-2-methyl- 1-methyl- IH-pyrrolo [2,3-c] pyridin-5- yDethyDthio-pyrimidine,
4-Amino-6-methylthio-2-( l-(2-methyl-l-methyl- IH-pyrrolo [2,3-c] pyridin-5- yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-methyl-l-methyl-lH-pyrrolo[2,3-c]pyridin-5- yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(2,3-dihydro-l-methyl-lH-pyrrolo[2,3-c]pyridin-5- yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3,3-dimethyl-2,3-dihydro-l-methyl-lH-pyrrolo[2,3- c]pyridin-5-yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-ethyl-l-methyl-lH-pyrrolo[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-(l-(7-chloro-3,3-dimethyl-2,3-dihydro-l-methyl-lH- pyrrolo[2,3-c] pyridin-5-yDethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(7-chloro-3-ethyl-l-methyl-lH-pyrrolo[2,3-c]pyridin-5- yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-(l-methylethyl)-l-methyl-lH-pyrrolo[2,3-c]pyridin-5- yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-chlorothieno[2,3-c]pyridin-5-yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-( l-(3,7-dichlorothieno [2,3-c] pyridin-5-yl)ethyl)thio- pyrimidine, 4-Amino-6-methylthio-2-(l-(3-bromothieno[2,3-c]pyridin-5-yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-bromo-7-chlorothieno[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-(l-(7-chloro-3-methylthieno[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-(l-(3-chloro-lH-pyrrolo[2)3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-( l-(3,7-dichloro- IH-pyrrolo [2,3-c] pyridin-5-yl EthyDthio- pyrimidine,
4-Amino-6-methylthio-2-(l-(3-bromo-lH-pyrrolo[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-(l-(3-bromo-7-chloro-lH-pyrrolo[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-(l-(7-chloro-3-methyl-lH-pyrrolo[2,3-c]pyridin-5- yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-chloro-l-methyl-lH-pyrrolo[2,3-c]pyridin-5- yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3,7-dichloro-l-methyl-lH-pyrrolo[2,3-c]pyridin-5- yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-bromo-l-methyl-lH-pyrrolo[2,3-c]pyridin-5- yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-bromo-7-chloro-l-methyl-lH-pyrrolo[2,3-c]pyridin-5- yl)ethyl)thio-pyrimidine, 4-Amino-6-methylthio-2-(l-(7-chloro-3-methyl-l-methyl-lH-pyrrolo[2,3-c]pyridin-5- yDethyDthio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-trifluoromethylthieno[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4-Amino-6-methylthio-2-(l-(7-chloro-3-trifluoromethylthieno[2,3-c]pyridin-5- yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(3-trifluoromethyl-lH-pyrrolo[2,3-c]pyridin-5-yl)ethyl)thio- pyrimidine,
4- Amino-6-methylthio-2-( l-(7-chloro-3-trifluoromethyl- IH-pyrrolo [2,3-c] pyridin-5- yl)ethyl)thio-pyrimidine ,
4-Amino-6-methylthio-2-(l-(3-trifluoromethyl-l-methyl-lH-pyrrolo[2,3-c]pyridin-5- yl)ethyl)thio-pyrimidine,
4-Amino-6-methylthio-2-(l-(7-chloro-3-trifluoromethyl-l-methyl-lH-pyrrolo[2,3- c] pyridin-5-yl)ethyl)thio-pyrimidine.
CHART A
Figure imgf000045_0001
CHART B
Figure imgf000046_0001
CH3S03H
Figure imgf000046_0002
FORMULAE
Figure imgf000047_0001
(S)-(-)βnantiomer Cp #1
Figure imgf000048_0001
Figure imgf000048_0002
Figure imgf000048_0003
Figure imgf000048_0004
Figure imgf000049_0001
Figure imgf000049_0002
Figure imgf000049_0003
Cpd #15
Cpd #14
Figure imgf000049_0004
Cpd #16
Figure imgf000050_0001
Figure imgf000050_0002
Figure imgf000050_0003
Cpd #21 Cpd #22
Figure imgf000050_0004
Cpd #23 Cpd #24
Figure imgf000051_0001
Cpd #25
Cpd #26
Figure imgf000051_0002
Cpd #27
Cpd #28
Figure imgf000051_0003
Cpd #29 Cpd #30
Figure imgf000051_0004
Cpd #32
Figure imgf000052_0001
Cpd #37
Cpd #36
Figure imgf000052_0002
Cpd #38
Cpd #39
Figure imgf000053_0001
Figure imgf000053_0002
Cpd #80
Cpd #81
Figure imgf000053_0003
Cpd #82 Cpd #83
Figure imgf000053_0004
Cpd #84
Figure imgf000054_0001
Cpd #85 Cpd #86
Figure imgf000054_0002
Cpd #87 Cpd #88
Figure imgf000054_0003
Cpd #89 Cpd #90
Figure imgf000054_0004
Cpd #91
Figure imgf000055_0001
Cpd #93
Figure imgf000056_0001
Cpd #100
Figure imgf000056_0002
Cpd #101 cis isomer Cpd #102
Figure imgf000056_0003
Figure imgf000056_0004
Cpd #105
Cpd #106
Figure imgf000057_0001
Cpd #107 Cpd #108
Figure imgf000057_0002
Cpd #109 Cpd #110
Figure imgf000058_0001
Figure imgf000058_0002
Figure imgf000058_0003
Figure imgf000058_0004
Cpd #117 Cpd #118
Figure imgf000059_0001
Cpd #119
Figure imgf000059_0002
Figure imgf000059_0003
Figure imgf000059_0004
Figure imgf000060_0001
Cpd #127
Figure imgf000060_0002
Figure imgf000060_0003
Cpd#130
Figure imgf000060_0004
Cpd #131
Figure imgf000060_0005
Figure imgf000061_0001
Figure imgf000061_0002
Cpd #137
Figure imgf000061_0003
Cpd #140
Figure imgf000061_0004
Figure imgf000062_0001
Cpt#145
Figure imgf000062_0002
Cpd #146
Figure imgf000062_0003
Cpd #148 Cpd #149
Figure imgf000062_0004
Cpd #151
Figure imgf000063_0001
Figure imgf000063_0002
Cpd #154
Figure imgf000063_0003
Cpd #156 Cpd #157
Figure imgf000063_0004
Cpd #158 Cpd #159
Figure imgf000064_0001
Figure imgf000064_0002
Figure imgf000064_0003
Figure imgf000065_0001
#168 pd #169
Figure imgf000065_0002
Cpd #170 Cpd #171
Figure imgf000065_0003
Cpd #172 Cpd #173
Figure imgf000065_0004
Cpd #174 Cpd #175
Figure imgf000066_0001
Figure imgf000066_0002
Cpd #178 Cpd #179
Figure imgf000066_0003
Cpd #180 Cpd #181
Figure imgf000066_0004
Cpd #182 Cpd #183
Figure imgf000067_0001
Cpd #184
Figure imgf000067_0002
Cpd #186 Cpd #187
Figure imgf000067_0003
Figure imgf000067_0004
Figure imgf000068_0001
Cpd #192
Figure imgf000068_0002
Cpd #195
Cpd #194
Figure imgf000068_0003
Cpd #196 Cpd #197
Figure imgf000068_0004
Cpd 199
Cpd #198
Figure imgf000069_0001
Figure imgf000069_0002
Cpd #202 Cpd #203
Figure imgf000069_0003
Cpd #207
Cpd #204
Figure imgf000070_0001
Cpd #208 Cpd #209
Figure imgf000070_0002
Cpd #210
Cpd #211
Figure imgf000070_0003
Cpd #212 Cpd #213
Figure imgf000071_0001
Figure imgf000071_0002
Figure imgf000071_0003
Figure imgf000072_0001
Figure imgf000072_0002
Cpd #223
Figure imgf000072_0003
Cpd #226
Figure imgf000073_0001
Figure imgf000073_0002
Cpd #230
Cpd #229
Figure imgf000073_0003
Figure imgf000074_0001
Figure imgf000074_0002
Cpd #237
Figure imgf000074_0003
Cpd #242
Cpd #240
Figure imgf000075_0001
Figure imgf000075_0002
Cpd #246
Figure imgf000075_0003
Cpd #248
Figure imgf000076_0001
Figure imgf000076_0002
Cpd #252
Cpd #251
Figure imgf000076_0003
Figure imgf000077_0001
Figure imgf000077_0002
Figure imgf000077_0003
Figure imgf000078_0001
Figure imgf000078_0002
Cpd #263
Figure imgf000079_0001
Figure imgf000079_0002
Cpd #286
Figure imgf000080_0001
Cpd #289
Cpd #290
Figure imgf000080_0002
Cpd #292
Cpd #291
Figure imgf000080_0003
racemate racemate
Cpd #29-3 .
Cpd #294
Figure imgf000081_0001
(RH+yenanttoffJpr Cpd B300
Figure imgf000081_0002
(S Henarrtiomer cpd #301
Figure imgf000081_0003
(SH+ENANTIOMH-
Cpd#302
Figure imgf000082_0001

Claims

1. A compound of Formula I
Figure imgf000083_0001
where m is 0 or 1;
R is selected from the group consisting of -CΓëíCH, -C02R53, -CONR54R55,
Figure imgf000083_0002
where s is 0 or land ^Q, R21. ^22' ^23' ^24' an(* ^25 are ^e same or different and are selected from -H, Cj-Cg alkyl, Cj-Cg alkenyl, Cj-Cg alkoxy, C1-C6 alkylthio, -C3-C8 cycloalkyl, -CF3, -N02, -halo, -OH, - CN, phenyl, phenylthio, -styryl, -CO2(R31), -CON(R31)(R32), -COCR^), -(CH2)n-N(R31)(R32), -CCOHXRgjKRgg), -(CH2)nN(R31)(CO(R33)), (CH2)nN(R31)(S0 (R33)), or where R20 and
Figure imgf000083_0003
and R22, or R22 and R23 are taken together to form a five or six-membered saturated or unsaturated ring containing 0 or 1 oxygen, nitrogen or sulfur, where the unsaturated ring may be optionally substituted with 1, 2 or 3, CrC6 alkyl, CrC6 alkoxy, -OH, -CH2OH, -(CH2)n- N(R31)(R32), -C3-C8 cycloalkyl, -CF3, -halo, -C02(R31), - CON(R31)(Rg2), -CO(R31),
Figure imgf000083_0004
- (CH2)nN(R31)(S02(R33)), -CN, -CH2CF3 or -CH(CF3)2, or phenyl, and the saturated ring may be optionally substituted with 1, 2 or 3, -Cj-Cg alkyl, -CrC6 alkoxy, -OH, -CH2OH or -(CH2)n-N(R31)(R32) or one oxo (=0); where n is 0-3 and R31, R32, and R33 are the same or different and are selected from -H,
C1-C6 alkyl, phenyl optionally substituted with 1, 2, or 3 -halo, C-^-Cg alkyl,
C1-C6 alkoxy, -CF3, -OH or -CN, or where R31 and R32 taken together with the attached nitrogen to form a ring selected from -pyrrolidinyl, -piperidinyl, -4-morpholinyl, -4-thiomorpholinyl, -4- piperazinyl, -4-(l-C1-C6alkyl)piperazinyl, or a member selected from the group consisting of: 1-cyclohexenyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-imidazolyl, 4-imidazolyl, 2-benzothiazolyl, 2-benzoxazolyl, 2-benzimidazolyl, 2-oxazolyl, 4-oxazolyl, 2-thiazolyl, 3-isoxazolyl, 5-isoxazolyl, 5-methyl-3-isoxazolyl, 5- phenyl-3-isoxazolyl, 4-thiazolyl, 3-methyl-2-pyrazinyl, 5-methyl-2-pyrazinyl, 6- methyl-2-pyrazinyl, 5-chloro-2-thienyl, 3-furyl, benzofuran-2-yl, benzothien-2- yl, 2H-l-benzopyran-3-yl, 2,3-dihydrobenzopyran-5-yl, l-methylimidazol-2-yl, quinoxalin-2-yl, piperon-5-yl, 4,7-dichlorobenzoxazol-2-yl, 4,6-dimethyl- pyrimidin-2-yl, 4-methylpyrimidin-2-yl, 2,4-dimethylpyrimidin-6-yl, 2- methylpyrimidin-4-yl, 4-methylpyrimidin-6-yl, 6-chloropiperon-5-yl, 5- chloroimidazo[l,2-a]pyridin-2-yl, l-H-inden-3-yl, l-H-2-methyl-inden-2-yl, 3,4- dihydronaphth-1-yl, S-4-isopropenylcyclohexen-l-yl or 4-dihydronaphth-2-yl; where R53 is selected from the group consisting of -H, Cj-Cgalkyl, C3- Cgcycloalkyl, phenyl (optionally substituted with 1, 2, or 3 -halo, Cj-C alkyl, Cj-Cg alkoxy, -CF3, -OH, -CN), or a five or six-membered unsaturated ring containing 0 or 1 oxygen, nitrogen or sulfur, where the unsaturated ring may be optionally substituted with -H, Cj-Cg alkyl,
CrC6 alkoxy, -OH, -CH2OH, or -(CH2)n-N(R31)(R32); where Rg4 and R55 being the same or different are selected from -H,
Cj-C alkyl, allyl, or phenyl (optionally substituted with 1, 2, or 3 - halo, Cj-C alkyl, Cj-Cg alkoxy or -CF3), or taken together with the attached nitrogen to form a ring selected from -pyrrolidinyl, - piperidinyl, -4-morpholinyl, -4-thiomorpholinyl, -4-piperazinyl, -4-(l- Cj-CgalkyDpiperazinyl;
R4j and R42. being the same or different, are selected from the group consisting of -H and Cj-^ alkyl;
R12 is selected from the group consisting of -H, Cj-C alkyl, -C3-C6 cycloalkyl, -CN, -C(0)NH2, -C(0)N(C1-C6alkyl)(C1-C6alkyl), -C02H, -C02(CrC6alkyl), -CH2OH, -CH2NH2 or -CF3; R13 is selected from the group consisting of -H, Cj-C alkyl or -CF3;
Y is selected from -S-, -S(O)-, -S(0)2, or -0-;
R4 is selected from the group consisting of -H, -OH, halo or -NR15R16 where R15 is -H and R16 is -H, Cj-C alkyl, -NH2 or R15 and R16 taken together with the -N form 1-pyrrolidino, 4-morpholino or 1-piperidino; R5 is selected from the group consisting of -H, -C2H4OH, -C2H4-0-TBDMS, halo, -C3-Cg cycloalkyl, Cj-C4 alkyl or Cj-Cjj alkoxy; or R4 and Rg are taken together to form a five or six-membered saturated or unsaturated ring which together with the pyrimidine ring form the group consisting of 7H-pyrrolo[2,3-d]pyrimidine, 5,6-dihydro-7H-pyrrolo[2,3-d]pyrimidine, furo[2,3- dlpjnrimidine, 5,6-dihydro-furo[2,3-d]pyrimidine, thieno[2,3-d]pyrimidine, 5,6-dihydro- thieno[2,3-d] pyrimidine, lH-pyrazolo[3,4-d] pyrimidine, lH-purine, pyrimido[4,5- dlpyrimidine, pteridine, pyrido[2,3-d]pyrimidine, or quinazoline, where the unsaturated ring may be optionally substituted with 1, 2 or 3, Cj-C alkyl, Cj-Cg alkoxy, -OH, -CH2OH, or -(CH2)n-N(R31)(R32), -C3-C8 cycloalkyl, -CF3, -halo, - C02(R31), -CON(R31)(R32), -CO(R31), -(CH2)nN(R31)(CO(R33)), -(CH2)nN(R31)
(S02(R33)), and the saturated ring may be optionally substituted with 1, 2 or 3, -Cj- C6 alkyl, -C1-C6 alkoxy, -OH, -CH2OH, or -(CH2)n-N(R31)(R32) or one oxo (=0); and
Rg is -S-Cj.g alkyl; or pharmaceutically acceptable salts, hydrates, N-oxides and solvates thereof;
2. A compound according to Claim 1 where m is 0, s is 0 and Y is -S.
3. A compound according to Claim 2 where R12 *s CH3 and R13 is -H.
4. A compound according to Claim 3 where R4 is NH2, 5 is -H, and Rg is
SCHg.
5. A compound according to Claim 3 where Rj is
Figure imgf000086_0001
6. A compound according to Claim 5 wherein R4 is NH2, R5 is -H, and Rg is
-SCH3.
7. A compound according to Claim 3 wherein R-^ is a five or six membered saturated or unsaturated ring selected from the group consisting of 3-isoquinolinyl, 1-isoquinolinyl, 2-quinolinyl, 3-quinolinyl, 3-(5,6,7,8-tetrahydro)-isoquinolinyl, 1- (5,6,7,8-tetrahydro)-isoquinolinyl, 2-(5,6,7,8-tetrahydro)-quinolinyl, 3-(5,6,7,8- tetrahydro)-quinolinyl, 3-(5,6-dihydro)-2H-2-pyrindinyl, l-(5,6-dihydro)-2H-2- pyrindinyl, 2-(5,6-dihydro)-lH-l-pyrindinyl, 3-(5,6-dihydro)-lH-l-pyrindinyl, 5- furo[2,3-c]pyridinyl, 6-furo[3,2-c] pyridinyl, 4-furo[3,2-c]pyridinyl, 7-furo[2,3- c.pyridinyl, 6-furo[2,3-b] pyridinyl, 5-furo[3,2-b]pyridinyl, 5-(2,3-dihydro)-furo[2,3- dpyridinyl, 6-(2,3-dihydro)-furo[3,2-c]pyridinyl, 4-(2,3-dihydro)-furo[3,2-c]pyridinyl, 7-(2,3-dihydro)-furo[2,3-c]pyridinyl, 6-(2,3-dihydro)-furo[2,3-b]pyridinyl, 5-(2,3- dihydro)-furo[3,2-b]pyridinyl, 6-(l,3-dihydro)-furo[3,4-c]pyridinyl, 4-(l,3-dihydro)- furo[3,4-c]pyridinyl, 2-(5,7-dihydro)-furo[3,4-b]pyridinyl, 6-(3,4-dihydro)-2H- pyrano[2,3-c]pyridinyl, 6-(3,4-dihydro)-lH-pyrano[3,4-c]pyridinyl, 7-(3,4-dihydro)-lH- pyrano[4,3-c]pyridinyl, 7-(3,4-dihydro)-2H-pyrano[3,2-c]pyridinyl, 5-(3,4-dihydro)-2H- pyrano[3,2-c]pyridinyl, 5-(3,4-dihydro)-lH-pyrano[4,3-c]pyridinyl, 8-(3,4-dihydro)-lH- pyrano[3,4-c]pyridinyl, 8-(3,4-dihydro)-2H-pyrano[2,3-c]pyridinyl, 7-(3,4-dihydro)-2H- pyrano[2,3-b] pyridinyl, 2-(5,6-dihydro)-lH-pyrano[3,4-b]pyridinyl, 2-(5,6-dihydro)-2H- pyrano[4,3-b]pyridinyl, 6-(3,4-dihydro)-2H-pyrano[3,2-b]pyridinyl, 5-lH-pyrrolo[2,3- c.pyridinyl, 6-lH-pyrrolo[3,2-c]pyridinyl, 4-lH-pyrrolo[3,2-c]pyridinyl, 7-1H- pyrrolo[2,3-c]pyridinyl, 6-lH-pyrrolo.2,3-b]pyridinyl, 5-lH-pyrrolo[3,2-b]pyridinyl, 5- (2,3-dihydro)-lH-pyrrolo[2,3-c]pyridinyl,"6-(2,3-dihydro)-lH-pyrrolot3,2-c]pyridinyl, 4- (2,3-dihydro)-lH-pyrrolo[3,2-c]pyridinyl, 7-(2,3-dihydro)-lH-pyrrolo[2,3-c]pyridinyl, 6- (2,3-dihydro)-lH-pyrrolo[2,3-b]pyridinyl, 5-(2,3-dihydro)-lH-pyrrolo[3,2-b]pyridinyl, 6-( 1 ,3-dihydro)- IH-pyrrolo [3,4-c] pyridinyl, 4-( 1,3-dihydro)- IH-pyrrolo [3,4-c] pyridinyl, 2-(5,7-dihydro)-lH-pyrrolo[3,4-b]pyridinyl, 6-1,7-naphthyridinyl, 6-2,7- naphthyridinyl, 7-2,6-naphthyridinyl, 7-1,6-naphthyridinyl, 5-1,6-naphthyridinyl, 5- 2,6-naphthyridinyl, 8-2,7-naphthyridinyl, 8-1,7-naphthyridinyl, 7-1,8-naphthyridinyl, 2-1,7-naphthyridinyl, 2-1,6-naphthyridinyl, 6-1,5-naphthyridinyl, 6-( 1,2,3,4- tetrahydro)-l,7-naphthyridinyl, 6-(l,2,3,4-tetrahydro)-2,7-naphthyridinyl, 7-(l,2,3,4- tetrahydro)-2,6-naphthyridinyl, 7-(l,2,3,4-tetrahydro)-l,6-naphthyridinyl, 5-(l,2,3,4- tetrahydro)-l,6-naphthyridinyl, 5-(l,2,3,4-tetrahydro)-2,6-naphthyridinyl, 8-(l,2,3,4- tetrahydro)-2,7-naphthyridinyl, 8-(l,2,3,4-tetrahydro)-l,7-naphthyridinyl, 7-(l,2,3,4- tetrahydro)-l,8-naphthyridinyl, 2-(5,6,7,8-tetrahydro)-l,7-naphthyridinyl, 2-(5,6,7,8- tetrahydro)-l,6-naphthyridinyl, 6-(l,2,3,4-tetrahydro)-l,5-naphthyridinyl, 1-naphthyl, 2-naphthyl, 5-(l,2,3,4-tetrahydro)-naphthyl, 6-(l,2,3,4-tetrahydro)-naphthyl, 4-(2,3- dihydro)-lH-indenyl, 5-(2,3-dihydro)-lH-indenyl, 5-benzofuranyl, 4-benzofuranyl, 6- benzofuranyl, 7-benzofuranyl, 5-(2,3-dihydro)-benzofuranyl, 4-(2,3-dihydro)- benzofuranyl, 6-(2,3-dihydro)-benzofuranyl, 7-(2,3-dihydro)-benzofuranyl, 4-(l,3- dihydro)-isobenzofuran, 5-(l,3-dihydro)-isobenzofuran, 4-lH-indolyl, 5-lH-indolyl, 6- lH-indolyl, 7-lH-indolyl, 4-(2,3-dihydro)-lH-indolyl, 5-(2,3-dihydro)-lH-indolyl, 6- (2,3-dihydro)-lH-indolyl, 7-(2,3-dihydro)-lH-indolyl, 4-(l,3-dihydro)-lH-isoindolyl, 5- (l,3-dihydro)-lH-isoindolyl, 5-(3,4-dihydro)-lH-2-benzopyranyl, 6-(3,4-dihydro)-lH-2- benzopyranyl, 7-(3,4-dihydro)-lH-2-benzopyranyl, 8-(3,4-dihydro)-lH-2-benzopyranyl, 5-(3,4-dihydro)-2H- 1-benzopyranyl, 6-(3,4-dihydro)-2H-l-benzopyranyl, 7-(3,4- dihydro)-2H-l-benzopyranyl, 8-(3,4-dihydro)-2H-l-benzopyranyl, 5-( 1,2,3,4- tetrahydro)-isoquinolinyl, 6-(l,2,3,4-tetrahydro)-isoquinolinyl, 7-(l,2,3,4-tetrahydro)- isoquinolinyl, 8-(l,2,3,4-tetrahydro)-isoquinolinyl, 5-(l,2,3,4-tetrahydro)-quinolinyl, 6- (l,2,3,4-tetrahydro)-quinolinyl, 7-(l,2,3,4-tetrahydro)-quinolinyl,
8-(l,2,3,4-tetrahydro)-quinolinyl, 5-thieno[2,3-c]pyridinyl, 6-thieno[3,2-c]pyridinyl, 4- thieno[3,2-c] pyridinyl, 7-thieno [2,3-c] pyridinyl, 6-thieno[2,3-b]pyridinyl, 5-thieno[3,2- blpyridinyl, 5-(2,3-dihydro)-thieno[2,3-c]pyridinyl, 6-(2,3-dihydro)-thieno[3,2- yridinyl, 4-(2,3-dihydro)-thieno[3,2-c]pyridinyl, 7-(2,3-dihydro)-thieno[2,3- clpyridinyl, 6-(2,3-dihydro)-thieno[2,3-b]pyridinyl, 5-(2,3-dihydro)-thieno[3,2- blpyridinyl, 6-(l,3-dihydro)-thieno[3,4-c]pyridinyl, 4-(l,3-dihydro)-thieno[3,4- c]pyridinyl, 2-(5,7-dihydro)-thieno[3,4-b]pyridinyl, 6-(3,4-dihydro)-2H-thiopyrano[2,3- cjpyridinyl, 6-(3,4-dihydro)-lH-thiopyrano[3,4-c]pyridinyl, 7-(3,4-dihydro)-lH- thiopjrrano[4,3ic]pyridinyl, 7-(3,4-dihydro)-2H-thiopyrano[3,2-c] pyridinyl, 5-(3,4- dihydro)-2H-thiopyrano[3,2-c]pyridinyl, 5-(3,4-dihydro)-lH-thiopyrano[4,3-c]pyridinyl, 8-(3,4-dihydro)-lH-thiopyrano[3,4-c]pyridinyl, 8-(3,4-dihydro)-2H-thiopyrano[2,3- clpyridinyl, 7-(3,4-dihydro)-2H-thiopyrano[2,3-b]pyridinyl, 2-(5,6-dihydro)-lH- thiopyrano[3,4-b]pyridinyl, 2-(5,6-dihydro)-2H-thiopyrano[4,3-b]pyridinyl, 6-(3,4- dihydro)-2H-thiopyrano[3,2-b]pyridinyl, 5-benzo[b]thiophenyl, 4-benzo_b]thiophenyl, 6-benzo[b]thiophenyl, 7-benzo[b]thiophenyl, 5-(2,3-dihydro)-benzo[b]thiophenyl, 4- (2,3-dihydro)-benzo[b]thiophenyl, 6-(2,3-dihydro)-benzo[b]thiophenyl, 7-(2,3-dihydro)- benzo[b]thiophenyl, 4-( l,3-dihydro)-benzo[c]thiophenyl, 5-( 1,3-dihydro)- benzo[c]thiophenyl, 5-(3,4-dihydro)-lH-2-benzothiopyranyl, 6-(3,4-dihydro)-lH-2- benzothiopyranyl, 7-(3,4-dihydro)-lH-2-benzothiopyranyl, 8-(3,4-dihydro)-lH-2- benzothiopyranyl, 5-(3,4-dihydro)-2H-l-benzothiopyranyl, 6-(3,4-dihydro)-2H-l- benzothiopyranyl, 7-(3,4-dihydro)-2H-l-benzothiopyranyl, or 8-(3,4-dihydro)-2H-l- benzothiopyranyl; or such five or six membered ring substituted with 1, 2 or 3, Cj- C6 alkyl, CrCg alkoxy, -OH, -CH2OH, -(CH^-N^XR^), -C3-C8 cycloalkyl, -CF3, -halo, -CO2(R31), -CON(R31)(R32), -CO^), -(CH2)nN(R31)(CO(R33)), - (CH2)nN(R31)(S02(R33)), -CN, -CH2CFg or -CH(CFg)2, or phenyl, and the saturated ring may be optionally substituted with 1, 2 or 3, -Cj-Cg alkyl, -Cj-Cg alkoxy, -OH, - CH2OH or -(CH2)n-N(R31)(R32) or one oxo (=O);
8. A compound according to Claim 7 wherein R4 is NH2, Rg is -H, and Rg is -SCHg.
9. A compound according to Claim 8 wherein R-^ is a five or six membered saturated or unsaturated ring selected from the group consisting of 3-isoquinolinyl, 1- isoquinolinyl, 2-quinolinyl, 3-quinolinyl, 3-(5,6,7,8-tetrahydro)-isoquinolinyl, 1- (5,6,7,8-tetrahydro)-isoquinolinyl, 2-(5,6,7,8-tetrahydro)-quinolinyl, 3-(5,6,7,8- tetrahydro)-quinolinyl, 3-(5,6-dihydro)-2H-2-pyrindinyl, l-(5,6-dihydro)-2H-2- pyrindinyl, 2-(5,6-dihydro)-lH-l-pyrindinyl, 3-(5,6-dihydro)-lH-l-pyrindinyl, 5- furo[2,3-c]pyridinyl, 6-furo[3,2-c]pyridinyl, 4-furo[3,2-c_pyridinyl, 7-furo[2,3- c]pyridinyl, 6-furo[2,3-b]pyridinyl, 5-furo[3,2-b]pyridinyl, 5-(2,3-dihydro)-furo[2,3- cjpyridinyl, 6-(2,3-dihydro)-furo[3,2-c]pyridinyl, 4-(2,3-dihydro)-furo[3,2-c]pyridinyl, 7-(2,3-dihydro)-furo[2,3-c_pyridinyl, 6-(2,3-dihydro)-furo[2,3-b]pyridinyl, 5-(2,3- dihydro)-furo[3,2-b]pyridinyl, 6-(l,3-dihydro)-furo[3,4-c]pyridinyl, 4-(l,3-dihydro)- furo[3,4-c]pyridinyl, 2-(5,7-dihydro)-furo[3,4-b]pyridinyl, 6-(3,4-dihydro)-2H- pyrano[2,3-c]pyridinyl, 6-(3,4-dihydro)-lH-pyranot3,4-c]pyridinyl, 7-(3,4-dihydro)-lH- pyrano[4,3-c]pyridinyl, 7-(3,4-dihydro)-2H-pyrano(3,2-c]pyridinyl, 5-(3,4-dihydro)-2H- pyranof3,2-c]pyridinyl, 5-(3,4-dihydro)-lH-pyranot4,3-c]pyridinyl, 8-(3,4-dihydro)-lH- pyrano[3,4-c]pyridinyl, 8-(3,4-dihydro)-2H-pyrano[2,3-c]pyridinyl, 7-(3,4-dihydro)-2H- pyrano[2,3-b]pyridinyl> 2-(5,6-dihydro)-lH-pyrano[3,4-b]pyridinyl, 2-(5,6-dihydro)-2H- pyrano[4,3-b]pyridinyl and 6-(3,4-dihydro)-2H-pyrano[3,2-b]pyridinyl or such five or six membered ring substituted 1, 2 or 3, C-^-C alkyl, Cj-Cg alkoxy, -OH, -CH2OH, -(CH2)n-N(R31)(R32), -C3-C8 cycloalkyl, -CF3, -halo, -002(113!), -CON(Rg1)(Rg2), - CCXRgi), -(CH2)nN(R31)(CO(R33)), -(CH-j^RgjXSO^Rgg)), -CN, -CH2CF3 or -
CH(CF3)2, or phenyl, and the saturated ring may be optionally substituted with 1, 2 or 3, -C1-C6 alkyl, -C1-C6 alkoxy, -OH, -CH2OH or -(CH2)n-N(R31XR32) or one oxo (=0).
10. A compound according to Claim 1 and selected from the group consisting of: (E )-NN-Diethyl-4- [(4-amino-6-methylthio-2-pyrimidinyl)thio] -2-butenamide
(Cpd# 194)
(i_.)-l-[4-[(4-amino-6-methylthio-2-pyrimidinyl)thio]-l-oxo-2-butenyl]pyrrolidine (Cρd# 199)
(£)-N-ethyl-N-methyl-4-[(4-amino-6-methylthio-2-pyrimidinyl)thio]-2-butenamide (Cpd# 203)
( )-N^V-Diethyl-4-[(4-amino-6-methylthio-2-pyrimidinyl)thio]-2-pentenamide (Cpd# 207)
4-Amino-6-methylthio-2-( l-(3-isoquinolyl)ethyl)thio-pyrimidine (Cpd# 230) 4-Amino-5-bromo-6-methylthio-2-(l-(3-isoquinolyl)ethyl)thio-pyrimidine (Cpd# 231)
4-Amino-6-methylthio-2-(l-(3-(5,6,7,8-tetrahydroisoquinolyl))ethyl)thio- pyrimidine (Cpd#233)
4-Amino-6-methylthio-2-(l-(7-chlorofuro[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine (Cpd# 237) 4-Amino-6-methylthio-2-( l-(furo[2,3-c]pyridin-5-yl)ethyl)thio-pyrimidine (Cpd#
238)
4-Amino-6-methylthio-2-(l-(7-chloro-2-methylfuro[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine (Cpd #240)
4-Amino-6-methylthio-2-(l-(2-methylfuro[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine (Cpd #242)
4-Amino-6-methylthio-2-(l-(2-methylfuro[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine (Cpd #243)
4-Amino-6-methylthio-2-(l-(3-methylfuro[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine (Cpd #246) 4-Amino-6-methylthio-2-(l-(2,3-dihydrofuro[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine (Cpd #247)
4-Amino-6-methylthio-2-(l-(3,3-dimethyl-2,3-dihydrofuro[2,3c]pyridine-5- yl)ethyl)thio-pyrimidine (Cpd #248)
4-Amino-6-methylthio-2-(l-(3-ethylfuro[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine (Cpd #249)
4-Amino-6-methylthio-2-(l-(7-chloro-3,3-dimethyl-2,3- dihydrofuro[2,3c]pyridine-5-yl)ethyl)thio-pyrimidine (Cpd #250)
4-Amino-6-methylthio-2-( l-(7-chloro-3-ethylfuro- [2,3c] pyridine-5-yl)ethyl)thio- pyrimidine (Cpd #251)
4-Amino-6-methylthio-2-(l-(3-(l-methylethyl)furo[2,3c]-pyridin-5-yl)ethyl)thio- pyrimidine (Cpd #252)
4-Amino-6-methylthio-2-(l-(3-chlorofuro[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine. (Cpd #282)
4-Aniino-6-methylthio-2-(l-(3,7-dichlorofuro[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine, (Cpd #283) 4-Amino-6-methylthio-2-(l-(3-bromofuro[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine, (Cpd #284)
4-Amino-6-methylthio-2-(l-(3-bromo-7-chlorofuro[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine, (Cpd #285)
4-Amino-6-methylthio-2-(l-(7-chloro-3-methylfuro[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine, (Cpd #286)
4-Amino-6-trifluoromethyl-2-(l-(7-chloro-3,3-dimethyl-2,3- dihydrofuro[2,3c]pyridine-5-yl)ethyl)thio-pyrimidine, (Cpd #287)
(R)-(+)-4-Amino-6-methylthio-2-(l-(3-methylfuro[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine (Cd #289) (S)-(-)-4-Amino-6-methylthio-2-(l-(3-methylfuro[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine Cpd #290
(S)-(-)-4-Amino-6-trifluoromethyl-2-(l-(3-methylfuro[2,3c]pyridin-5- yl)ethylthio)-pyrimidine (Cpd #297)
(S)-(-)-4-Amino-6-methylthio-2-( l-(furo [2,3c] pyridin-5-yl)ethylthio)-pyrimidine (Cpd #1); and pharmaceutically acceptable salts, hydrates, N-oxides and solvates thereof.
11. A method of treating an individual infected with the human immunodeficiency virus (HIV) which comprises administering an effective amount of an anti-AIDS compound of Formula I
Figure imgf000091_0001
where m is 0 or 1;
R is selected from the group consisting of -CΓëíCH, -C02R53, -CONR54R55,
Figure imgf000091_0002
where s is 0 or land I^Q, R2I' ^22' ^23' ^24' an<* ^25 are ^e same or different and are selected from -H, Cj-Cg alkyl, C-j-Cg alkenyl, Cj-Cg alkoxy, C1-C6 alkylthio, -C3-C8 cycloalkyl, -CFg, -N02, -halo, -OH, - CN, phenyl, phenylthio, -styryl, -CO2(R31), -CON(R31)(R32), -CO(R31), -(CH2)n-N(R31)(R32), -C(OH)(R31)(R33), -(CH2)nN(R31)(CO(R33)), (CH2)nN(R31)(S02 (R33)), or where ^Q and I^j, or I^ and R22, or R22 and ^3 are taken together to form a five or six-membered saturated or unsaturated ring containing 0 or 1 oxygen, nitrogen or sulfur, where the unsaturated ring may be optionally substituted with 1, 2 or 3, CrC6 alkyl, CrC6 alkoxy, -OH, -CH2OH, -(CH2)n- N(R31XR32), -C3-C8 cycloalkyl, -CF3, -halo, -CO^R^), - CON(R31)(R32), -COtR^), -(CH2)nN(R31)(CO(R33)), - (CH2)nN(R31)(S02(R33)), -CN, CH2CF3 or -CH(CF3)2, or phenyl, and the saturated ring may be optionally substituted with 1, 2 or 3, -Cj-Cg alkyl, -CrC6 alkoxy, -OH, -CH2OH or -(CH2)n-N(R31)(R32) or one oxo (=O); where n is 0-3 and R3j, R32, and R33 are the same or different and are selected from -H,
CrC6 alkyl, phenyl optionally substituted with 1, 2, or 3 -halo, C^-Cg alkyl, CrC6 alkoxy, -CF3, -OH or -CN, or where Rgj and Rg2 taken together with the attached nitrogen to form a ring selected from -pyrrolidinyl, -piperidinyl, -4-morpholinyl, -4-thiomorpholinyl, -4- piperazinyl, -4-( 1-C ^CgalkyDpiperazinyl, or a member selected from the group consisting of: 1-cyclohexenyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-imidazolyl, 4-imidazolyl, 2-benzothiazolyl, 2-benzoxazolyl, 2-benzimidazolyl, 2-oxazolyl,
4-oxazolyl, 2-thiazolyl, 3-isoxazolyl, 5-isoxazolyl, 5-methyl-3-isoxazolyl, 5- phenyl-3-isoxazolyl, 4-thiazolyl, 3-methyl-2-pyrazinyl, 5-methyl-2-pyrazinyl, 6- methyl-2-pyrazinyl, 5-chloro-2-thienyl, 3-furyl, benzofuran-2-yl, benzothien-2- yl, 2H-l-benzopyran-3-yl, 2,3-dihydrobenzopyran-5-yl, l-methylimidazol-2-yl, quinoxalin-2-yl, piperon-5-yl, 4,7-dichlorobenzoxazol-2-yl, 4,6-dimethyl- pyrimidin-2-yl, 4-methylpyrimidin-2-yl, 2,4-dimethylpyrimidin-6-yl, 2- methylpyrimidin-4-yl, 4-methylpyrimidin-6-yl, 6-chloropiperon-5-yl, 5- chloroimidazo[l,2-a]pyridin-2-yl, l-H-inden-3-yl, l-H-2-methyl-inden-2-yl, 3,4- dihydronaphth-1-yl, S-4-isopropenylcyclohexen-l-yl or 4-dihydronaphth-2-yl; where R53 is selected from the group consisting of -H, Cj-Cgalkyl, C3-
Cgcycloalkyl, phenyl (optionally substituted with 1, 2, or 3 -halo, C-j-Cg alkyl, C-j^-Cg alkoxy, -CFg, -OH, -CN), or a five or six-membered unsaturated ring containing 0 or 1 oxygen, nitrogen or sulfur, where the unsaturated ring may be optionally substituted with -H, Cj-C alkyl, CrC6 alkoxy, -OH, -CH2OH, or -(CH2)n-N(R31)(R32); where R54 and R55 being the same or different are selected from -H, Cj-Cg alkyl, allyl, or phenyl (optionally substituted with 1, 2, or 3 -halo, Cj-Cg alkyl, Cj-Cg alkoxy or -CFg), or taken together with the attached nitrogen to form a ring selected from -pyrrolidinyl, -piperidinyl, -4-morpholinyl, -4-thiomorpholinyl, -4-piperazinyl, - 4-(l-C1-C6alkyl)piperazinyl;
R41 and R42, being the same or different, are selected from the group consisting of -H and C1-C4 alkyl;
R12 is selected from the group consisting of -H, Cj-Cg alkyl, -Cg-Cg cycloalkyl, -CN, -C(0)NH2, -C(0)N(C1-C6alkyl)(C1-C6alkyl), -C02H, -C02(CrC6alkyl), -CH2OH, -CH2NH2 or -CF3;
R13 is selected from the group consisting of -H, C1-Cg alkyl or -CF3; Y is selected from -S-, -S(O)-, -S(0)2, or -0-;
R4 is selected from the group consisting of -H, -OH, halo or -NRjgRj where Rjg is -H and Rj is -H, C^-Cg alkyl, -NH2 or R15 and R16 taken together with the -N form 1-pyrrolidino, 4-morpholino or 1-piperidino; Rg is selected from the group consisting of -H, -C2H4OH, -C2H rO-TBDMS, halo, -Cg-Cg cycloalkyl, C-|_-C4 alkyl or Cj-Cg alkoxy; or R4 and Rg are taken together to form a five or six-membered saturated or unsaturated ring which together with the pyrimidine ring form the group consisting of 7H-pyrrolo[2,3-d]pyrimidine, 5,6-dihydro-7H-pyrrolo{2,3-d]pyrimidine, furo[2,3- dlpyrimidine, 5,6-dihydro-furo[2,3-d]pyrimidine, thieno[2,3-d]pyrimidine, 5,6-dihydro- thieno[2,3-d]pyrimidine, lH-pyrazolo[3,4-d]pyrimidine, lH-purine, pyrimido[4,5- d]pyrimidine, pteridine, pyrido[2,3-d]pyrimidine, or quinazoline, where the unsaturated ring may be optionally substituted with 1, 2 or 3, C-^Cg alkyl, Cj-Cg alkoxy, -OH, -CH2OH, or
-(CH2)n-N(R31)(R32), -C3-C8 cycloalkyl, -CF3, -halo, -C02(R31), -CON(R31XRg2), - CO R^), -(CH2)nN(Rg1XCO(R33)), -(CH2)nN(R31) (S02(R33)), and the saturated ring may be optionally substituted with 1, 2 or 3, -Cj-Cg alkyl, -Cj^-Cg alkoxy, -OH, - CH2OH, or -(CH2)n-N(R31)(R32) or one oxo (=0); and R6 is -S-CrC6 alkyl; and pharmaceutically acceptable salts, hydrates, N-oxides and solvates thereof;
12. A method according to Claim 11 where m is 0, s is 0 and Y -S.
13. A method according to Claim 12 where R12 is CH3 and R13 is -H.
14. A method according to Claim 13 where R4 is NH^, Rg is -H, and Rg is -SCHg.
15. A method according to Claim 12 where Rj is
Figure imgf000093_0001
16. A method according to Claim 15 wherein R4 is NH2, R5 is -H, and Rg is - SCH3.
17. A method according to Claim 14 wherein R^ is a five or six membered saturated or unsaturated ring selected from the group consisting of 3-isoquinolinyl, 1-isoquinolinyl, 2-quinolinyl, 3-quinolinyl, 3-(5,6,7,8-tetrahydro)-isoquinolinyl, 1- (5,6,7,8-tetrahydro)-isoquinolinyl, 2-(5,6,7,8-tetrahydro)-quinolinyl, 3-(5,6,7,8- tetrahydro)-quinolinyl, 3-(5,6-dihydro)-2H-2-pyrindinyl, l-(5,6-dihydro)-2H-2- pyrindinyl, 2-(5,6-dihydro)-lH-l-pyrindinyl, 3-(5,6-dihydro)-lH-l-pyrindinyl, 5- furo[2,3-c]pyridinyl, 6-furo [3, 2-c] pyridinyl, 4-furo[3,2-c]pyridinyl, 7-furo[2,3- c]pyridinyl, 6-furo[2,3-b]pyridinyl, 5-furo[3,2-b]pyridinyl, 5-(2,3-dihydro)-furo[2,3- c]pyridinyl, 6-(2,3-dihydro)-furo[3,2-c]pyridinyl, 4-(2,3-dihydro)-furo[3-2-c]pyridinyl, 7-(2,3-dihydro)-furo[2,3-c]pyridinyl, 6-(2,3-dihydro)-furo[2,3-b]pyridinyl, 5-(2,3- dihydro)-furo[3,2-b]pyridinyl, 6-(l,3-dihydro)-furo[3,4-c]pyridinyl, 4-(l,3-dihydro)- furo[3,4-c]pyridinyl, 2-(5,7-dihydro)-furo[3,4-b]pyridinyl, 6-(3,4-dihydro)-2H- pyrano[2,3-c]pyridinyl, 6-(3,4-dihydro)-lH-pyrano[3,4-c]pyridinyl, 7-(3,4-dihydro)-lH- pyrano[4,3-c]pyridinyl, 7-(3,4-dihydro)-2H-pyrano[3,2-c]pyridinyl, 5-(3,4-dihydro)-2H- pyrano[3,2-c]pyridinyl, 5-(3,4-dihydro)-lH-pyrano[4,3-c]pyridinyl, 8-(3,4-dihydro)-lH- pyrano [3,4-c] pyridinyl, 8-(3,4-dihydro)-2H-pyrano[2,3-c]pyridinyl, 7-(3,4-dihydro)-2H- pyrano[2J3-b]pyridinyl, 2-(5,6-dihydro)-lH-pyrano[3,4-b]pyridinyl, 2-(5,6-dihydro)-2H- pyrano[4,3-b]pyridinyl, 6-(3,4-dihydro)-2H-pyrano[3,2-b]pyridinyl, 5-lH-pyrrolo[2,3- c]pyridinyl, 6-lH-pyrrolo[3,2-c]pyridinyl, 4-lH-pyrrolo[3,2-c]pyridinyl, 7-1H- pjτrolo[2,3-c]pyridinyl, 6-lH-p3nτolo[2,3-b]p3rridinyl, 5-lH-pyrrolo[3,2-b]pyridinyl, 5- (2,3-dihydro)-lH-pyrrolo[2,3-c]pyridinyl, 6-(2,3-dihydro)-lH-pyrrolo[3,2-c]pyridinyl, 4- (2,3-dihydro)-lH-pyrrolo[3,2-c]pyridinyl, 7-(2,3-dihydro)-lH-pyrrolo[2,3-c]pyridinyl, 6- (2,3-dihydro)-lH-pyrrolo[2,3-b]pyridinyl, 5-(2,3-dihydro)-lH-pyrrolo[3,2-b]pyridinyl, 6-(l,3-dihydro)-lH-pyrrolo[3,4-c]pyridinyl, 4-(l,3-dihydro)-lH-pyrrolo[3,4-c]pyridinyl, 2-(5,7-dihydro)-lH-pyrrolo[3,4-b]pyridinyl, 6-1,7-naphthyridinyl, 6-2,7- napKthyridinyl, 7-2,6-naphthjrridinyl, 7-1,6-naphthyridinyl, 5-1,6-naphthyridinyl, 5- 2,6-naphthyridinyl, 8-2,7-naphthyridinyl, 8-1,7-naphthyridinyl, 7-1,8-naphthyridinyl, 2-1,7-naphthyridinyl, 2-1,6-naphthyridinyl, 6-1,5-naphthyridinyl, 6-(l,2,3,4- tetrahydro)-l,7-naphthyridinyl, 6-(l,2,3,4-tetrahydro)-2,7-naphthyridinyl, 7-(l,2,3,4- tetrahydro)-2,6-naphthyridinyl, 7-(l,2,3,4-tetrahydro)-l,6-naphthyridinyl, 5-(l,2,3,4- tetrahydro)-l,6-naphthyridinyl, 5-(l,2,3,4-tetrahydro)-2,6-naphthyridinyl, 8-(l,2,3,4- tetrahydro)-2,7-naphthyridinyl, 8-(l,2,3,4-tetrahydro)-l,7-naphthyridinyl, 7-(l,2,3,4- tetrahydro)-l,8-naphthyridinyl, 2-(5,6,7,8-tetrahydro)-l,7-naphthyridinyl, 2-(5,6,7,8- tetrahydro)-l,6-naphthyridinyl, 6-(l,2,3,4-tetrahydro)-l,5-naphthyridinyl, 1-naphthyl, 2-naphthyl, 5-(l,2,3,4-tetrahydro)-naphthyl, 6-(l,2,3,4-tetrahydro)-naphthyl, 4-(2,3- dihydro)-lH-indenyl, 5-(2,3-dihydro)-lH-indenyl, 5-benzofuranyl, 4-benzofuranyl, 6- benzofuranyl, 7-benzofuranyl, 5-(2,3-dihydro)-benzofuranyl, 4-(2,3-dihydro)- benzofuranyl, 6-(2,3-dihydro)-benzofuranyl, 7-(2,3-dihydro)-benzofuranyl, 4-(l,3- dihydro)-isobenzofuran, 5-(l,3-dihydro)-isobenzofuran, 4-lH-indolyl, 5-lH-indolyl, 6- lH-indolyl, 7-lH-indolyl, 4-(2,3-dihydro)-lH-indolyl, 5-(2,3-dihydro)-lH-indolyl, 6- (2,3-dihydro)-lH-indolyl, 7-(2,3-dihydro)-lH-indolyl, 4-(l,3-dihydro)-lH-isoindolyl, 5- (l,3-dihydro)-lH-isoindolyl, 5-(3,4-dihydro)-lH-2-benzopyranyl, 6-(3,4-dihydro)-lH-2- benzopyranyl, 7-(3,4-dihydro)-lH-2-benzopyranyl, 8-(3,4-dihydro)-lH-2-benzopyranyl, 5-(3,4-dihydro)-2H-l-benzopyranyl, 6-(3,4-dihydro)-2H-l-benzopyranyl, 7-(3,4- dihydro)-2H-l-benzopyranyl, 8-(3,4-dihydro)-2H-l-benzopyranyl, 5-(l,2,3,4- tetrahydro)-isoquinolinyl, 6-(l,2,3,4-tetrahydro)-isoquinolinyl, 7-(l,2,3,4-tetrahydro)- isoquinolinyl, 8-(l,2,3,4-tetrahydro)-isoquinolinyl, 5-(l,2,3,4-tetrahydro)-quinolinyl, 6- (l,2,3,4-tetrahydro)-quinolinyl, 7-(l,2,3,4-tetrahydro)-quinolinyl, 8-(l,2,3,4- tetrahydro)-quinolinyl, 5-thieno[2,3-c]pyridinyl, 6-thieno[3,2-c]pyridinyl, 4-thieno[3,2- c]pyridinyl, 7-thieno [2,3-c] pyridinyl, 6-thieno[2,3-b]pyridinyl, 5-thieno[3,2- b]pyridinyl, 5-(2,3-dihydro)-thieno[2,3-c]pyridinyl, 6-(2,3-dihydro)-thieno[3,2- φyridinyl, 4-(2,3-dihydro)-thieno[3,2-c]pyridinyl, 7-(2,3-dihydro)-thieno[2,3- clpyridinyl, 6-(2,3-dihydro)-thieno[2,3-b]pyridinyl, 5-(2,3-dihydro)-thieno[3,2- blpyridinyl, 6-(l,3-dihydro)-thieno[3,4-c]pyridinyl, 4-(l,3-dihydro)-thieno[3,4- c]pyridinyl, 2-(5,7-dihydro)-thieno[3,4-b]pyridinyl 6-(3,4-dihydro)-2H- thiopyrano [2,3-c] pyridinyl, 6-(3,4-dihydro)-lH-thiopyrano[3,4-c]pyridinyl, 7-(3,4- dihydro)-lH-thiopyrano[4,3-c]pyridinyl, 7-(3,4-dihydro)-2H-thiopyrano[3,2-c]pyridinyl, 5-(3,4-dihydro)-2H-thiopyrano[3,2-c]pyridinyl, 5-(3,4-dihydro)-lH-thiopyrano[4,3- cjpyridinyl, 8-(3,4-dihydro)-lH-thiopyrano[3,4-c]pyridinyl, 8-(3,4-dihydro)-2H- thiopyrano[2,3-c]pyridinyl, 7-(3,4-dihydro)-2H-thiopyrano[2,3-b]pyridinyl, 2-(5,6- dihydro)-lH-thiopyrano[3,4-b] pyridinyl, 2-(5,6-dihydro)-2H-thiopyrano[4,3- blpyridinyl, 6-(3,4-dihydro)-2H-thiopyrano[3,2-b]pyridinyl, 5-benzo[b]thiophenyl, 4- benzo[b]thiophenyl, 6-benzo[b]thiophenyl, 7-benzo[b]thiophenyl, 5-(2,3-dihydro)- benzo[b]thiophenyl, 4-(2,3-dihydro)-benzo[b]thiophenyl, 6-(2,3-dihydro)- benzo[b]thiophenyl, 7-(2,3-dihydro)-benzo[b]thiophenyl, 4-(l,3-dihydro)- benzo[c]thiophenyl, 5-(l,3-dihydro)-benzo[c]thiophenyl, 5-(3,4-dihydro)-lH-2- benzothiopyranyl, 6-(3,4-dihydro)-lH-2-benzothiopyranyl, 7-(3,4-dihydro)-lH-2- benzothiopyranyl, 8-(3,4-dihydro)-lH-2-benzothiopyranyl, 5-(3,4-dihydro)-2H-l- benzothiopjπ-anyl, 6-(3,4-dihydro)-2H-l-benzothiopyranyl, 7-(3,4-dihydro)-2H-l- benzothiopyranyl or 8-(3,4-dihydro)-2H-l-benzothiopyranyl; or such five or six membered ring substiuted with 1, 2 or 3, Cj-Cg alkyl, Cj-Cg alkoxy, -OH, -CH2OH, - (CH2)n-N(R31)(R32), -C3-C8 cycloalkyl, -CF3, -halo, -C02(R31), -CON(R31)(R32), - CO(R31), -(CH2)nN(R31)(C0(R33)), -(CH2)nN(R31)(S02(R33)), -CN, -CH2CF3 or - CH(CF3)2, or phenyl, and the saturated ring may be optionally substituted with 1, 2 or 3, -CrC6 alkyl, -CrC6 alkoxy, -OH, -CH2OH or -(CH2)n-N(R31)(R32) or one oxo (=0).
18. A method according to Claim 17 wherein R4 is NH2, R5 is -H, and Rg is -SCH3.
19. A method according to Claim 18 wherein Rj^ is a five or six membered saturated or unsaturated ring selected from the group consisting of 3-isoquinolinyl, 1- isoquinolinyl, 2-quinolinyl, 3-quinolinyl, 3-(5,6,7,8-tetrahydro)-isoquinolinyl, 1- (5,6,7,8-tetrahydro)-isoquinolinyl, 2-(5,6,7,8-tetrahydro)-quinolinyl, 3-(5,6,7,8- tetrahydro)-quinolinyl, 3-(5,6-dihydro)-2H-2-pyrindinyl, l-(5,6-dihydro)-2H-2- pyrindinyl, 2-(5,6-dihydro)-lH-l-pyrindinyl, 3-(5,6-dihydro)-lH-l-pyrindinyl, 5- furo[2,3-c]pyridinyl, 6-furo[3,2-c]pyridinyl, 4-furo[3,2-c]pyridinyl, 7-furo[2,3- clpyridinyl, 6-furo[2,3-b]pyridinyl, 5-furo[3,2-b]pyridinyl, 5-(2,3-dihydro)-furo[2,3- clpyridinyl, 6-(2,3-dihydro)-furo[3,2-c]pyridinyl, 4-(2,3-dihydro)-furo[3,2-c]pyridinyl, 7-(2,3-dihydro)-furol2,3-c]pyridinyl, 6-(2,3-dihydro)-furo[2,3-b]pyridinyl, 5-(2,3- dihydro)-furo [3,2-b] pyridinyl, 6-( l,3-dihydro)-furo [3,4-c] pyridinyl, 4-( 1 ,3-dihydro)- furo[3,4-c]pyridinyl, 2-(5,7-dihydro)-furo[3,4-b]pyridinyl, 6-(3,4-dihydro)-2H- pyrano[2,3-c]pyridinyl, 6-(3,4-dihydro)-lH-pyrano[3,4-c]pyridinyl, 7-(3,4-dihydro)-lH- pyrano[4,3-c]pyridinyl, 7-(3,4-dihydro)-2H-pyrano[3,2-c]pyridinyl, 5-(3,4-dihydro)-2H- pyrano [3, 2-c] pyridinyl, 5-(3,4-dihydro)-lH-pyrano[4,3-c]pyridinyl, 8-(3,4-dihydro)-lH- pyrano[3,4-c]pyridinyl, 8-(3,4-dihydro)-2H-pyrano[2,3-c]pyridinyl, 7-(3,4-dihydro)-2H- pyrano[2,3-b]pyridinyl, 2-(5,6-dihydro)-lH-pyranol3,4-b]pyridinyl, 2-(5,6-dihydro)-2H- pyrano[4,3-b] pyridinyl and 6-(3,4-dihydro)-2H-pyrano[3,2-b]pyridinyl or such five or six membered ring with 1, 2 or 3, Cj-Cg alkyl, Cj-Cg alkoxy, -OH, -CH2OH, - (CH2)n-N(R31)(R32), -C3-C8 cycloalkyl, -CF3, -halo, -C02(R31), -CON(R31)(R32), - CO Rgj), -(CH2)nN(R31)(C0(R33)), -(CH2)nN(R31XS02(R33)), -CN, -CH2CF3 or - CH(CF3)2, or phenyl, and the saturated ring may be optionally substituted with 1, 2 or 3, -CrC6 alkyl, -CrC6 alkoxy, -OH, -CH2OH or -(CH^-N R^ Rgg) or one oxo (=0).
20. A method of treating an individual infected with the human immunodeficiency virus (HIV) according to Claim 11 where the (1) infected individual is asymptomatic but tests positive for the HIV antigen, (2) infected individual is symptomatically sick but does not have "full blown AIDS", (3) individual infected with the human immunodeficiency virus (HIV) has "full blown AIDS"..
21. A method of treating an individual infected with the human immunodeficiency virus (HIV) according to claim 11 where the administration is oral and the effective dose is from about 0.10 mg/kg day to about 500 mg/kg/day.
22. A method of treating an individual infected with the human immunodeficiency virus (HIV) according to claim 11 where the compound is selected from the group consisting of
(£)-NN-Diethyl-4-[(4-amino-6-methylthio-2-pyrimidinyl)thio]-2-butenamide (Cpd# 194)
(E)- 1- [4- [(4-amino-6-methylthio-2-pyrimidinyl)thio] - l-oxo-2-butenyl] pyrrolidine (Cpd# 199)
(£)-N-ethyl-N-methyl-4-[(4-amino-6-methylthio-2-pyrimidinyl)thio]-2-butenamide (Cpd# 203) (E)-NN-Diethyl-4-[(4-amino-6-methylthio-2-pyrimidinyl)thio]-2-pentenamide
(Cpd# 207)
4-Amino-6-methylthio-2-( l-(3-isoquinolyl)ethyl)thio-pyrimidine (Cpd# 230) 4-Amino-5-bromo-6-methylthio-2-(l-(3-isoquinolyl)ethyl)thio-pyrimidine (Cpd# 231) 4-Amino-6-methylthio-2-(l-(3-(5,6,7,8-tetrahydroisoquinolyl))ethyl)thio- pyrimidine (Cpd#233)
4-Amino-6-trifluoromethyl-2-(l-(3-(5,6,7,8-tetrahydro-isoquinolyl))ethyl)thio- pyrimidine (Cpd# 234)
4-Amino-6-methylthio-2-(l-(7-chlorofuro[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine (Cpd# 237)
4-Amino-6-methylthio-2-(l-(furo [2,3-c] pyridin-5-yl)ethyl)thio-pyrimidine (Cpd# 238)
4-Amino-6-trifluoromethyl-2-(l-(furo[2,3-c]pyridin-5-yl)ethyl)thio-pyrimidine (Cpd# 239) 4-Amino-6-methylthio-2-(l-(7-chloro-2-methylfuro[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine (Cpd # 240) 4-Amino-6-trifluoromethyl-2-(l-(7-chloro-2-methylfuro[2,3c]pyridine-5- yl)ethyl)thio-pyrimidine (Cpd# 241)
4-Amino-6-methylthio-2-(l-(2-methylfuro[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine (Cpd #242) 4-Amino-6-trifluoromethyl-2-(l-(2-methylfuro[2,3c]pyridine-5-yl).ethyl)thio- pyrimidine (Cpd #243)
4-Amino-6-methylthio-2-(l-(3-methylfuro[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine (Cpd #246)
4-Amino-6-methylthio-2-(l-(2,3-dihydrofuro[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine (Cpd #247)
4-Amino-6-methylthio-2-(l-(3,3-dimethyl-2,3-dihydrofuro[2,3c]pyridine-5- yl)ethyl)thio-pyrimidine (Cpd# 248)
4-Amino-6-methylthio-2-(l-(3-ethylfuro[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine (Cpd# 249) 4-Amino-6-methylthio-2-( l-(7-chloro-3,3-dimethyl-2,3- dihydrofuro[2,3c]pyridine-5-yl)ethyl)thio-pyrimidine (Cpd #250)
4-Amino-6-methylthio-2-(l-(7-chloro-3-ethylfuro-[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine (Cpd #251)
4-Amino-6-methylthio-2-(l-(3-(l-methylethyl)furo[2,3c]-pyridin-5-yl)ethyl)thio- pyrimidine (Cpd #252)
4-amino-6-chloro-2-(l-(4-(l-methylpropyl)-2-pyridyl)-ethyl)thio-pyrimidine (Cpd #256)
4-amino-6-trifluoromethyl-2-( l-(4-( l-dimethylethyl)-2-pyridyl)- ethyDthio-pyrimidine (Cpd #269) 4-amino-6-trifluoromethyl-2-(2-naphthylmethyl)thio-pyrimidine (Cpd #270)
4-amino-6-trifluoromethyl-2-((4-(l-methylethyl)- 2-pyridyl)methyl)thio-pyrimidine (Cpd #271)
4-amino-6-trifluoromethyl-2-( l-(4-( 1-methylethyl)- 2-pyridyl)ethyl)thio-pyrimidine (Cpd #272) 4-amino-6-trifluoromethyl-2-((4-(l,l-dimethylethyl)-
2-pyridyl)methyl)thio-pyrimidine (Cpd #273)
6-amino-2-(2-naphthylmethyl)thio-4-pyrimidine carbonitrile (Cpd 277), 4-Amino-6-methylthio-2-(l-(3-chlorofuro[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine. (Cpd #282) 4-Amino-6-methylthio-2-(l-(3,7-dichlorofuro[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine, (Cpd #283) 4-Amino-6-methylthio-2-(l-(3-bromofuro[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine, (Cpd #284)
4-Amino-6-methylthio-2-(l-(3-bromo-7-chlorofuro[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine, (Cpd #285) 4-Amino-6-methylthio-2-( l-( 7-chloro-3-methylfuro [2,3c] pyridine-5-yl)ethyl)thio- pyrimidine, (Cpd #286)
4-Amino-6-trifluoromethyl-2-(l-(7-chloro-3,3-dimethyl-2,3- dihydrofuro[2,3c]pyridine-5-yl)ethyl)thio-pyrimidine, (Cpd #287) ???
(R)-(+)-4-Amino-6-methylthio-2-( l-(3-methylfuro [2,3c] pyridine-5-yl)ethyl)thio- pyrimidine (Cpd #289)
(S)-(-)-4-Amino-6-methylthio-2-(l-(3-methylfuro[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine Cpd (#290)
(S)-(-)-4-Amino-6-trifluoromethyl-2-(l-(3-methylfuro[2,3c]pyridin-5- yl)ethylthio)-pyrimidine (Cpd #297)
(S)-(-)-4-Amino-6-methylthio-2-(l-(furo[2,3c]pyridin-5-yl)ethylthio)-pyrimidine (Cpd #1); and pharmaceutically acceptable salts, hydrates and solvates thereof.
22. A method according to Claim 21 where the compound is selected from the group consisting of (S)-(-)-4-Amino-6-methylthio-2-(l-(3-methylfuro[2,3c]pyridine-5- yl)ethyl)thio-pyrimidine;
(S)-(-)-4-Amino-6-methylthio-2-(l-(3-methylfuro[2,3c]pyridin-5-yl)ethylthio)- pyrimidine esylate salt; (S)-(-)4-Amino-2-(3-methyl-furano[2,3c]pyridin-5-yl)ethylthio-6- trifluoromethyl-pyrimidine mesylate salt;
(S)-(-)-4-Amino-6-methylthio-2-(l-(furo[2,3c]pyridin-5-yl)ethylthio)-pyrimidine and
(S)-(-)-4-Amino-6-methylthio-2-(l-(furo[2,3c]*pyridin-5-yl)ethylthio)-pyrimidine mesylate salt.
23. A compound according to Claim 1 and selected from the group consisting of (S)-(-)-4-Amino-6-methylthio-2-(l-(3-methylfuro[2,3c]pyridine-5-yl)ethyl)thio- pyrimidine; (S)-(-)-4-Amino-6-methylthio-2-( l-(3-methylfuro [2,3c] pyridin-5-yl)ethylthio)- pyrimidine esylate salt; (S )-(- )-4-Amino-6-methylthio-2-( 1 -( furo [2 , 3c] pyridin-5-yl )ethylthio )-pyrimidine and
(S)-(-)-4-Amino-6-methylthio-2-(l-(furo[2,3c]pyridin-5-yl)ethylthio)-pyrimidine mesylate salt.
PCT/US1998/018507 1997-09-25 1998-09-21 Alpha-alkylthio substituted pyrimidine ethers and thioethers as viral reverse transcriptase inhibitors WO1999019304A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2000515877A JP2002526378A (en) 1997-09-25 1998-09-21 Thioalkyl-alpha-substituted pyrimidine compounds
EP98966441A EP1034167A1 (en) 1997-09-25 1998-09-21 Alpha-alkylthio substituted pyrimidine ethers and thioethers as viral reverse transcriptase inhibitors
AU23050/99A AU750917B2 (en) 1997-09-25 1998-09-21 Thioalkyl alpha substituted pyrimidine compounds
US09/157,975 US6124306A (en) 1997-09-25 1998-09-21 Thioalkyl alpha substituted pyrimidine compounds
NZ503586A NZ503586A (en) 1997-09-25 1998-09-21 Thioalkyl alpha substituted pyrimidine compounds for treating HIV.
CA002301800A CA2301800A1 (en) 1997-09-25 1998-09-21 Thioalkyl alpha substituted pyrimidine compounds
KR1020007003158A KR20010024271A (en) 1997-09-25 1998-09-21 Thioalkyl Alpha Substituted Pyrimidine Compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5965697P 1997-09-25 1997-09-25
US60/059,656 1997-09-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/157,975 Continuation US6124306A (en) 1997-09-25 1998-09-21 Thioalkyl alpha substituted pyrimidine compounds

Publications (3)

Publication Number Publication Date
WO1999019304A2 true WO1999019304A2 (en) 1999-04-22
WO1999019304A9 WO1999019304A9 (en) 1999-07-08
WO1999019304A3 WO1999019304A3 (en) 2001-12-20

Family

ID=22024371

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/018507 WO1999019304A2 (en) 1997-09-25 1998-09-21 Alpha-alkylthio substituted pyrimidine ethers and thioethers as viral reverse transcriptase inhibitors

Country Status (9)

Country Link
US (1) US6124306A (en)
EP (1) EP1034167A1 (en)
JP (1) JP2002526378A (en)
KR (1) KR20010024271A (en)
CN (1) CN1309656A (en)
AU (1) AU750917B2 (en)
CA (1) CA2301800A1 (en)
NZ (1) NZ503586A (en)
WO (1) WO1999019304A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138404B2 (en) * 2001-05-23 2006-11-21 Hoffmann-La Roche Inc. 4-aminopyrimidine derivatives
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
KR20120132582A (en) * 2004-07-28 2012-12-05 다케다 야쿠힌 고교 가부시키가이샤 PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE
ES2625406T3 (en) 2010-03-25 2017-07-19 Oregon Health & Science University CMV glycoproteins and recombinant vectors
ES2667425T3 (en) 2011-06-10 2018-05-10 Oregon Health & Science University CMV recombinant glycoproteins and vectors
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
ES2631608T3 (en) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Env-glycoprotein variant of HIV-1
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2023137041A1 (en) * 2022-01-12 2023-07-20 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0124630A1 (en) * 1983-05-05 1984-11-14 LUDWIG HEUMANN &amp; CO GMBH Pyrimidinethioalkyl pyridine derivatives, process for their preparation and medicines containing these compounds
EP0694538A2 (en) * 1994-07-15 1996-01-31 Kureha Kagaku Kogyo Kabushiki Kaisha 2-benzyloxy-4-phenoxypyrimidine derivative, processes for producing the derivative and herbicidal composition containing the derivative
WO1996035678A1 (en) * 1995-05-08 1996-11-14 Pharmacia & Upjohn Company Alpha-substituted pyrimidine-thioalkyl and alkylether compounds as inhibitors of viral reverse transcriptase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE300230C (en) *
GB744867A (en) * 1952-10-29 1956-02-15 American Cyanamid Co Improvements relating to 2-substituted-mercapto-4-amino-6-disubstituted-aminopyrimidines and acid addition salts thereof
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5668136A (en) * 1990-09-25 1997-09-16 Eisai Co., Ltd. Trisubstituted benzene derivatives, composition and methods of treatment
DD300230A5 (en) * 1990-10-01 1992-05-27 Univ Leipzig PROCESS FOR THE PREPARATION OF 2,4,6- (TRI-ALKYLTHIO) -PYRIMIDINE-5-CARBONITRILES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0124630A1 (en) * 1983-05-05 1984-11-14 LUDWIG HEUMANN &amp; CO GMBH Pyrimidinethioalkyl pyridine derivatives, process for their preparation and medicines containing these compounds
EP0694538A2 (en) * 1994-07-15 1996-01-31 Kureha Kagaku Kogyo Kabushiki Kaisha 2-benzyloxy-4-phenoxypyrimidine derivative, processes for producing the derivative and herbicidal composition containing the derivative
WO1996035678A1 (en) * 1995-05-08 1996-11-14 Pharmacia & Upjohn Company Alpha-substituted pyrimidine-thioalkyl and alkylether compounds as inhibitors of viral reverse transcriptase

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 104, no. 3, 20 January 1986 Columbus, Ohio, US; abstract no. 19434g, K. HASHIZUME, S. INOUE: "Model experiments on surugatoxin synthesis. III. Synthesis of 2,4-dibenzyloxy-6-ethylsulfonyl-5-nitropyr imidine" page 468; XP002086427 & YAKUGAKU ZASSHI, vol. 105, no. 4, 1985, pages 362-367, *
CHEMICAL ABSTRACTS, vol. 80, no. 21, 27 May 1974 Columbus, Ohio, US; abstract no. 120861, P. VAINILAVICIUS ET AL.: "Hydrazones based on 5-ethyl-6-methyl-2-thiouracil" page 431; XP002086426 & LIET. TSR AUKST. MOKYLU MOKSLO DARB., CHEM. CHEM. TECHNOL., no. 14, 1972, pages 145-151, *
I. W. ALTHAUS ET AL.: "The Benzylthio-Pyrimidine U-31,355, a potent Inhibitor of HIV-1-Reverse Transcriptase" BIOCHEM. PHARMACOL., vol. 51, 1996, pages 743-750, XP000578772 *
M. CHEBIB, R. J. QUINN: "1-Phenylpyrazolo[3,4-dÜpyrimidines as Adenosine antagonists: the Effects of Substituents at C4 and C6" BIOORG. MED. CHEM., vol. 5, no. 2, 1997, pages 311-322, XP002086425 *

Also Published As

Publication number Publication date
WO1999019304A9 (en) 1999-07-08
WO1999019304A3 (en) 2001-12-20
CN1309656A (en) 2001-08-22
EP1034167A1 (en) 2000-09-13
KR20010024271A (en) 2001-03-26
JP2002526378A (en) 2002-08-20
US6124306A (en) 2000-09-26
CA2301800A1 (en) 1999-04-22
NZ503586A (en) 2002-03-28
AU750917B2 (en) 2002-08-01
AU2305099A (en) 1999-05-03

Similar Documents

Publication Publication Date Title
AU712404B2 (en) Alpha-substituted pyrimidine-thioalkyl and alkylether compounds
EP1869037B1 (en) Heterobicylic inhibitors of hvc
EP1054887B1 (en) Bicyclic pyridine and pyrimidine derivatives as neuropeptide y receptor antagonists
KR100354309B1 (en) Pyrimidine-thioalkyl and alkyl ether compounds
US20120094987A1 (en) SUBSTITUTED PYRIDO [3&#39;, 2&#39;: 4, 5] THIENO [3, 2-D] PYRIMIDINES AND PYRIDO [3&#39;, 2&#39;: 4, 5] FURO [3, 2-D] PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF-alpha
US6124306A (en) Thioalkyl alpha substituted pyrimidine compounds
US9115093B2 (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
CN108658972A (en) A kind of substituted lactams compounds and its preparation method and application
EP2917185B1 (en) Sulfoximine substituted quinazolines for pharmaceutical compositions
EP2403853A1 (en) Pyrrolopyrimidines used as kinase inhibitors
KR20150114575A (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
TW200804364A (en) New compounds
JPWO2002102807A1 (en) Novel isoxazolopyridone derivatives and uses thereof
WO2019154395A1 (en) Tetrahydroisoquinoline compound, preparation method therefor, pharmaceutical composition containing same, and use thereof
TW201139434A (en) 5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives, preparation thereof and therapeutic use thereof
WO2018050108A1 (en) Deuterated 3-(4,5-substituted pyrimidinamine) phenyl derivatives and applications thereof
WO2017108203A1 (en) Novel substituted indoline compounds as phosphodiesterase inhibitors
EP1619196A1 (en) Substituted Pyrido[3&#39;,2&#39;:4,5]thieno[3,2-d]pyrimidines and Pyrido[3&#39;,2&#39;:4,5]furo[3,2-d]-pyrimidines for use as inhibitors of PDA-4 and/or TNF-alpha release
CN108658855A (en) A kind of nitrogenous dicyclic compound and its preparation method and application
MXPA00002849A (en) Thioalkyl alpha substituted pyrimidine compounds
USRE47493E1 (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
WO2023001133A1 (en) Prmt5 inhibitor

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98808715.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1-80, DESCRIPTION, REPLACED BY NEW PAGES 1-80; PAGES 81-98, CLAIMS, REPLACED BY NEW PAGES 81-97; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase

Ref document number: 2301800

Country of ref document: CA

Ref document number: 2301800

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998966441

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2000 515877

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/002849

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 503586

Country of ref document: NZ

Ref document number: 23050/99

Country of ref document: AU

Ref document number: 1020007003158

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998966441

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020007003158

Country of ref document: KR

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWG Wipo information: grant in national office

Ref document number: 23050/99

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 1020007003158

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1998966441

Country of ref document: EP